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Abstract 
 
Infectious pulmonary complications limit the success of hematopoietic stem cell 
transplant (HSCT) therapy in both autologous and allogeneic patients. Susceptibility to 
pathogens, like Pseudomonas aeruginosa and Staphylococcus aureus, persists despite successful 
immune reconstitution. Despite high incidence of infectious pulmonary complications following 
HSCT, relatively little is known about the mechanisms promoting enhanced susceptibility.  
Alveolar macrophages (AMs) are the sentinel phagocytes in the lung and following infection 
polymorphonuclear neutrophils (PMNs) assist in bacterial clearance. Previous human studies 
implicate AM and PMN impairment post-HSCT. Using a murine syngeneic or allogeneic bone 
marrow transplant (BMT) model, our studies explore the mechanisms involved in promoting 
HSCT AM and PMN defects. We show that syngeneic BMT mice display increased 
susceptibility to both P. aeruginosa and S. aureus, which correlated with impaired AM function. 
Altered class A scavenger receptors impaired AM uptake of P. aeruginosa but not S. aureus, 
while defective bacterial killing conferred overall susceptibility to these pathogens. Syngeneic 
BMT AM susceptibility is promoted by upregulation of prostaglandin E2 (PGE2) and its rate-
limiting enzyme, cyclooxygenase-2 (COX)-2. Studies exploring the etiology of enhanced COX-2 
expression revealed a loss in DNA methylation of the COX-2 promoter mediated by 
transforming growth factor (TGF)-ß-induced miRNA-29b, resulting in elevated COX-2. 
Previous data show COX-2/PGE2 impaired PMN bacterial killing but had no effect on 
phagocytosis post-syngeneic BMT. Here we show that upregulation of COX-2/ PGE2 inhibits 
PMN extracellular trap (NET) formation post-syngeneic and allogeneic BMT, a novel finding 
 xiii 
that identifies PGE2 as a physiologically relevant inhibitor of NETosis.  Together, these findings 
highlight the importance of epigenetic changes (DNA methylation and miRNA) in BMT AMs, as 
they directly and indirectly result in increased COX-2 expression and PGE2 production. 
Upregulation of this pathway establishes an immunosuppressive environment in the lung through 
the inhibition of AM and PMN functions. Moreover, these findings identify potential therapeutic 
avenues to further explore in HSCT patients. 
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Chapter 1: 
 
Introduction 
1.1 Immune Cells 
The mammalian immune system is composed of white blood cells that can originate in 
the hematopoietic compartment of the bone marrow. Here, self-renewing hematopoietic stem 
cells (HSCs) give rise to progenitor cells that further differentiate into myeloid and lymphoid 
cells that make up our immune system, e.g. T cells, B cells, monocytes/macrophages, PMNs, 
eosinophils, etc. (1). These cells localize to different parts of the body and may remain resident 
at those sites or may circulate. Macrophages, for example, can strategically reside at different 
locations in the body and offer rapid protection to the host in the event of an infection (2). PMNs, 
on the other hand, remain in the peripheral blood, circulating until they receive cues for 
extravasation from the blood vessels and into the site of infection/injury where they can assist in 
the proper clearance of invading pathogens (1, 3, 4). 
The main functions of the immune system are to differentiate between foreign and host 
substances (self versus nonself), and to effectively remove the foreign substances. Our immune 
cells are dynamic and are constantly interacting with their environment and each other. Innate 
cells like macrophages and dendritic cells are constantly uptaking particles and/or clearing dying 
cells (5). However, upon recognition of foreign material, like bacteria or viruses, the cells 
become activated and in an effort to resolve the infection, they produce cytokines and 
chemokines to effectively recruit and activate other immune cells (6). Recognition of pathogens 
occurs through the identification of pathogen-associated molecular patterns or PAMPs via 
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pattern recognition receptors, like toll-like receptors and scavenger receptors (7, 8). Dendritic 
cells in particular, can process and present antigens acquired from these pathogens on major 
histocompatibility complex I or II molecules and these dendritic cells then travel to the nearest 
lymphoid organ, where upon interaction with T and B cells, they assist in their activation and 
further differentiation into specific T cell subsets or antibody-secreting B cells (1, 3, 4, 7). With 
both the innate and adaptive arms of the immune system activated, the body is able to resolve the 
infection and develop memory responses.   
    
1.2 Hematopoietic Stem Cell Transplantation (HSCT) Overview 
Early observations made in the 1950s paved the way for the development of HSCT.  In 
1951, Lorenz et al. showed that animals exposed to radiation could be protected by infusion of 
bone marrow cells (9).  These studies, together with the observation that the deleterious effects 
of ionizing radiation could be prevented in mice by shielding organs with lead, pushed 
transplantation forward as a possible therapy for patients suffering from hematologic 
malignancies (10).  HSCT is now used to treat a variety of disorders, including malignant, 
congenital, and autoimmune disorders (11, 12). Depending on the underlying disease, a patient 
will receive either an autologous [self donation of HSCs] or allogeneic [human leukocyte antigen 
(HLA)-matched related or unrelated hematopoietic stem cell donor] transplant (12). 
Prior to receiving a graft, HSCT recipients undergo conditioning regimens that include 
total body irradiation (TBI), chemotherapy, or a combination of TBI and chemotherapy (13, 14).  
These regimens subject the recipients’ organs, including the lungs, to their cytotoxic effects.  The 
hope is to eradicate the malignant or autoimmune cells and replenish the patient with healthy 
HSCs.  If the intensity of the conditioning regimen is myeloablative, repopulation of 
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hematopoietic cells will predominantly come from the donor HSCs (14, 15).  Non-myeloablative 
conditioning, also known as reduced intensity conditioning (RIC) will allow repopulation from 
both donor and host HSCs. A recent study analyzing the global use of transplantation reported 
that autologous HSCT continues to be more highly implemented than allogeneic transplant (16).  
Although autologous transplant recipients are unlikely to suffer from graft versus host disease 
(GvHD), which arises when the donor leukocytes mount an immune response against different 
HLA antigens expressed by the host, autologous transplants performed for hematologic 
malignancies lack the beneficial effects of graft-versus-leukemia (GvL).  GvL reactions can be 
observed in allogeneic transplantation when the allogeneic donor HSCs recognize and remove 
leukemic cells within the host by virtue of HLA mismatches (17).  
Traditionally, HSCs were aspirated from the bone marrow of donor patients and later 
infused into recipients.  This procedure was often painful for the donor.  However, technical 
advances now allow for mobilization of HSCs into the peripheral blood with the use of the 
growth factor, granulocyte-colony stimulating factor (G-CSF) (11, 12).  Treatment of donors 
with G-CSF allows HSCs to be collected with a simple blood draw.  Additionally, HSCs can also 
be harvested from umbilical cord blood (18, 19).   
 
1.3 Pulmonary Complications in HSCT Human Patients 
Although HSCT has become standard care for malignant and nonmalignant disorders, its 
success is significantly limited by the different pulmonary complications that arise following 
either allogeneic or autologous transplantation (12, 20-23). The engraftment process can be 
characterized by three distinct phases: the pre-engraftment (0-30 days), early post-engraftment 
(30-100 days), and late post-engraftment phases (beyond 100 days) (23-25).  HSCT recipients 
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are more susceptible to infections prior to engraftment and early after engraftment.  During this 
early time period, the increased susceptibility is mostly due to the incomplete recovery of the 
immune cell compartment, and is often associated with decreased PMN numbers or function 
(26).  Although engraftment indicates the transplant was successful in reconstituting 
hematopoietic cell populations, it is evident that this does not correlate with recovery of a fully 
normal immune system, as patients remain susceptible to diverse complications (including 
infections) long after engraftment occurs (23, 24, 27).  Pulmonary complications, both infectious 
and noninfectious, have been reported to affect up to 60% of transplant recipients (12, 27).  
Similarly, autopsy studies performed on both allogeneic and autologous transplant recipients 
revealed pulmonary complication rates of 80-89% (21).  Although allogeneic transplants have 
increased incidence of infectious pulmonary complications, this may be attributed, in part, to the 
use of immunosuppressive therapy required to prevent GvHD.  Additionally, GvHD can cause 
mucosal barrier disruptions that also increase susceptibility to pathogens.  Interestingly, however, 
autologous HSCT recipients also continue to suffer from increased susceptibility to pulmonary 
infections even though this form of transplant does not require immunosuppressive therapies 
(28).   
RIC has evolved as an alternative to the more traditional myeloablative conditioning 
regimens for individuals that would have otherwise been unable to undergo transplantation as a 
therapy due to age, co-morbidities, or disorders associated with high-risk non-relapse mortality 
(29).  Interestingly, despite a reduction in intensity regimens, recipients of RIC HSCT display 
similar incidence of infectious complications and infection-related mortality (30).  A 
retrospective analysis conducted on a cohort of patients over the age of 50 who received either a 
myeloablative or nonmyeloablative conditioning regimen prior to an allogeneic HSCT found that 
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patients receiving nonmyeloablative therapy were protected from non-infectious pulmonary 
complications whereas 40% of patients receiving myeloablative therapy developed these lung 
problems (31). While Alyea and colleagues saw a reduction in non-infectious complications with 
nonmyeloablative conditioning, they still noted that infection remained a major cause for 
nonrelapse mortality in both the myeloablative and nonmyeloablative groups.  Furthermore, 
disease relapse was significantly higher in patients receiving nonmyeloablative conditioning 
regimens than those receiving myeloablative regimens. Thus, although reduced conditioning 
therapy does offer some lung protection and therapeutic advantage, myeloablation remains more 
effective in preventing disease relapse over time.  
Taken together, these observations highlight the inherent dysfunction of the immune 
response following transplant and suggest that some degree of impaired function is independent 
of the immunosuppressive therapies, GvHD, and possibly even myeloablation.  Thus, the 
susceptibility may be due to phenotypic changes that occur in the alveolar environment. The 
alveolus is composed primarily of type I and type II epithelial cells (structural cells), as well as 
alveolar macrophages (AMs) (32). Alveolar epithelial cells (AECs) are vital for proper lung 
function (i.e. gas exchange, secretion of surfactant) (32) while AMs are the sentinel phagocytes 
in the alveolus, highlighting their importance in initiating an immune response against an 
invading pathogen in the lower airways (33).  As AMs are integral in the early response to 
invading pathogens or inhaled materials, it is possible that AMs might be defective post-
transplant. The idea that AMs are inherently less functional post-HSCT is supported by previous 
observations that AMs obtained from pulmonary lavage of allogeneic HSCT patients late in the 
post-engraftment phase were functionally defective even in the absence of overt pulmonary 
infection (34).  Defects noted in AMs from these patients included defects in chemotaxis, 
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phagocytosis and killing of Candida pseudotropicalis as well as phagocytosis and killing of 
bacteria including Staphylococcus aureus and Listeria monocytogenes.  This same study 
suggested that the defects may be primarily confined to the lung as the function of peripheral 
blood monocytes in these same assays was similar to control patients (34). 
Noninfectious complications that arise following transplant include peri-engraftment 
respiratory distress syndrome, diffuse alveolar hemorrhage, idiopathic pneumonia syndrome, and 
bronchiolitis obliterans syndrome (21, 23, 27, 28, 35, 36).  These occur throughout the different 
engraftment phases but bronchiolitis obliterans syndrome in particular, is more commonly seen 
late post-engraftment (35).  Malignant relapse or secondary malignancy also complicate 
successful transplants (12, 37).  Often, noninfectious complications can manifest in conjunction 
with infectious complications (21, 38).  Additionally, infections are risk factors for development 
of some forms of non-infectious lung injury which may occur later, such as idiopathic 
pneumonia syndrome (39). Importantly, infections with bacterial, viral and fungal pathogens can 
afflict both allogeneic and autologous HSCT recipients at multiple times post-transplant (23, 40).  
Viral infections are common in HSCT patients.  Cytomegalovirus (CMV) infections 
predominate in the late phase of engraftment and are associated with increased mortality (41-43).  
The advent of prophylactic and antiviral therapy usage has proven to be beneficial in limiting 
infection in HSCT patients; however, CMV can be particularly difficult to detect and treat (43).  
One autopsy study revealed that 65% of CMV infections were not diagnosed ante mortem, thus 
highlighting the frequency of missed detection (44).  Thus, HSCT patients are highly susceptible 
to CMV as well as other herpesviruses (27, 45, 46).  Fungal pathogens are one of the major 
causes of significant morbidity and mortality in HSCT recipients (47).  Prior to the use of azole-
based anti-fungal prophylaxis, Candida spp. were the leading fungal pathogen following HSCT 
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(48). However, following implementation of this anti-fungal prophylactic treatment, Aspergillus 
spp. have become the predominant fungal pathogens causing invasive fungal infections in the 
lungs of both autologous and allogeneic HSCT populations (48, 49). When considering bacterial 
infections, a shorter time to engraftment and the use of broad-spectrum antibiotics have reduced 
the incidence of bacterial infections, specifically Gram-negative bacteria (50, 51).  However, 
bacterial pneumonias remain a significant cause of mortality in this immunocompromised 
population (46, 50).  Pseudomonas aeruginosa (a Gram-negative bacterium) is the most common 
pathogen isolated within 100 days post-engraftment and is associated with high recurrence rates 
due to increasing antibiotic resistance (52).  Streptococcus pneumoniae is the leading Gram-
positive bacterium, and together with another Gram-positive agent, Staphylococcus aureus, 
afflicts patients in the early and late post-engraftment phase and causes significant mortality (46, 
53) (Figure 1.1).   
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Figure 1.1. Timeline of main infectious pulmonary complications post-HSCT (adapted 
from Coomes et al. 2011). 
 
As AMs mediate an early immune response to pathogens invading the lower airways and 
their function has been shown to be impaired post-HSCT, studies have been focused on 
understanding the mechanisms driving the defects in this cell population.  These studies have 
largely been conducted using animal models of HSCT. 
 
1.4 HSCT Animal Modeling 
Murine BMT models for both syngeneic (genetically identical donor), to model human 
autologous HSCT, and allogeneic (non-identical) transplantation offer the opportunity to study 
  9 
changes in the pulmonary immune system and microenvironment following transplantation. In 
these systems, donor cells are harvested from the femur and tibia of genetically inbred mice and 
introduced into lethally irradiated syngeneic or allogeneic mice to reconstitute ablated 
hematopoietic compartments.  In order to force reconstitution of myeloid cells from 
hematopoietic donors, myeloablative conditioning is employed.  This can be done via TBI or via 
chemotherapy regimens, but TBI is most common. Turnover of murine lung AMs require 
radiation levels of at least 9 Gy (54).  One note of caution however, is that different strains of 
mice have differing susceptibilities to TBI dosage.  For instance, in our laboratory we routinely 
use 13 Gy split dose of TBI to myeloablate C57Bl/6 mice and only 10 Gy for the same purpose 
in Balb/c mice. Addition of splenic T cells along with the donor bone marrow inoculum can 
hasten reconstitution in syngeneic transplants (55) and can be a source of alloreactive T cells in 
models of allogeneic BMT hoping to study GvHD or GvL responses (56, 57).   
Studies comparing conditioning regimens for their ability to reconstitute AMs in recipient 
syngeneic BMT mice showed that both dual chemotherapy regimens (4 days of 25 mg/kg 
busulfan followed by 2 days of 100 mg/kg cyclophosphamide) and 13 Gy TBI regimens induced 
greater than 50% reconstitution of AMs and spleen cells from donor stem cells by week 5 post-
BMT (54).  Thirteen Gy TBI, when compared to dual chemotherapy, was the more effective 
conditioning regimen.  With 13 Gy TBI conditioning, donor reconstitution, measured by the 
percentage of CD45.1 donor cells in CD45.2 recipient mice, was observed at 82% ± 2% in AMs 
and 95% ± 1% in spleen cells (54).  The percentages of donor-derived AMs and spleen cells with 
dual-chemotherapy were 56% ± 6.2% and 72.3% ± 2.1% (54).  
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Figure 1.2. Syngeneic and allogeneic bone marrow transplantation animal model. 
1.5 Defective pulmonary innate immunity to bacteria 
Despite the use of antibiotic prophylaxis, infectious pulmonary complications continue to 
afflict both autologous and allogeneic HSCT recipients throughout the process of engraftment 
and well into the late post-engraftment phase (>100days) (46, 53).  Although reported to 
predominantly manifest in the pre-engraftment and early post-engraftment phases, P. 
aeruginosa-driven pneumonia is also seen in some cases more than a year post-initial transplant 
(53).  To understand how alterations following transplantation enhance susceptibility of HSCT 
patients to bacterial infections, the Moore lab previously exposed syngeneic BMT mice to a 
sublethal dose of P. aeruginosa (PAO1 strain; 5x105 CFU) (24, 55, 58, 59) via intratracheal (i.t.) 
injection and measured bacterial burden in the lungs and blood following twenty-four hours. 
Using this model, the lab found that syngeneic BMT mice were more susceptible to bacterial 
infection as they are unable to effectively clear P. aeruginosa (24, 55, 58-60) from the lung and 
contain higher levels of bacterial dissemination compared to untransplanted, infected control 
mice.   
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1.6 Cytokine and eicosanoid dysregulation post-BMT 
In humans, bacterial infection is commonly seen in the neutropenic phase due to a slow 
or incomplete engraftment, or the use of immunosuppressive therapy (23, 24).  However, in our 
syngeneic BMT model, there was prolonged susceptibility to bacterial infection even after full 
hematopoietic engraftment had occurred.  These observations suggested that the environment of 
the lung post-BMT may be suppressing the function of the innate immune cells which had 
repopulated the alveolar space.  These studies revealed that syngeneic BMT mice are unable to 
successfully induce tumor necrosis factor (TNF) α or interferon (IFN) γ in the lung following 
infection with P. aeruginosa (55).  TNFα in particular, has been shown to be especially 
important in controlling a P. aeruginosa infection (61, 62). Balb/c mice are naturally resistant to 
P. aeruginosa and have been shown to produce higher levels of TNFα in the lung following 
infection while the susceptible C57BL/6 strain produces significantly lower levels of TNFα post-
infection (63, 64).  Interestingly, in vivo treatment of Balb/c mice with an anti-murine TNFα 
monoclonal antibody reversed resistance to infection and the anti-TNFα-treated mice exhibited 
higher bacterial loads in the lung (64).  Similarly, a separate study showed that TNFα-knockout 
mice suffered from significantly higher bacterial burden in the lungs following challenge with P. 
aeruginosa compared to their TNFα-sufficient wild-type controls (65).  These data highlight the 
importance of TNFα in mediating clearance of P. aeruginosa and suggest that loss of the 
mediator post-BMT likely contributes to impaired clearance of this pathogen.  
In addition to TNFα, IFNγ is also important for the activation of macrophages.  IFNγ 
functions to prime macrophages to undergo classical activation but does not alone activate 
macrophages (66, 67).  It requires a second signal, provided by either exogenous TNFα or Toll-
like receptor (TLR)-induced TNFα (66).  However, as both IFNγ and TNFα were decreased in 
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the alveolar space and TNFα production was decreased by AMs following BMT in response to 
i.t. challenge with P. aeruginosa, it is possible that the lack of activation signals for macrophages 
contribute to the inability to control and clear bacterial insult post-BMT (55). 
Eicosanoids derive from arachidonic acid and are lipid mediators produced by different 
cell types, including AECs, AMs, and PMNs (58, 68, 69).  Prostaglandins and leukotrienes are 
end-products of arachidonic acid metabolism via the COX and 5-lipoxygenase enzymatic 
pathways, respectively (69) (Figure 1.2).  These eicosanoids have diverse effects on cells.  
Leukotrienes (LTB4 and cysteinyl leukotrienes or cysLTs) seem to have an overall pro-
inflammatory effect on innate immune cells as they have been shown to promote bacterial 
phagocytosis and killing in both AMs and PMNs (70-73).  Similarly, cysLTs have been shown to 
be involved in the induction of TNFα production by both AMs and recruited PMNs (74, 75).   
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Figure 1.3. Arachidonic acid metabolism pathway. 
 
Studies on the effects of prostaglandins, particularly PGE2, however, suggest they may 
negatively regulate innate immune responses (76).  PGE2 signals through four distinct G protein-
coupled seven transmembrane spanning E prostanoid (EP) receptors (77, 78).  The inhibitory 
effects of PGE2 have been attributed to binding of EP2 and EP4.  Stimulation of the EP2 or EP4 
receptors results in the induction of intracellular cyclic adenosine monophosphate (cAMP) and 
activation of the downstream cAMP targets: protein kinase A (PKA) and the exchange protein 
activated by cAMP (Epac-1) (76, 79).  Activation of PKA and/or Epac-1 has been shown to 
impair both AM and PMN function as well as inhibit the production of pro-inflammatory 
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mediators, leukotrienes and reactive oxygen species (79, 80).  Interestingly, PGE2 has also been 
shown to induce IL-10, an immunosuppressive cytokine (81, 82).  
 
Figure 1.4 PGE2 is elevated in bronchoalveolar lavage fluid of HSCT patients. 
 
Table 1.1 Healthy and HSCT characteristics for PGE2 studies shown in Figure 1.4 
Patient Age Gender Days post-
transplant 
Conditioning Underlying 
disease 
Untransplanted 
Ctl 
49 Male N/A N/A No disease 
Auto 1 
 
71 Male 14 BEAM/Rituximab Mantle cell 
lymphoma 
Auto 2 77 Male 98 BEAM/Rituximab Diffuse large B 
cell lymphoma 
 
Allo 1 
62 Female 363 FluMel 
Precursor B-cell 
Acute 
lymphoblastic 
leukemia 
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Allo 2 72 Male 699 FluBu/TBI 
Acute Erythroid 
Leukemia 
 
Allo 3 50 Male 615 FluBu/Rituximab 
Mantle Cell 
Lymphoma 
Allo 4 
 71 Male 348 FluBu/TBI AML/NOS 
Allo 5 
 
59 Female 819 FluBu 
Acute 
Myelomonocytic 
Leukemia 
Allo 6 
51 Male 344 FluBu 
Acute Myeloid 
Leukemia, NOS 
Allo 7 
63 Male 2221 FluBu 
Chronic 
Idiopathic 
Myelofibrosis 
Allo 8 
57 Male 906 FluBu/TBI 
Mantle Cell 
Lymphoma 
Allo 9 
68 Female 39 FluBu 
Atypical chronic 
myeloid 
leukemia 
Allo 10 66 Male 118 FluBu Acute Myeloid 
Leukemia,NOS 
Allo 11 66 Male 631 FluBu Chronic 
Idiopathic 
myelofibrosis 
Allo 12 10 Male 51 FluBu/ATG/Thymo
globulin 
RAEB-1 
Allo 13 58 Male 303 FluBu Follicular 
lymphoma, 
Grade II 
Allo 14 38 Female 211 FluMel Mycosis 
fungoides 
Allo 15 23 Male 800 FluBu/TLI Acute myeloid 
leukemia without 
maturation 
Allo 16 65 Male 357 FluBu Acute 
Myelomonocytic 
leukemia 
Auto, autologous; Allo, allogeneic; Refractory anemia with excess blasts (RAEB-1); MEL, 
melphalan; BEAM, BCNU-Etoposide-AraC-Melphalan; Flu, fludarabine; Bu, busulfan; TLI, 
total lymphocyte infusion; TBI, total body irradiation; Clo, clofarabine; Cy, cytoxan; ATG, anti-
thymocyte globulin; BAC bendamustine and cytarabine. 
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PGE2 has been reported to be elevated in the serum of autologous HSCT recipients (83).  
This increase in PGE2 was not specific to a particular conditioning regimen indicating that all 
HSCT patients are susceptible to overproduction of PGE2 (83).  We have previously reported that 
PGE2 is elevated in the lungs of mice following syngeneic BMT (58) and have confirmed this 
observation in HSCT patients (Figure 1.4, Table 1.1).  PGE2 overproduction in syngeneic BMT 
mice was localized to AMs, recruited PMNs, and structural cells, whereas cysLTs are decreased 
in BMT AMs (58).  The increased production of PGE2 is likely to be systemic as BMT peritoneal 
lavage fluid also displayed higher PGE2 levels (58).  Although it is tempting to suspect PGE2-
induced IL-10 expression may be responsible for the impaired immune environment post-BMT, 
IL-10 was decreased in the BMT lung following infectious stimuli indicating that the inhibitory 
effects of PGE2 were likely independent of the immunosuppressive effects of IL-10 (55).  
Interestingly, pharmacological inhibition of the COX pathway post-BMT limited PGE2 
production and restored cysLT levels in AMs indicating that PGE2 negatively regulates cysLTs 
in the setting of BMT (58).  The importance of cysLTs in supporting the clearance and resolution 
of pulmonary infections post-BMT is observed in mice that received HSCs from granulocyte 
macrophage colony stimulating factor (GM-CSF)-/- mice (59).  GM-CSF-/- BMT mice are 
defective in cysLT production post-infection and are more susceptible to P. aeruginosa infection. 
GM-CSF is an important cytokine for regulating innate immune cells, particularly 
macrophages.  Previous studies have shown that GM-CSF is required for effective clearance of 
P. aeruginosa even in untransplanted mice (84).   Untransplanted GM-CSF-/- mice had increased 
bacterial burden compared to wild-type controls.  However, the source and amount of GM-CSF 
is critical to determining host defense function post-BMT.  AMs from wild-type syngeneic BMT 
mice show an overproduction of GM-CSF post-BMT.  Interestingly, in human HSCT literature, 
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elevated production of GM-CSF by AMs during the pancytopenia period was also noted (85).  
While we initially thought excess AM-derived GM-CSF would be beneficial, this was not the 
case because the excess GM-CSF in AMs post-BMT drove upregulation of the EP2 receptor on 
AMs (59).  The inhibitory effects of PGE2 signaling via upregulated EP2 in the wild-type BMT 
mice impaired bacterial phagocytosis and killing as well as cysLT and TNFα production.  When 
GM-CSF-/- HSCs were used to repopulate WT mice, host defense improved (59).  Without AM-
derived GM-CSF post-BMT, EP2 receptors were not elevated and mice showed improved host 
defense despite the fact that PGE2 levels were still elevated post-BMT.  In the absence of EP2 
elevations, the GM-CSF-/- BMT mice retained production of cysLTs and TNFα.  It is important 
to stress that improved host defense was only seen in the situation where GM-CSF production 
was blocked in hematopoietic cells post-transplant.  When WT HSCs were transplanted into 
GM-CSF-/- mice, host defense was once again impaired (59).  These data highlight the 
importance of cross-talk between AECs and AMs post-BMT.  AEC-derived GM-CSF is 
beneficial post-BMT whereas AM-derived GM-CSF is detrimental.  In the human HSCT 
literature mentioned above, elevations of AM-derived GM-CSF in human allogeneic HSCT 
recipients predicted development of later lung disease (85). This complex homeostatic regulation 
of GM-CSF means blocking this cytokine needs to be targeted specifically to the AMs to be 
beneficial.  Newer approaches to create microparticle delivery vesicles that are readily uptaken 
by phagocytes, but not structural cells, may offer a way to deliver antibody or siRNA-based anti-
GM-CSF therapies in the future (86).   
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1.7 Cellular alterations 
1.7.1 Alveolar epithelial cells (AECs) 
AECs are the structural cells lining the alveolus. Type II AECs are important secretors of 
pulmonary surfactant, are progenitors to type I AECs that line the majority of the lung, and act as 
immunomodulators via interactions with immune cells. Exposure to ionizing radiation induces 
damage to the alveolar epithelial barrier causing changes in gene expression, particularly 
cytokine expression (87).  We have previously shown that upon transplantation, AECs from 
BMT mice are negatively affected by the transplant process. Specifically, AECs overproduce 
PGE2 as well as TGF-β which as discussed above inhibits AM function (58, 88, 89).  
Furthermore, AECs are defective in the synthesis of GM-CSF (59, 84) which as discussed above 
is important for modulating AM function.  Another important defect that has been described 
post-BMT is the loss of surfactant protein A (SPA) which is predominantly synthesized by AECs 
(90, 91).  As SPA can serve as a collectin (91) which can bind pathogens to help facilitate 
phagocytosis via the class A scavenger receptor A (SR-A) (92), loss of SPA post-BMT may be 
another reason why host defense is impaired in the setting of HSCT.  The fact that SPA can bind 
to SR-AI/II (the receptor that is retained on BMT AMs, see my results in Chapter 3) may suggest 
that exogenous SPA therapy could prove beneficial post-HSCT. 
 
1.7.2 Alveolar macrophages (AMs) 
AMs compose 95% of all leukocytes in the airspaces and thus, are the sentinel phagocytic 
cells in the lungs (93, 94).  They have been implicated as critical innate immune cells for 
clearance of bacteria as depletion of AMs through clodronate liposomes resulted in impaired host 
defense against P. aeruginosa (95).  As AMs are important first responders to infection in the 
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lung, their function is essential for preventing bacterial dissemination as well as promoting 
bacterial clearance by engulfment and removal of infectious pathogens, and also by releasing 
chemokines to stimulate the recruitment and activation of immune cells (94).  However, data 
suggest that BMT AMs demonstrate altered cytokine and eicosanoid production, which impair 
their innate immune function and predispose the host to infections post-BMT.  
AMs have been reported to exhibit decreased ability to phagocytize and kill bacteria 
following allogeneic HSCT (34).  Murine BMT AMs display an impaired ability to phagocytize 
and kill P. aeruginosa (55, 58, 96, 97).  This defect has been shown to be dependent on PGE2 
signaling as pharmacological inhibition of the COX pathway through the use of indomethacin 
can restore productive host defense against bacteria both in vitro and in vivo post-BMT.    
Furthermore, blocking the EP2 receptor (using AH 6809 a strong EP2 antagonist with weaker 
activity at the EP1 and DP1 receptors) in BMT AMs inhibits PGE2 signaling and restores 
phagocytosis of P. aeruginosa (58).  PGE2 is significantly overproduced by BMT AMs (58).  
The cause for elevated basal levels of PGE2 in the AMs post-BMT may be multifactorial.  It is 
possible that differences in differentiation of AMs from donor-derived HSCs versus a resident 
AM stem cell may influence the amount of PGE2 observed after transplant (98).  However, 
studies indicate that this cannot fully explain the defect since mice receiving a lower dose of 
irradiation (8 Gy) contain a large percentage of host-derived AMs (~36%)  that also overproduce 
PGE2 post-transplant, albeit at approximately a 3-fold lower level than seen in AMs derived from 
donor HSCs (54).  Thus, although the etiology of increased PGE2 was unclear at this time (and is 
a question addressed in this dissertation), its importance in mediating impaired AM function was 
highlighted in our model and experiments exploring mechanisms through which PGE2 mediates 
inhibition of AM phagocytosis and bacterial killing post-BMT are discussed below. 
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Endocytosis of pathogens can occur in a number of ways with two major ways being 
through opsonized and non-opsonized phagocytosis.  As bacterial uptake is impaired post-BMT, 
we sought to better understand the reasons for this.  Phosphatase and tensin homolog deleted on 
chromosome 10 (PTEN) functions to dephosphorylate both protein and lipid targets, and has 
been traditionally known for its effects on PI3K/AKT signaling through dephosphorylation of 
phosphatidylinositol (3-5)-triphosphate (PIP3) (99).  Previous studies have shown that PGE2-
induced PTEN activity can inhibit FcγR-mediated phagocytosis and PI3K/AKT activation (100).   
In the syngeneic BMT model, overproduction of PGE2 stimulates increased PTEN activity, 
resulting in decreased serum-opsonized phagocytosis (97).  Using myeloid-specific PTEN 
conditional knockout (PTEN CKO) mice as BMT donors, recipient mice had improved, but not 
completely restored, host defense to in vivo bacterial challenge.  This rescued response correlated 
with recovered serum-opsonized phagocytosis by AMs and improved killing of P. aeruginosa by 
both AMs and PMNs.  Interestingly, non-opsonized phagocytosis in AMs was only partially 
recovered (97).  This partial restoration may be due to persistent elevation of the IL-1 receptor-
associated kinase-M (IRAK-M) post-BMT.   
 A member of the IRAK family of serine/threonine kinases, IRAK-M functions as a 
negative regulator of MyD88-dependent TLR signaling (101).  Our BMT model revealed that 
PGE2 can upregulate IRAK-M in AMs (96).  Furthermore, BMT mice receiving genetically 
ablated IRAK-M-/- donor HSCs were able to control and clear the bacterial infection similarly to 
untransplanted controls.  This recovery also correlated with rescued TNFα, cysLTs, and AM 
function (including non-opsonized phagocytosis and killing) (96).  Interestingly, these mice 
retained overproduction of PGE2 and overexpression of the inhibitory receptor, EP2.  Thus, these 
data suggest that the inhibitory effects of PGE2 are dependent on IRAK-M and that IRAK-M is a 
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critical downstream mediator of inhibitory PGE2 signaling (96).  Taken together, these studies 
suggest that PGE2 signals through IRAK-M independently of PTEN and increased activity of 
IRAK-M and PTEN promote differential effects on serum-opsonized and non-opsonized 
phagocytosis.  Furthermore, the PTEN macrophage conditional knock out studies highlight the 
importance of non-opsonized phagocytic responses in the lung following transplant, as complete 
recovery of serum-opsonized phagocytosis and bacterial killing did not completely abrogate in 
vivo susceptibility measured 24 h post-infection (97).  
Non-opsonized phagocytosis is primarily mediated by scavenger receptors (SRs), 
specifically Class A SRs (102).  Within this family of SRs are SR-AI and II (SR-AI/II), 
macrophage receptor with a collagenous structure (MARCO), SR with C-type lectin (SRCL), 
and SR receptor A5 (SCARA5) (103).  SR-AI and II are splice variants, and together with 
MARCO, have been associated with mediating non-opsonized phagocytosis in macrophages 
(103).  Their importance in bacterial clearance is highlighted by the susceptibility of individual 
MARCO-/- and SR-AI/II-/- mice to clear S. pneumoniae (104, 105).  Defective phagocytosis of 
S. pneumoniae in SR-AI/II-/- mice has also been reported (104). BMT effects on AM SR profiles 
and SR contribution to AM function post-BMT were not known previous to this work and are 
explored in Chapter 3.   
 
1.7.3 Polymorphonuclear neutrophils (PMNs)  
A major role for PMNs lies in their ability to be recruited to the lung upon inflammation 
or infection and assist in the killing and ultimate clearance of pathogens (106, 107).  Several 
studies have looked at the function of human PMNs post-autologous HSCT [reviewed in (108)].  
These human studies noted decreased respiratory burst, decreased phagocytosis of Candida 
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albicans, and decreased killing of S. aureus (109).  Interestingly the role of GM-CSF in restoring 
PMN function is mixed (109-111).  In the context of murine syngeneic BMT, PMNs were shown 
to have intact phagocytic ability but were defective in their ability to kill the engulfed bacteria 
(58).  Genetic ablation of GM-CSF in donor marrow improved, but did not fully restore, PMN 
killing of P. aeruginosa (59).  
PTEN-deficient PMNs have been reported to exhibit enhanced host immune responses 
(112, 113).  Previous studies had shown that alleviating the repressive effect of PTEN on PMNs, 
augmented PMN chemotaxis (113).  Similar to these studies, our PTEN CKO BMT mice had 
elevated basal levels of PMNs in the alveolar space compared to untransplanted wildtype 
controls and recovered their ability to kill intracellular bacteria (97).  However, despite a rescued 
PMN phenotype, PTEN CKO BMT mice were still susceptible to acute P. aeruginosa infection, 
highlighting the importance AM function, specifically the need for non-opsonized phagocytosis, 
post-BMT.       
Together with AMs, the impaired function of PMNs can also be attributed to elevated 
PGE2, as pharmacological inhibition of PGE2 synthesis completely resolved their defect (58).  
Unlike BMT AMs, PMNs do not exhibit a phagocytic defect and IRAK-M is not elevated in 
recruited PMNs.  Thus, it is likely that PGE2 is mediating impaired killing through PTEN, as we 
have previously shown that PGE2 can induce PTEN activity (97). A summary of the changes 
characterized using the syngeneic BMT model is described in Table 1.2. 
Table 1.2. Summary of observed cellular alterations following syn BMT 
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1.8 Unanswered questions addressed by my studies 
As noted above, at the initiation of my studies, we understood that overproduction of PGE2 
mediated by COX-2 in AMs impaired function, but we did not know why COX-2 was 
persistently elevated in AMs post-BMT.  In addition, we knew that AM phagocytosis of the 
Gram-negative P. aeruginosa was impaired, but it was not known whether this was true for a 
Gram-positive pathogen like S. aureus.  It was known that SRs regulated non-opsonized bacterial 
uptake, but the regulation of SR expression post-BMT was unknown.  Finally, while PMNs were 
known to have bacterial killing defects, it was not known whether this related only to 
intracellular killing or if other mechanisms of bactericidal activity by PMNs (e.g. induction of 
NETs) were similarly impaired, and if so, if PGE2 was also responsible.  In the work that will be 
discussed in this dissertation, we have identified a number of epigenetic modifications that help 
answer these questions, and as such, the following introductory background is provided. 
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Figure 1.5. Summary of known alveolar macrophage and polymorphonuclear neutrophil 
dysfunction post-BMT. 
 
1.9 Epigenetics 
Epigenetic regulation of gene expression is important for normal biological processes like 
immune cell development, immune responses, and differentiation from HSCs. Furthermore, it is 
well understood that epigenetic mechanisms can include DNA methylation, histone modification, 
and more recently, microRNAs (miRNA). Interestingly, aberrant epigenetic modification can 
also promote pathology in many diseases like cancer.   
Epigenetics can be defined as potentially heritable changes to gene expression that are 
independent of changes to the DNA sequence (114).  Epigenetic regulation can involve DNA 
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methylation and histone modification. More, recently, miRNA have been included to this 
category of regulation as some miRNA can regulate various epigenetic-modifying enzymes.  In 
this section, discussion of epigenetic changes in HSCT will be restricted to miRNA effects on 
DNA methylation. 
 
1.10 DNA Methylation 
Epigenetic regulation of gene expression via DNA methylation has been studied 
extensively due to its importance in regulating diverse biological processes.  Though dispensable 
and nonexistent in some organisms like Caenorhabditis elegans (C. elegans), DNA methylation 
is widely conserved across prokaryotes and most eukaryotes (115). Studies in bacteria suggest 
DNA methylation as an important mechanism for distinguishing self/host DNA from invading 
phage DNA (116). In mammals, DNA methylation has been extensively studied in natural 
processes (e.g. embryogenesis) as well as disease processes (e.g. cancer). We now know that in 
mammals, methylation occurs on DNA whereby a cytosine base is converted to a 5-
methylcytosine via de novo (DNMT3a/3b) or maintenance (DNMT1) DNA methyltransferases 
(DNMTs) (117).  Although DNA methylation in mammals is primarily regulated by DNMT1, 
DNMT3a, and DNMT3b, two separate DNMTs have also been identified known as DNMT3L 
and DNMT2.  DNMT3L is implicated in the regulation of DNMT 3a and 3b while DNMT2 has 
been renamed tRNA aspartic acid methyltransferase for its role in methylated tRNA rather than 
DNA (117, 118).  
Maintenance DNMTs are vital for conserving inherited DNA methylation patterns 
following cellular replication, while de novo DNMTs function to create DNA methylation at new 
or previously unmethylated CpG sites. DNMT1 has traditionally been highlighted as a 
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maintenance DNMT. This was primarily due to studies indicating that de novo methylation 
remained intact despite DNMT1 knockout in embryonic stem (ES) cells (119). A separate study 
had similarly observed that deletion of DNMT1 in these same cells, resulted in a significant 
reduction in methylated cytosines (120). DNMT3a and DNMT3b, were coined de novo DNMTs  
due to intact inherited DNA methylation patterns in ES cells (121) and overexpression of 
DNMT3a resulted in increased de novo DNA methylation (122).  However, other data suggest 
that these de novo DNMTs may exhibit properties of maintenance DNMTs under particular 
circumstances as in a DNMT1 knockout adenocarcinoma cell line exhibiting intact DNA 
methylation patterns (123). It is also possible, that other maintenance DNMTs have not yet been 
identified.  
Though DNA is scattered with cytosine bases, the importance of the methylation of 
cytosines on gene expression localizes to regions of the DNA that are more highly concentrated 
with cytosine-phosphate-guanine (CpG) dinucleotides, also known as CpG islands (Figure 1.5). 
The mechanism by which DNMTs target certain CpG islands within genes is not entirely 
understood.  
  
Figure 1.6. Methylation effects on gene expression. CpG sites, or regions where cytosine 
nucleotides are next to guanine nucleotides, are present in the promoter as well as transcribed 
regions and can be subjected to regulation by DNA methylation.  DNA methyltransferases can 
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methylate CpG sites resulting in the downregulation of gene expression, whereas decreased 
methylation (unmethylated) supports genetic expression. 
 
DNA methylation-regulated gene expression has also been studied in the context of 
disease. ICF (immunodeficiency, centromeric region instability, and facial anomalies) syndrome 
is a recessive autosomal disease characterized by mutated DNMT3b, resulting in targeted 
chromosome breakage and decreased serum immunoglobulin levels despite normal B cell counts 
(124).  In idiopathic pulmonary fibrosis, some fibroblasts lose responsiveness to inhibitory 
effects of PGE2 signaling via increased DNA methylation of the EP2 receptor (125).  In addition, 
various studies have pointed to dysregulated DNA methylation patterns as cofactors for 
development of cancer (126).  Global DNA hypomethylation and hypermethylation of specific 
genes, like tumor suppressor genes, was previously observed in tumor cells (127, 128).  
Hypomethylation of CpG islands in the promoter of COX-2 has been previously associated with 
increased expression of COX-2 mRNA and contributes to progression of many human cancers 
(129-131).  In gastric cancer, increased expression of COX-2 directly correlated with increased 
risk of death from gastric cancer compared to patients that did not exhibit induced expression of 
COX-2 (132). That aberrant COX-2 expression is associated with altered methylation status of 
CpG regions in the promoter and this suggests an important role in epigenetic regulation of this 
gene.  Taken together, the above data prompted us to examine the DNA methylation patterns of 
COX-2 post-BMT as part of the studies presented in this dissertation.  
 
1.11 MicroRNAs (miRNAs) 
 MiRNAs are small, noncoding RNAs that can modulate gene expression post-
transcriptionally, affecting mRNA stability as well as inhibiting protein translation.  Originally 
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discovered in C. elegans (133), the presence of miRNA has been described in both animal and 
plant cells. Since the initial description of miRNA, many studies have tried to understand how 
miRNAs are processed and the mechanism behind RNA interference (RNAi) as a form of 
regulation of gene expression.  In humans, it is estimated that about a quarter of miRNA genes 
are encoded in intronic regions while others are found clustered throughout the genome (134, 
135). We now know that miRNAs arise from noncoding RNA, primarily transcribed by RNA 
polymerase II.  These long noncoding RNA, also known as pri-miRNA, contain stem-loop 
structures, and go through various processing steps to ultimately yield mature miRNA, roughly 
about 22 nucleotides in length.  Interestingly, multiple miRNA can arise from a single pri-
miRNA (136, 137).  Cleavage and further processing of these stem-loop structures can occur in 
one of two identified pathways: the canonical Drosha pathway or a Drosha-independent 
pathway. The latter pathway has been investigated primarily in Drosophila and C. elegans, and 
these studies suggest that some intron-originating miRNA can form pre-miRNA from pri-
miRNA via a Drosha-independent splicing mechanism (138, 139).  In contrast, the canonical 
Drosha pathway involves cleavage via a complex containing DiGeorge syndrome critical region 
gene 8 (DGCR8) and the RNase type III, Drosha. Also known as the microprocessor complex, 
DGCR8 and Drosha are responsible for mediating the formation of pre-miRNAs from pri-
miRNA, the primary miRNA transcript (134, 140). Interaction with exportin-5-Ran-GTP 
supports transportation of the pre-miRNA to the cytoplasm from the nucleus, where it can be 
further processed by Dicer, a dsRNase type III, to yield a double stranded miRNA at its mature 
length.  This double stranded miRNA contains a functional strand, (the mature miRNA), which 
is loaded onto the RNA-induced silencing complex (RISC) together with Argonaute proteins, 
and a nonfunctional (passenger) strand, which is degraded.  
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Unlike small interfering RNA (siRNA) which form approximately 21-23 base-paired 
duplexes that are complementary to any region of the target mRNA and trigger degradation via 
Argonaute proteins (141), mature miRNA guide the RISC complex via identification of target 
sequences in 3’ untranslated regions (3’UTR) of mRNA to affect mRNA stability and/or inhibit 
translation (140, 142).  It remains the general rule that recognition of a target mRNA by a 
miRNA requires complete complementarity between the target sequence in the 3’UTR of the 
mRNA and the ‘seed’ region, defined as nucleotides 2-8 of the 5’ end of the miRNA.  However, 
exceptions to this rule do exist and have been summarized elsewhere (141).  Although such 
exceptions can complicate studies focused on understanding the effects of miRNA on gene 
expression, it is important to remember that when performing such studies, targeting of the 
miRNA to the gene sequence under investigation should be verified.    
 
1.12 MiRNA and immune responses 
 The importance of miRNA on developmental, cellular, and physiological processes was 
previously underappreciated. However, multiple studies have now shown that miRNA are 
important for basic biological processes like hematopoiesis as well as regulating immune cell 
development and immunological responses (143).  Initiation of innate immune responses are 
important not just for the immediate attack on invading pathogens, but also for the further 
activation of the adaptive immune response, which can confer protective and long-lasting 
immunity.  One way that innate immune cells sense pathogens is through membrane-bound 
TLRs (7). Binding to these receptors triggers the activation of intracellular signaling cascades 
that result in a variety of responses, e.g. activation of pro-inflammatory genes. These pathways 
have been studied extensively. However, what has been more recently observed is that miRNA 
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can exert regulatory functions that can either support or antagonize these innate immune 
responses.  MiR-146a/b, for example, has been shown to be induced by TLRs expressed on the 
cell surface and not TLRs bound to intracellular membranes (7, 144). Interestingly, miR-146 
targets adaptor proteins important for TLR signaling suggesting that miR-146 functions as a 
negative regulator of TLR-initiated immune responses (144).  MiRNA-mediated gene regulation 
is extremely complex because of the broad and various mRNA targets. Studies focused on miR-
155 regulation of immune responses highlight the complexity of miRNA-mediated regulation.  
 
1.12.1 MiR-155 
Both bacterial and viral products, through recognition primarily mediated by TLRs, as 
well as various proinflammatory cytokines (e.g. IFN-β, TNFα) can induce miR-155 expression 
in macrophages (144, 145). Furthermore, miR-155 can stabilize TNFα, and thus promote 
translation of TNFα and support proinflammatory responses, particularly in macrophages (146). 
Studies on macrophage polarization have shown a role for miRNA regulation (125). In one 
study, overexpression of miR-155 on tumor-associated macrophages, which typically resemble 
alternatively activated macrophages and exhibit anti-inflammatory functions, resulted in a switch 
in polarization to a classically activated macrophage (147). However, similar to miR-146a/b, 
miR-155 can also serve as a negative regulator of inflammatory responses, as genes involved in 
LPS-induced signaling have been identified as targets of miR-155 (148). Thus, miRNA can have 
multifunctional roles and harbor both positive and negative effects on immune responses.  
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1.12.2 MiR-29b 
The miR-29 family is composed of miR-29a, -29b, and 29-c, and all contain identical 
seed regions, important for mediating the specificity for their targets. Because they harbor the 
same seed sequence, it is thought that the range of targets is largely overlapping. Interestingly 
though, members in this family have been shown to differentially regulate target genes, 
suggesting the possibility that the specific cellular environment or cell type is important in 
regulating the outcome of miR-29b expression (149, 150). The miR-29 family contains multiple 
transcription factor binding sites that may regulate expression, however, the exact mechanism(s) 
driving differential expression of miR-29a/b/c remains elusive. It is thought that perhaps in 
addition to regulation by transcription factors, miR-29a/b/c expression may also be influenced by 
rate of decay, as well as alternative splicing of primary RNA (151, 152). Functionally, miR-29 
members are particularly interesting. Similar to other miRNAs, they can modulate gene 
expression directly, through the direct targeting of 3’UTRs with their complimentary miRNA 
seed regions and often result in decreased target gene expression; however, they are also able to 
regulate expression indirectly by initially targeting de novo DNA methyltransferases and 
blocking the DNA methylation of various genes (153, 154). The latter supports the 
demethylation of genes, resulting in their aberrantly induced expression. 
MiR-29 has been associated with mediating multiple cellular effects, including regulation 
of the extracellular matrix via directly targeting the 3’UTR of extracellular matrix proteins, e.g. 
collagen, laminin g1, elastin, and integrin β1, and the development of fibrosis in multiple organs 
(heart, kidney, lung) (149). Further highlighting their importance in disease models, miR-29s 
have been implicated to play important tumor suppressor roles in cancer as they regulate 
apoptosis, cell proliferation and differentiation.  Expression levels of miR-29s were reported to 
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correlate with cancer models and progression, as decreased expression of miR-29s were 
associated with higher incidence of cancer relapse (155, 156).  This is not entirely surprising as 
many miR-29 targets are known oncogenes.  Because miRNA expression can be modulated and 
increased miR-29 expression may improve prognosis, it is an attractive therapeutic avenue for 
cancer therapy and studies implementing exogenous miR-29 members in acute myeloid leukemia 
models show promising results (157). 
 Recently, a role for miR-29 members in regulating immune responses has been 
suggested. It is well known that macrophage activation as well as T helper 1 (Th1) cell 
development is supported by interferon-gamma production to enhance immune responses against 
intracellular pathogens.  In a study performed by Ma et al., IFNγ production indirectly correlated 
with miR-29b expression.  Transgenic mice were developed that express a ‘sponge’ target that 
effectively competes with miR-29 target genes and thus sequestered miR-29b preventing 
function in vivo.  These mice exhibited lower L. monocytogenes burden, enhanced Th1 
responses, and higher serum IFNγ (158).    
 
1.13 PMN Extracellular Traps (NETs) 
Elie Metchnikoff initially observed the existence of PMNs, which he previously called 
microphagocytes. Since then, PMN immune function was primarily attributed to the engulfment 
and killing of pathogens through the unloading of the antimicrobicidal and antimicrobistatic 
granular proteins into the pathogen-containing vacuole (159, 160).  However, we now know that 
PMNs harbor an additional immune mechanism. Originally discovered in 2004 by Brinkmann et 
al., NETs are a fibrous network composed of chromatin and nucleic and cytoplasmic proteins 
with antimicrobial properties (160).  NETosis is a novel form of cell death, distinct from 
  33 
apoptosis and necrosis (161), whereby NETs are released and can trap and kill pathogens 
extracellularly, like S. aureus (160).  Similarly, NETs were productive in preventing 
dissemination of S. pneumoniae from the lung, but production of endogenous DNases and 
catalases by a variety of Gram-positive bacteria confer protection against extensive entrapment 
by facilitating the degradation of NETs (161-164). 
 
The following chapters will detail the methods (Chapter 2) utilized and the results 
obtained in addressing several pressing questions regarding the regulation of innate immune 
function post-BMT. 
1) Chapter 3: Why are pathogens differentially phagocytized by AMs post-BMT and is this 
effect mediated by elevated PGE2 post-BMT?  Results of this chapter have been 
published in the J.Immunol. 
2) Chapter 4: Is the upregulation of PGE2 synthesis post-BMT regulated by 
hypomethylation of the COX-2 gene? Results of this chapter have been published in the 
J. Immunol. 
3) Chapter 5: How does TGF-β production post-BMT regulate the expression of COX-2? 
Results of this chapter have been submitted for publication. 
4) Chapter 6: Finally, as PGE2 is known to impact PMN killing, but not PMN phagocytosis, 
is this effect mediated by alteration of NETosis? Results of this chapter have been 
prepared for submission.
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Chapter 2: 
Materials and Methods
 
2.1 Animals 
Wild type C57BL/6 (B6), SRAI/II-/- mice (C57BL/6 background), and wild type 
BALB/c were obtained from The Jackson Laboratory (Bar Harbor, Maine). Mice expressing 
dominant-negative TGF-β receptor II (TGF-βRII) under the CD11c promoter (CD11cdnR) in the 
C57BL/6 background were provided by Dr. Laouar (University of Michigan) (165, 166).  Mice 
were bred and housed under specific pathogen-free conditions and monitored daily by veterinary 
staff. All mice were euthanized by CO2 asphyxiation. The University of Michigan Committee on 
the Use and Care of Animals approved these experiments.  
2.2 Human Subjects 
Bronchoalveolar lavage cell samples from 14 HSCT patients (both autologous and 
allogeneic) and six healthy volunteers were used in the microRNA study.  Bronchoalveolar 
lavage cells samples from 21 HSCT patients (both autologous and allogeneic) and one healthy 
volunteer were used in the PGE2 study shown in Figure 1.4 and Table 1.1. Studies and consent 
procedures were performed in accordance with the Declaration of Helsinki at the University of 
Michigan (HSCT patients) and the VA Ann Arbor Healthcare System (volunteers for miR-29b 
study) and were approved by their respective Institutional Review Boards.  All human subjects 
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gave their written informed consent before any research procedures.  Patient and healthy donor 
characteristics are outlined in Table 5.1. PMNs from four healthy volunteers (one male and three 
female) were harvested from peripheral blood and were used in the PMN extracellular traps 
study. The study outlined here was approved by the University of Michigan IRB and all human 
subjects gave a written informed consent.  
2.3 Bone Marrow Transplantation (BMT) 
Recipient mice received 13 Gy of TBI (orthovoltage x-ray source) for syngeneic (B6 
donors and recipients) or 10 GY of TBI for allogeneic (B6 donors, BALB/c recipients) BMTs. 
TBI doses were split in two fractions, 3 hours (h) apart. Whole bone marrow was harvested from 
the femur and tibia of C57Bl/6 WT or CD11cdnR donor mice and resuspended in serum-free 
medium (SFM; DMEM, 0.1% BSA, 1% penicillin-streptomycin, 1% l-glutamine, and 0.1% 
amphotericin B).  Bone marrow cells (5 × 106) were administered by tail vein injection into 
lethally irradiated C57Bl/6 recipient mice. All experiments with BMT mice were performed 5–6 
wk post-BMT. The percentage of donor-derived cells was approximately 95% ±1% in the spleen 
and 82% ±2% in the lung at this time point, as assessed by transplanting CD45.1+ bone marrow 
into C57BL/6 CD45.2+ mice (54). 
2.4 Harvesting AMs and PMNs via bronchoalveolar lavage (BAL) 
Resident AMs from mice were obtained via ex vivo lung lavage, using a previously 
described protocol (58).  Briefly, these cells were collected in lavage fluid consisting of complete 
medium (DMEM, 1% penicillin-streptomycin, 1% L-glutamine, 10% FCS, 0.1% Fungizone) and 
5 mM EDTA. PMNs were recruited into the lungs by an i.t. injection of 25 µg/mL of 
Pseudomonas-derived lipopolysaccharide (LPS) (Sigma) in 50 µL doses, diluted in saline. 
Following 18 h, PMNs were collected by ex vivo lung lavage, as described for resident AMs, or 
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by bone marrow harvest. However, cells were collected using GIBCO RPMI media with L-
glutamine, without phenol red. Red blood cells (RBCs) were lysed with 3 mL of RBC lysis 
buffer for 2 min on ice, diluted in 10 mL of DPBS, and centrifuged. Pelleted cells were 
reconstituted and enumerated by counting on a hemocytometer before plating.  
2.5 Isolation of human PMN from peripheral blood 
PMNs were isolated using a protocol provided by Carolyne Smith (Mariana Kaplan Lab). 
PMNs were harvested from the peripheral blood of four healthy human volunteers. Peripheral 
blood was layered over ficoll and spun at 1440 rpm with no acceleration and no break at room 
temperature for 20 min. The red blood cell layer (bottom layer) containing PMNs were collected 
and mixed with 20% dextran (1:2 ratio; dextran:red blood cell layer). Mixture was allowed to sit 
for 15 min at room temperature prior to the addition of PBS. Following 30 min incubation at 
room temperature, the top layer containing the PMNs were collected, PBS was added, and cells 
were spun at 1600 rpm with acceleration and brake.  RBCs in the cell pellet were removed via 
addition of 0.2% and 1.8% NaCl in sterile water and incubation at room temperature for 3 min. 
Cells were spin down at 1600 rpm, washed with PBS. Following a last spin at 1600 rpm, cells 
were dissolved in RPMI without phenol red (+L-glut). 
2.6 P. aeruginosa PAO1 and S. aureus (MRSA; USA300/NRS384) preparation and FITC 
labeling 
P. aeruginosa PAO1 and S. aureus USA300 stock were grown in tryptic soy broth and 
nutrient broth (Difco; BD), respectively. The culture concentration was determined via 
absorbance measurements as previously described (55).  For fluorescein isothiocyanate (FITC)-
labeling, a culture was centrifuged and washed two times by resuspending the pellet in 1 mL 
sterile PBS and transferring into a sterile tube.  The bacteria were heat-killed by autoclaving for 
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20 minutes and resuspended at 109 - 1010 CFU/mL in 0.1 M NaHCO3 (pH 9.2).  0.2 mg/mL FITC 
(Sigma) in DMSO was added to heat-killed P. aeruginosa or S. aureus and allowed to incubate 
in the dark for 1 h on a rocker at room temperature.  Following FITC-labeling, heat-killed P. 
aeruginosa or S. aureus were washed three times and resuspended in sterile PBS at 6 x 109 
CFU/ml.   
2.7 Intratracheal (i.t.) injection with P. aeruginosa or S. aureus 
A culture of P. aeruginosa or S. aureus was grown as described above, and an inoculum 
was prepared.  Mice were anesthetized and i.t. injected with 50 μL of inoculum to provide either 
a sublethal dose of 5 x 105 PAO1 CFU as previously described (55, 58) or a sublethal dose of 
7x107 USA300 CFU. 
2.8 Quantification of bacterial burden in the lung 
Mice were euthanized 24 h following i.t. infection with P. aeruginosa or S. aureus.  As 
previously described (58), lungs were collected from each mouse, homogenized and the bacterial 
burden of each specimen was assessed by performing a CFU assay. Data are expressed as total 
CFU per lung. 
2.9 Molecular cloning of COX-2 promoter into luciferase expression vector 
The full-length (long) murine COX-2 promoter (1179 bp) DNA as defined in (167) and a 
shorter COX-2 promoter (702 bp) was amplified using primers to create cloning sites shown in 
Table 2.12 by standard PCR from genomic DNA from AMs. The 1179 bp amplified COX-2 
promoter DNA was digested with restriction endonucleases KpnI and BglII (New England 
BioLabs, Inc.) while the 702 bp COX-2 promoter was digested with Mlu I and BglII (New 
England BioLabs, Inc.).  pGL3-basic luciferase reporter vector (Promega) was digested with 
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either KpnI and BglII or MluI and BglII.  The digested DNA and vectors were ligated with T4 
DNA ligase for 24 h.  E. coli strain MC1061 was made competent by CaCl2 and was transformed 
with ligated DNA. Positive colonies were selected with Ampicillin (100 mg/mL) and correct 
insert was verified restriction digestion and PCR. 
2.10 In vitro DNA methylation 
The COX-2 promoters , both the longer (1179 bp) and the partially deleted COX-2 
promoter (702 bp), inserted into the luciferase reporter plasmid pGL3-basic (Promega) were in 
vitro methylated with CpG methyltransferase M.SssI (New England BioLabs, Inc.) as specified 
by the manufacturer for 4 h.  DNA Methylation was confirmed by digestion with methylation-
sensitive restriction enzyme SmaI. 
2.11 In vitro transfections and dual luciferase assay 
MHS cells were transfected using Lipofectamine LTX and PLUS Reagent (Invitrogen) 
following manufacturer's optimized RAW 264.7 protocol.  Briefly, 6.2 x104 MHS cells were 
cultured in complete media containing RPMI, 10% fetal calf serum, 1% penicillin-streptomycin, 
1% L-glutamine and 0.5 mM 2-mercaptoethanol overnight.  Following 24 h, MHS cells were 
transfected with COX-2 promoter-driven luciferase reporter plasmid and pRL-SV40 in a 50:1 
ratio for a total of 0.3 μg of DNA using lipofectamine LTX and PLUS Reagent (Invitrogen). 
Transfections were performed with unmethylated or methylated, entire or partially deleted COX-
2 luciferase reporter plasmid for 48 h. Where indicated, cells were treated with 10 μg/mL LPS or 
1 ng/mL porcine TGF-β1 for 48 h (together with the transfections).     
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2.12 Real-time RT-PCR 
Gene-specific primers and probes were designed using Primer Express software (PE 
Biosystems, Foster City, CA) as published previously (58, 168).  Sequences for primers and 
probes used can be found in Table 2.2. SnoR142, snoR202, miR-155, and miR-29b expression 
were measured using TaqMan® MicroRNA Assays (Applied Biosystems/Life Technologies).  
Each AM sample was pooled from two to three mice and was run in duplicate. MicroRNA 
expression was determined by first converting TRIzol-isolated RNA into cDNA using TaqMan® 
Universal PCR Master Mix, No AmpErase® UNG (Applied Biosystems/Life Technologies, 
Foster City, CA). Real-time RT-PCR was performed on an ABI Prism 7000 thermocycler 
(Applied Biosystems). Average cycle threshold (CT) was determined for each sample and was 
normalized to β-actin or snoR142 or snoR202. Relative gene expression was calculated as 
described previously (59).  
Table 2.12. Primers and probes for semiquantitative real-time RT-PCR and PCR 
RT-PCR primers and probes Sequence (5’- 3’) 
β-Actin forward CCGTGAAAAGATGACCCAGATC 
β-Actin reverse CACAGCCTGGAGGCTACGT 
β-Actin probe TTTGAGACCTTCAACACCCCAGCCA 
COX-2 forward TGACCCCCAAGGCTCAAAT 
COX-2 reverse GAACCCAGGTCCTCGCTTATG 
COX-2 probe TTTGCCCAGCACTTCACCCACAGT 
MARCO forward CCTGGACGAGTCGGTCAGAA 
MARCO reverse CTTCAGCTCGGCCTCTGTT 
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MARCO probe CCAACGCGTCCGGATCATGGGT 
SR-AI/II forward TGAAGGACTGGGAACACTCACA 
SR-AI/II reverse CAGTAAGCCCTCTGTCTCCCTTT 
SR-AI/II probe TTCATTCAAGGGCCTCCTGGACCC 
PCR primers for cloning Sequence (5’- 3’) 
COX-2 forward long CACAGTAGGAAGGTACCCAACACTATC 
COX-2 reverse long CTGCTAGAAAGGAGATCTGAGCCTGAG 
COX-2 forward short CCGGTAGCTGTACGCGTGCTCTGAGC 
COX-2 reverse short AGATCGCAGATCTGAGCCTGAGG 
 
2.13 DNA methyltransferase or histone deacetylase inhibition 
AMs or MHS cells (an alveolar macrophage cell line) were treated with either varying 
concentrations of the methyltransferase inhibitor 5-aza-2′-deoxycytidine (Sigma) or the histone 
deacetylase (HDAC) inhibitor trichostatin A (Sigma) for 72 h. Primary AMs were initially 
stimulated with (1 ng/ml) recombinant murine GM-CSF (R&D Systems) for 24 h to promote 
proliferation before receiving the appropriate treatments for the following 72 h.  
2.14 ELISA/enzyme immunoassay 
MHS cells were cultured at 5 × 105 cells/ml in a 24-well plate for 72 h. MHS cells were 
grown in complete media for 48 h, then switched to serum-free media for 24 h. Supernatants 
were collected for enzyme immunoassay. Production of PGE2 and thromboxane B2 (TXB2; a 
metabolite of thromboxane A2 [TXA2]) was measured by enzyme immunoassay (Cayman 
Chemical), according to the manufacturer’s instructions.  
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2.15 Bisulfite conversion and pyrosequencing 
Using the DNeasy Kit (Qiagen), DNA was isolated from ∼1 × 106 cells or from 2 x105 
primary AMs previously transfected with control miRNA or miR-29b (30 nM) for 24 h. For 
DNA methylation studies from miR-transfected AMs, three wells were pooled per sample. The 
Zymo Research EZ DNA Methylation kit was used to bisulfite modify 500 ng of genomic DNA. 
Bisulfite modification was performed according to manufacturer’s instructions. Briefly, genomic 
DNA was denatured with Dilution Buffer and further treated with CT Conversion Reagent.  
Samples were processed following the alternative incubation conditions recommended by 
manufacturer whereby samples were incubated in a thermocycler under the following conditions: 
(95°C 30sec; 50°C 60 min) x 16 cycles; 4°C hold. Following bisulfite conversion, the PTGS2 
(COX-2) promoter (-449 to +70 from ATG) was PCR amplified and sequenced on a 
Pyrosequencer (Qiagen).  Amplification and sequencing primers for murine PTGS2 were 
obtained from EpigenDx, Inc, Worcester, MA (assay ADS2001 and ADS2002).  The PCR 
conditions for determining the methylation profile of the DNA using ADS2001 are as follows: 
95°C 15 min; 45 x (95°C 30 s; 54°C 30s; 72°C 30s); 72°C 5 min; 4°C hold. PCR conditions 
using ADS2002: 95°C 15 min; 45 x (95°C 30 s; 60°C 30s; 72°C 30s); 72°C 5 min; 4°C hold. 
The primers used for amplification and sequencing of CpG sites 1-6 of the COX-2 promoter 
were: Forward primer: AGATGTGGATTTTGATAGAGGATATT; Reverse primer: 
CTACCCTTAACTACCCCAAATAATAC; Sequencing primer: 
ATTTTATTAAAAATAGAAGAAA.   
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2.16 In vitro phagocytosis assay 
AMs isolated by BAL were plated at 2 x 105 cells per well in 100 μl and cultured 
overnight in complete media on a 96-well, flat-bottomed, half-area tissue culture plate (Costar). 
The following day, FITC-labeled heat-killed P. aeruginosa (prepared as described above) was 
added at 300:1 MOI.  Two h following incubation at 37ºC in dark, 50 μL of trypan blue (250 
μg/mL in 0.09 M citrate buffer solution; Sigma) was added to each well for 1 min to quench 
fluorescence of non-phagocytized FITC-labeled bacteria.  AM phagocytosis of FITC-labeled 
bacteria was measured using a microplate fluorimeter and expressed in arbitrary fluorescence 
intensity units.  For possible differences in AM adherence to tissue culture plate, data were 
normalized for cell number using a LDH Cytotoxicity Detection Kit (Roche Diagnostics) as 
previously described (58). 
2.17 Tetrazolium dye reduction assay of bacterial killing 
The ability of AMs from control and BMT mice to kill P. aeruginosa and S. aureus was 
quantified using a tetrazolium dye reduction assay, as described elsewhere (72, 169). Briefly, 
AMs from WT and BMT mice were aliquoted into duplicate 96-well plates: one experimental 
(37oC) plate and one control (4oC).  Cells from both plates were infected with IgG-opsonized P. 
aeruginosa or S. aureus (2 x 108 CFU/ml; multiplicity of infection (MOI), 50:1) for 30 min at 
37oC.  The cells on the experimental plate were washed then incubated at 37oC for 2 h while the 
cells on the control plate were washed then lysed with TSB and 0.5% saponin (Sigma) and 
placed at 4oC.  After 2 h, the cells from the experimental plate were lysed with 0.5% saponin in 
tryptic soy broth.  Both plates were then incubated at 37oC for 3 h (P. aeruginosa) or 4 h (S. 
aureus).  Five mg/ml of MTT (Sigma) was added to each plate and incubated for 30 min or until 
purple precipitate was visible.  Solubilization solution was added to dissolve formazan salts and 
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the absorbance was read at 595 nm.  Results were expressed as percentage of survival of ingested 
bacteria normalized to the percent of control, where the A595 experiment values were divided by 
the average of the A595 control values. Survival of ingested bacteria = (A595 experimental 
plate/A595 control plate) x 100%. The results were expressed as “percent of control” to indicate 
the percentage of survival of ingested bacteria normalized to the percentage of control. 
2.18 Flow Cytometry 
5 × 105 primary AMs from untransplanted control and BMT mice were stained for flow 
cytometry using a primary antibody (2 μg/mL) against the cell surface receptor MARCO (Hycult 
Biotech) after incubation with anti-CD16/CD32 (FcBlock; BD Biosciences).  Fluorochrome-
conjugated secondary antibody, donkey anti-rat PE, (Jackson Immunoresearch) was used to 
detect the primary antibody.  Cells were resuspended in PBS and fixed with 4% 
paraformaldehyde. Data were analyzed using flow cytometry analysis software (FlowJo, version 
7.5; Tree Star, Inc., Ashland, OR). 
2.19 In vitro miRNA transfection 
Primary AMs were harvested by BAL from untransplanted C57BL/6 mice as described 
above. 2x105 cells were transfected with the antagomir of miR-155 (Dharmacon/Thermo Fisher 
Scientific) or anti-miR™ miRNA inhibitor negative control #1 (Ambion®/Life Technologies) 
for 24 h when measuring mRNA expression and 48 h for phagocytosis assays. Transfections 
were performed using Lipofectamine® RNAiMAX Reagent (Invitrogen/Life Technologies) as 
described by the manufacturer. Briefly, antagomir or control miR were diluted in Opti-MEM® I 
Reduced Serum Media (Life Technologies) and mixed with Lipofectamine® RNAiMAX 
Reagent prior to transfecting the cells. 
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2.20 Sytox Green Fluorescence Assays 
PMN extracellular traps were quantified using a cell-impermeable nucleic acid dye, 
Sytox Green (Invitrogen). The protocol was generously provided by Dr. Mariana Kaplan and 
modified for adequate measurement of NETosis in our model. Briefly, PMNs were recruited into 
the lungs as described above. Using a Costar black, clear bottom, non-treated, flat bottom 96-
well plate, 100,000 cells in 200 μL of RPMI 1640 without Phenol Red were plated for 20 min at 
37°C 5% CO2. Following removal of non-adherent cells, treatments were added with 0.2 μM 
Sytox to the adhered cells for 5 h (mice) or 3 h (human). One hundred microliters of 4% 
paraformaldehyde was carefully added to the plate and the plate was stored at 4°C overnight, 
covered with aluminum foil (to protect from the light). The next day, the plate was brought to 
room temperature, spun down to remove air bubbles, and fluorescence was measured at an 
excitation wavelength of 485 nm, and an emission wavelength of 525 nm. Sytox assays do not 
distinguish NETs from other types of cell death. To date, no publications have described a Sytox 
assay that is able to do this. Thus, all Sytox assays should be confirmed with 
immunofluorescence studies.   
2.21 Immunofluorescence studies 
The immunofluorescence protocol for the visual detection of NETs was provided by Dr. 
Mariana Kaplan. Briefly, PMNs from mice or humans were collected as described above. Using 
coverslips previously coated with 0.001% poly-lysine for 20 min at room temperature, 200,000 
cells in RPMI 1640 without phenol red were seeded for 20 min at 37°C 5% CO2. Treatments 
were added directly for 7 h (mice) or 3 h (human), fixed with 4% paraformaldehyde, washed 
with PBS, and blocked with 0.2% gelatin in PBS overnight at 4 °C.  Primary antibody 
(myeloperoxidase, MPO, 1:500; PMN elastase, NE, 1:100) were diluted in blocking solution and 
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incubated for 30 min. Following a washing step, secondary antibody (1:250; diluted in blocking 
solution) was added for 30 min at 37°C, 5% CO2.  Following two washing steps, Hoescht, 
diluted in PBS (1:1000), was added for 10 min at room temperature. Upon removal of Hoescht 
and a washing step, the coverslips were allowed to dry prior to their placement onto a slide 
containing a drop of Prolong Gold. Slides were allowed to dry overnight, prior to any 
microscope analysis. 
2.22 Western Blot Analysis for NETs 
PMNs were recruited into the lung as described above (Section 2.4). PMNs were plated at  
200,000 cells in 300 µL (per well) Gibco RPMI with L-glutamine, without phenol red in a 24 
well plate.  PMNs receiving PGE2 treatment were pretreated with PGE2 during adherence. 
Following 30 min adherence and pretreatment, supernatants were pulled and treatments were 
added for 5 h. Cells were incubated at 37°C with 5% CO2.  Following 5 h, supernatants were 
pulled and 30 µg of DNase 1 (from bovine pancreas; Sigma) was added (DNase was made fresh 
each time and resuspended in 50 mM Tris-HCl, 10 mM Mg Cl, pH=7.5 as recommended by 
Sigma). Supernatants were incubated with DNase 1 for 1 h at 37°C. Following DNase treatment, 
acetone precipitation was performed as described by Thermo Scientific. Briefly, cold (-20°C) 
acetone was added to each sample at four times the volume (1200 µL of acetone was added to 
each 300 µL sample). Samples were vortexed and incubated overnight at -20°C.  The following 
day, samples were centrifuged for 10 min at 15,000 x g.  Supernatants were decanted carefully so 
as not to dislodge the pellet. The pellet was incubated at room temperature for 5 min, uncapped, 
to allow for the evaporation of leftover acetone. Pellets were dissolved in Pierce RIPA buffer 
(Thermo).  To determine protein concentrations, Pierce BCA protein assay kit (Thermo) was 
used. Samples were diluted to a final concentration of 20 µg of total protein per sample with 6x 
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laemmli SDS loading buffer containing β-mercaptoethanol. Following electrophoresis, a wet 
transfer was performed using a PVDF membrane. Blocking was performed using 5% milk-TBS-
tween for 1 h at room temperature. The primary polyclonal rabbit anti-human myeloperoxidase 
(Dako, Denmark) antibody was used at 1:500 and incubated with the membrane overnight in 5% 
milk-TBS-tween at 4°C. Secondary antibody was incubated at 1:250 for 1 h rocking in 5% milk-
TBS-tween at room temperature. Chemiluminescence was determined by 3 min incubation with 
working solution of super signal west pico chemiluminscence substrate (Thermo) in a 1:1 ratio. 
Detection was recorded using autoradiography films. 
2.23 Pharmacological Agents 
Indomethacin was used as a non-selective cyclooxygenase inhibitor (Sigma).  PF-
04418948, a specific EP2 antagonist was generously supplied by Pfizer through their compound 
transfer program (170, 171). The protein kinase A (PKA)-specific cAMP analog 6-Bnz-cAMP 
and the guanine nucleotide exchange protein (Epac)-1-specific camp analog 8-pCPT-2’-O-Me-
cAMP were purchased from Biolog Life Science Institute, diluted in dimethyl sufloxide (DMSO) 
and were used at 500 µM doses. 
2.24 Statistical analysis 
To determine statistical significance, the GraphPad Prism 6.0 statistical program was 
utilized. Comparisons between two experimental groups were determined using the Student t test 
and error bars denote the standard error of the mean. Comparison between three or more groups 
utilized one-way ANOVA analyses followed by a Bonferroni post-test and standard error of the 
mean were graphed.  A p value <0.05 was considered statistically significant. 
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Chapter 3: 
Prostaglandin E2-induced changes in alveolar macrophage scavenger receptor profiles 
differentially alter phagocytosis of P. aeruginosa and S. aureus post-bone marrow 
transplantation
 
3.1 Background 
HSCT is a widely used treatment to address a variety of inherited and genetic disorders in 
patients. Though effective, HSCT patients show increased susceptibility to numerous 
complications, many involving the lung, in the months to years following treatment (27, 28, 
172). Infectious and non-infectious complications arise in HSCT recipients despite differences in 
stem cell source (172, 173). Autopsy reports found 80-89% pulmonary complication rates in 
both allogeneic and autologous HSCT patients (21, 173) and a recent study found that pulmonary 
complications manifested in more than 25% of autologous HSCT recipients, with the majority of 
the complications being infectious (28).  
Bacterial pulmonary complications in HSCT recipients manifest at different times post-
transplant and are varied in pathogen species (Gram-positive vs. Gram-negative).  Although 
allogeneic transplant recipients develop pulmonary infectious complications more frequently 
(potentially due to barrier disruptions secondary to GvHD), autologous HSCT patients also 
experience infectious complications and there is no difference in the types of infections that 
manifest in autologous and allogeneic HSCT recipients in the first 30 days post-transplant (pre-
engraftment phase) (23). While it is not surprising that infections are common in the pre-
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engraftment phase (174), or in allogeneic HSCT patients on immunosuppressive therapy, it is 
less understood why infections have also been reported to occur in autologous HSCT recipients 
in the late post-transplant phase (175).  Both Gram-negative and Gram-positive infections can be 
problematic in HSCT patients.  Prophylactic antibiotics have lowered the incidence of 
Pseudomonas aeruginosa infection, but invasive Pseudomonas remains a concern in this 
population (52, 176).  Additionally, infections caused by Gram-positive bacteria, particularly the 
Streptococcus and Staphylococcus species, have risen as predominant infections in HSCT 
recipients (23). 
 In order to better understand the immunological alterations that may characterize innate 
immune cells in the lung and predispose the host to bacterial infection post-engraftment, our lab 
developed a syngeneic (syn) BMT animal model. This model allows for an investigation of 
transplant-related immune alterations that are not caused by immunosuppressive drugs or 
impaired barrier function secondary to graft vs. host disease.  We previously demonstrated that 
C57BL/6 mice that have received a syn BMT are more susceptible to infection by Gram-negative 
P. aeruginosa (55). Increased susceptibility to P. aeruginosa was related to overproduction of 
PGE2 post-BMT (58). Elevations of PGE2 post-BMT impaired AM phagocytosis and killing of 
ingested bacteria, and also limited PMN-mediated killing (58).  Some of the effects of PGE2 
signaling on AMs post-BMT were to upregulate IRAK-M and activation of PTEN (96, 97).  
These changes limited inflammatory cytokine production and non-opsonized and opsonized 
phagocytosis of P. aeruginosa as well as bacterial killing. 
The current studies were undertaken to determine whether syn BMT mice also displayed 
increased susceptibility to a Gram-positive, S. aureus infection and if so, whether the 
mechanisms of susceptibility were related to PGE2 production and impaired phagocytosis 
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mediated by SRs.  Similar to our previous studies with P. aeruginosa, we find syn BMT mice are 
more susceptible to S. aureus and this is related to overproduction of PGE2.  Surprisingly 
however, phagocytosis of S. aureus is enhanced, not diminished post-BMT.  Our mechanistic 
studies identify PGE2-induced changes, including alterations in miRNAs which alter the 
functional profile of scavenger receptors to differentially regulate phagocytosis.  Despite the fact 
that phagocytosis of S. aureus is improved post-BMT, bacterial killing is impaired, explaining 
the overall defect in host defense. 
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3.2 Results 
Syn BMT mice are more susceptible to S. aureus 
 To determine the susceptibility of BMT mice to S. aureus, untransplanted (control) and 
syn BMT mice were i.t. injected with a methicillin-resistant strain of S. aureus or with the PAO1 
strain of P. aeruginosa for comparison. Lungs were harvested 24 h post-infection for CFU 
analysis.  BMT mice were more susceptible to both P. aeruginosa (Figure 3.1A) and S. aureus 
(Figure 3.1B) pulmonary infections. 
 
Figure 3.1. Syn BMT are more susceptible to P. aeruginosa and S. aureus. Untransplanted 
control (Ctrl) or syn BMT mice received (A) P. aeruginosa (n=5-6/group) or (B) S. aureus 
(n=10/group) i.t. and lungs were collected for CFU analysis 24 h later; *p<0.05, ***p<0.001. 
 
 
Syn BMT AMs exhibit a defect in phagocytosis of P. aeruginosa, but enhanced phagocytosis of S. 
aureus 
 Because AMs are the predominant immune cell in the lung during an initial infection 
(177), we hypothesized that AM function was compromised in a BMT setting. Using AMs 
harvested from BAL of control and syn BMT mice, phagocytosis of P. aeruginosa by AMs was 
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measured. As we have previously published (58), syn BMT AMs exhibited decreased 
phagocytosis of FITC-P. aeruginosa compared to controls (Figure 3.2A).   Surprisingly, syn 
BMT AMs incubated with FITC-S. aureus displayed augmented phagocytosis compared to 
controls (Figure 3.2B). 
 
Figure 3.2. Syn BMT AMs exhibit defective phagocytosis of P. aeruginosa but not S. aureus. 
Primary AMs were harvested and phagocytosis of (A) FITC-P. aeruginosa or (B) FITC-S. aureus 
was determined (n=5-10 per group). Data are normalized to LDH levels per well to standardize 
for cell numbers. Results are presented relative to the average of untransplanted control values 
set to 100%; ***p<0.001. 
 
SR profiles are altered post-BMT 
 Class A SRs are pattern recognition receptors reported to play important roles in the 
recognition of non-opsonized Gram-positive and –negative bacteria and endogenous ligands 
(178). Studies have shown that MARCO, a class A SR, is important for in vivo host response 
against Streptococcus pneumoniae, a Gram-positive bacterium (105), and SR-A I/II have been 
previously reported to recognize S. aureus (179). However, it remains unclear which SR is 
important for recognition of P. aeruginosa in the lung.  As MARCO and SRAI/II have been 
implicated in the recognition and initiation of an immune response within macrophages (178), 
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we wanted to determine whether the difference in phagocytosis between P. aeruginosa and S. 
aureus could be explained by an alteration in SR expression on AMs.  Using RNA isolated from 
control and BMT AMs, MARCO mRNA expression decreased post-BMT (Figure 3.3A, left) 
while SR-AI/II mRNA increased (Figure 3.3B) compared to control. A decrease in MARCO 
surface expression was confirmed by flow cytometry (Figure 3.3A, right), correlating with 
MARCO mRNA analysis.  Commercially available antibodies against SRAI/II do not recognize 
the allele in the C57BL/6 mice, precluding our ability to measure protein expression of this 
receptor by flow cytometry in our model. 
 
Figure 3.3. MARCO is decreased on syn BMT AMs while SR-AI/II is increased. AMs were 
harvested from untransplanted control B6 and syn BMT mice and MARCO (A, left) mRNA was 
detected by real-time RT-PCR. Expression of one control AM sample was set to n=1 for 
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comparisons, n=3. (A, right) MARCO protein levels were detected by flow cytometry, n=3.  (B) 
SR-AI/II mRNA expression was measured by real-time RT-PCR. Analysis was performed as 
described with MARCO above, n=3. **p<.01, ***p<.001. 
MARCO is negatively regulated by PGE2 and is important for P. aeruginosa phagocytosis 
To further understand how an altered SR profile on AMs post-BMT contributes to AM 
function, control AMs were treated with class A SR inhibitors and AM phagocytic capacity 
against non-opsonized P. aeruginosa was determined. Interestingly, soluble MARCO 
(sMARCO) inhibited internalization of P. aeruginosa significantly compared to no treatment (no 
txt) and treatment with control compounds poly C and chondroitin sulfate (ChSO4) (Figure 
3.4A). Furthermore, the decrease in AM phagocytosis induced by sMARCO was comparable to 
the inhibition noted with the pan class A SR inhibitors [fucoidan and polyinosinic acid (poly I)], 
suggesting that MARCO may be the primary SR for P. aeruginosa phagocytosis by AMs.  
Cytochalasin D (cyto D) is an inhibitor of actin polymerization and was included as a negative 
control for phagocytosis.  Although scavenger receptor with C-type lectin (SRCL) mRNA 
expression decreased in syn BMT AMs (data not shown), blocking SRCL did not affect uptake 
of non-opsonized P. aeruginosa in control AMs (Figure 3.4A) suggesting that this receptor is not 
used for P. aeruginosa uptake. Soluble mannan did not inhibit P. aeruginosa engulfment either, 
suggesting the mannose receptor is not involved in recognition of P. aeruginosa (not shown).  
Finally, Figure 3.4B shows that control AMs treated with sMARCO exhibited a similar defect in 
engulfment of P. aeruginosa as syn BMT AMs when compared to untreated control AMs. This 
highlights MARCO as the dominant P. aeruginosa-recognizing SR in AMs.   
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Figure 3.4. MARCO is necessary for P. aeruginosa phagocytosis and expression is regulated 
by PGE2 post-BMT.  (A) AMs were harvested and pretreated with pan class A SR inhibitors 
(fucoidin, poly I and DxSO4) or the control compounds poly C and ChSO4, as well as with anti-
SRCL or soluble MARCO and phagocytosis of P. aeruginosa was measured. Cytochalasin D 
(cyto D) inhibits phagocytosis by limiting actin polymerization. Values are presented relative to 
the no treatment (no txt) control set to 100% for one sample; n=3 per group. (B) Phagocytic 
ability of control, soluble MARCO-treated control, or syn BMT AMs was measured. Results are 
presented relative to the average of untransplanted control values set to 100%, n=3.  (C) AMs 
from control mice were treated for 24 h with 1µM PGE2 or control DMSO (veh).  MARCO 
mRNA levels were determined by real-time RT-PCR.  Expression of one control AM sample was 
set to n=1 for comparisons; n=3. *p<0.05, ***p<0.001. 
 
Our laboratory has previously shown that the defect in AMs post-BMT is, in part, 
mediated by upregulated COX-2 expression and overproduction of PGE2.  Treatment with 
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indomethacin, a COX inhibitor, rescues host defense in BMT mice in vivo and restores the 
ability of BMT AMs to phagocytose P. aeruginosa (58). However, whether decreased MARCO 
post-BMT is driven by PGE2 remains unknown. Therefore, untransplanted AMs were treated 
with 1 μM PGE2 or vehicle DMSO in vitro. Following 24 h, RNA was harvested and real-time 
RT-PCR analysis of MARCO mRNA expression indicated that decreased MARCO expression is 
PGE2-driven (Figure 3.4C).   
 
SR-AI/II mediates phagocytosis of S. aureus, but not P. aeruginosa by AMs 
 Syn BMT AMs exhibited increased S. aureus phagocytosis compared to control AMs 
(Figure 3.2A) and SR-AI/II mRNA expression was increased post-BMT (Figure 3.3B). To 
determine whether the observed AM phagocytosis of S. aureus may be due to increased SR-AI/II 
on macrophages following transplant, chinese hamster ovary (CHO) cells (which do not express 
class A SRs) were transfected with SR-AI.  Transfected and untransfected CHO cells were 
measured for internalization of S. aureus. SR-AI-transfected CHO cells were more efficient at 
phagocytizing S. aureus than untransfected CHO cells (Figure 3.5A left), while P. aeruginosa 
internalization was unaffected by SR-AI transfection in CHO cells (Figure 3.5A right). These 
data verify that SR-AI is utilized for the recognition of S. aureus and explain why SR-A 
elevations do not influence P. aeruginosa uptake.  To confirm this result post-BMT, AMs 
harvested from BMT mice that received HSCs from SR-AI/II-/- mice (SR-AI/II-/- BMT) were 
unable to phagocytize S. aureus compared to WT BMT AMs (Figure 3.5B). 
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Figure 3.5. SRAI/II is important for AM phagocytosis of S. aureus. (A) Phagocytosis of 
FITC-S. aureus (left) or FITC-P. aeruginosa (right) by control CHO or SR-A-I-transfected CHO 
cells was measured. Results are presented relative to the average of control CHO values set to 
100%; n=12/group; (B) Phagocytosis of FITC-S. aureus by WT BMT (n=4) or SR-A-/- BMT 
(n=3) AMs was measured. Data are normalized to LDH levels per well. Results are presented 
relative to the average of WT BMT values set to 100%; (C) SR-AI/II expression measured in 
AMs (2x10
5
) treated with 10 μM of PGE2 or DMSO (Veh) for 24 h; n=3, **p<.01, ***p<.001. 
SR-AI/II negatively regulates MARCO expression  
 The fact that the phagocytic ability of AMs from SR-AI/II-/- BMT mice was not 
completely abolished (Figure 3.5B) suggested that there may be some compensatory 
upregulation of MARCO expression in these mice which allowed phagocytosis of S. aureus.  
MARCO has previously been shown to mediate S. aureus uptake (180, 181).  To determine if 
this were true, we compared the percent of MARCO-expressing AMs in untransplanted WT and 
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SR-AI/II-/- mice (Figure 3.6A).  Interestingly, loss of SR-AI/II resulted in compensatory 
upregulation of MARCO, suggesting a possible negative role of SR-AI/II on MARCO 
expression.  To study the effect of this in vivo, we created all combinations of chimeric BMT 
mice.  In Figure 3.6B, untransplanted control C57BL/6 mice or SR-AI/II-/- mice were compared 
to BMT mice created with the following donor→host combinations:  WT→WT, SR-AI/II-/-
→SR-AI/II-/- or SR-AI/II-/-→WT.  When looking at in vivo host defense against S. aureus, non-
transplanted SR-AI/II-/- mice had similar lung CFU as control C57BL/6 mice, presumably 
reflecting adequate MARCO expression in each strain at baseline.  All BMT combinations were 
more susceptible than untransplanted mice, but there was no difference between the BMT 
groups.  This suggests that uptake of S. aureus is mediated by either SR-AI/II or MARCO post-
BMT as long as either receptor is available. In contrast, when looking at in vivo responses to P. 
aeruginosa, a bacterium that can be recognized by MARCO but not SR-A, the SR-AI/II-/-→WT 
mice (which likely have a compensatory MARCO upregulation) showed decreased lung and 
blood CFU burden when compared to the WT→WT BMT mice.  There was no difference 
between WT→WT and WT→SR-AI/II-/- BMT mice. 
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Figure 3.6. SR-AI/II negatively regulates MARCO expression. (A) MARCO protein 
expression was determined on AMs from untransplanted SR-AI/II−/− mice by flow cytometry (n 
= 3 individual mice). Untransplanted B6 (Ctrl), untransplanted SR-AI/II−/−, or chimeric BMT 
mice were challenged in vivo with S. aureus (n = 3–4) (B) or P. aeruginosa (n = 4–5) (C) via i.t. 
injection 24 h prior to lung and blood harvest for CFU analysis. *p < 0.05, **p < 0.01, ***p < 
0.001. 
SR-AI/II expression is regulated by PGE2 and miR-155 post-BMT 
Figure 3.5 suggests SR-A plays a prominent role in the recognition and phagocytosis of 
S. aureus. However, why SR-AI/II is upregulated post-BMT is unclear. To determine whether 
PGE2 signaling could upregulate SR-AI/II, control AMs were treated with PGE2 in vitro and SR-
AI/II mRNA expression was analyzed by real-time RT-PCR.  Figure 3.7A demonstrates that 
PGE2 signaling increases SR-AI/II mRNA expression. Elevations in SR-AI/II mRNA in AMs 
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post-BMT (Figure 3.3B)(which have a high basal PGE2 production (58)) and in exogenous 
PGE2-treated macrophages (Figure 3.7A), suggest that changes in the transcriptional machinery 
or actions of key microRNAs indeed play a role in PGE2-enhanced SR-AI/II expression. To our 
knowledge, this receptor does not have a cyclic AMP responsive binding element (CREB) (the 
main transcription factor induced by cAMP) secondary to PGE2 signaling within the promoter 
region. Rather, SR-A type I contains a predicted target sequence in its 3’ UTR for miR-155 
(TargetScan). Thus, we hypothesized that miRNAs are involved in SR regulation post-BMT.  
Since SR-AI/II mRNA expression increased post-BMT and PGE2 treatment, the data suggested 
the loss of a regulatory miRNA.  
Analysis of miRNA expression profiles with a focused miRNA array revealed miR-155 
as the only miRNA significantly downregulated (Table 3.1). To confirm that miR-155 was in 
fact decreased after BMT, miR-155 expression was determined by real-time RT-PCR using miR-
155-specific primers. Our data show that there was a 6-fold decrease in miR-155 expression in 
syn BMT (Figure 3.7B) correlating well with the PCR array data. To determine whether the 
decrease in miR-155 expression was related to overproduction of PGE2 in the lung after BMT, 
control AMs were harvested and treated with 10 μM PGE2 for 24 h. MiR-155 mRNA expression 
decreased upon treatment with PGE2 compared to AMs treated with DMSO (vehicle; Veh) 
control (Figure 3.7C). These data suggest that PGE2 can negatively regulate miR-155 and it is 
likely that overexpression of PGE2 in the lung following BMT is acting to inhibit miR-155. 
However, studies blocking PGE2 (EP2 antagonist) in BMT AMs and then measuring miR-155 
would be needed to confirm that PGE2 signaling is promoting downregulation of this miRNA.  
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Figure 3.7. miR-155 mRNA expression is decreased in syn BMT AMs. (A) SR-AI/II 
expression was measured in AMs treated with10 μM PGE2 or DMSO (Veh) for 24 h (n=3). 
Expression of one control AM samples was set to n=1 for comparisons. (B) miR-155 expression 
was measured by real-time RT-PCR in syn BMT AMs (n=2 samples pooled from multiple mice). 
Expression was normalized to snoRNA142 and one control AM sample was set to n=1 for 
comparison. (C) Primary AMs were treated with 10 μM PGE2 or control DMSO (Veh) for 24 h 
prior to RNA isolation and cDNA conversion. miR-155 expression was compared to snoR142 
(n=2 samples pooled from multiple mice); *p<0.05, ***p<0.001. 
 
MiR-155 regulates SR-AI/II expression and S. aureus phagocytosis 
Because miR-155 is decreased post-BMT, regulation of SR-AI/II by miR-155 was further 
explored. An antagomir of miR-155 (anti-miR-155) was transfected into control AMs to inhibit 
miR-155 endogenous expression. SR-AI/II mRNA expression was increased upon transfection of 
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anti-miR-155 compared to cells transfected with a control antisense oligomer (anti-miR) (Figure 
3.8A). As SR-AI/II was shown in Figure 3.5 to be important for S. aureus internalization, we 
were interested in understanding whether a decrease in miR-155 would have a functional effect 
on S. aureus internalization. AMs transfected with anti-miR-155 at increasing concentrations 
were measured for their ability to phagocytize S. aureus. Figure 3.8B shows S. aureus 
internalization increased dose-dependently with anti-miR-155.  
 
Figure 3.8. Anti-miR-155-transfected AMs exhibit increased expression of SR-AI/II and 
increased phagocytosis of FITC-SA . (A) Primary AMs were transfected with either control 
anti-miR (10 nM) or anti-miR-155 (2 or 10 nM) for 24 h prior to harvesting RNA. SR-AI/II 
mRNA expression was determined by real-time RT-PCR and the expression of one control AM 
sample was set to n=1 for comparison; n=3-4 from 2 combined experiments. (B) Primary AMs 
were transfected with either control anti-miR (10 nM) or anti-miR-155 (2 or 10 nM) for 48 h 
prior to the two h incubation with FITC-SA for phagocytosis measurement. Values are 
normalized to LDH levels per well. Results are presented relative to the average of control values 
set to 100%; n=3-4; *p<0.05, **p<0.01. 
 
Syn BMT AMs are compromised in intracellular killing of P. aeruginosa and S. aureus 
Bacterial clearance by AMs relies not only on phagocytosis of the pathogen, but also on 
intracellular killing of the organism. While a defect in phagocytosis, as shown in Figure 3.2A, 
would increase susceptibility to P. aeruginosa, AMs collected from syn BMTs are also unable to 
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kill P. aeruginosa (Figure 3.9A) as we have previously published (58). Because the BMT mice 
are more susceptible to S. aureus in vivo (Figure 3.1B), yet display enhanced phagocytosis of this 
Gram-positive bacteria (Figure 3.2B), we examined the ability of BMT AMs to kill ingested S. 
aureus and found that killing of this pathogen was impaired in syn BMT AMs when compared to 
control AMs (Figure 3.9B).  Thus, killing defects likely account for the in vivo susceptibility to 
infection despite enhanced phagocytosis.  Taken together, it is interesting to speculate that 
because both phagocytosis and killing are defective for P. aeruginosa, this could explain the 
approximately 4-log increase in bacterial susceptibility to this pathogen in BMT mice in vivo, 
whereas the improved phagocytosis of S. aureus moderates the killing defect to account for an 
approximate 1 log difference in susceptibility to this pathogen in BMT mice in vivo. 
 
 
Figure 3.9. Syn BMT mice have defective killing of P. aeruginosa and S. aureus. Primary 
AMs from untransplanted control B6 and syn BMT mice were assessed for killing of serum-
opsonized (A) P. aeruginosa (n=8-10) and (B) S. aureus (n=4-6). ***p<0.001.  
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3.3 Discussion 
 Syn BMT mice show increased in vivo susceptibility to both S. aureus and P. aeruginosa, 
with the latter observations confirming previously published data (55, 58).  While this impaired 
host response can be explained by an inability of BMT AMs to engulf P. aeruginosa, the same is 
not true with S. aureus. In fact, BMT AMs exhibit enhanced phagocytosis of S. aureus.  This 
difference suggested that receptors mediating phagocytosis may have been altered following 
transplantation.   Although MARCO and SR-AI/II have both been reported to have the ability of 
recognizing Gram-positive and –negative bacteria (105, 179, 180, 182) and SR-AI/II has 
previously been linked to recognition of S. aureus (179), it was unclear which receptor was 
important for P. aeruginosa in control cells, and nothing was known about the regulation of 
these SRs post-BMT. Here, we show that MARCO is significantly downregulated at both the 
mRNA and protein levels, while SR-AI/II mRNA expression is increased post-BMT. These data 
indicate that MARCO is important for P. aeruginosa internalization as elevated levels of SR-
AI/II were unable to rescue phagocytosis of this Gram-negative pathogen in BMT AMs or CHO 
cells. This observation was further supported by the finding that control AMs pre-treated with 
soluble MARCO were unable to phagocytize P. aeruginosa as efficiently.    
A surprising result was the enhanced phagocytosis of S. aureus given that BMT mice 
were more susceptible to infection in vivo. As SR-AI/II can regulate S. aureus phagocytosis 
(179), elevations in SR-AI/II may explain this result.   Here we show that CHO cells expressing 
SR-AI only, were able to phagocytize S. aureus but not P. aeruginosa.  Furthermore, recipient 
mice reconstituted with SR-AI/II-/- donor marrow showed a reduction in S. aureus phagocytosis 
when compared to mice transplanted with wild-type (C57BL/6) marrow.  These data support the 
importance of SR-AI/II for S. aureus and MARCO for P. aeruginosa phagocytosis.  
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Interestingly, the fact that phagocytosis of S. aureus in the SR-AI/II-/- BMT mice was not 
completely abolished suggested there may be some compensatory upregulation of MARCO in 
these mice as MARCO has been shown to recognize S. aureus (180, 181).  These data highlight 
an interesting inhibitory role of SR-AI/II on MARCO expression. SR-AI/II-/- untransplanted 
mice have a higher percentage of MARCO positive cells in the absence of infection. Therefore, it 
is also possible that the overexpression of SR-AI/II observed post-BMT may contribute to the 
decreased expression of MARCO in addition to the PGE2 signaling.  We believe the inhibitory 
effects of SR-AI/II on MARCO may not be immediate as transfection of the anti-miR-155 which 
upregulated SR-AI/II expression within 48 h did not yet alter MARCO expression, whereas 
PGE2 stimulation reduced MARCO in 24 h.  Ultimately, SR-AI/II-/- BMT mice may upregulate 
MARCO to improve their host defense against both pathogens, which is consistent with the 
observations in.  The co-regulation of these receptors is complex, but on the whole our in vivo 
results are consistent with the conclusion that MARCO is uniquely responsible for P. aeruginosa 
uptake while S. aureus can be recognized by either MARCO or SRAI/II.  Our findings of SR-
AI/II inhibition of MARCO expression are also consistent with previously published data that 
suggest SR-AI/II may have an inhibitory role on inflammatory responses (183, 184).  
MicroRNA analysis of BMT AMs indicated that altered miRNA expression may be 
responsible for the upregulation of SRAI/II post-BMT.  Specifically, miR-155 expression was 
decreased 6-fold and SR-AI contains a putative target sequence for miR-155 in its 3’UTR.  As 
miRNAs generally function to destabilize or inhibit protein translation of the targets they 
regulate, we hypothesized decreased expression of miR-155 would be responsible for the 
increase in SR-AI/II observed post-BMT.  Anti-mir-155-transfected AMs showed a significant 
increase in SR-AI/II expression.  To determine whether this correlated with the functional 
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phenotype observed after transplant, anti-mir-155-transfected AMs measured for phagocytosis of 
S. aureus exhibited a dose-dependent increase in S. aureus internalization.  This provided 
evidence that after transplant it is likely that the elevation of SR-AI/II was regulated by 
decreased miR-155 expression. As PGE2 could inhibit miR-155 and induce SR-AI/II, it is 
possible that the overproduction of PGE2 post-BMT promotes overexpression of SR-AI/II by 
negatively regulating its inhibitor, miR-155. PGE2 also decreases MARCO, but the mechanism 
does not appear to involve miR-155.  This finding provides new insight into intracellular 
regulation of scavenger receptors by microRNA. A recent study suggested miR-155 as a novel 
therapeutic target for improving graft vs. host disease (185). This is likely to also cause an 
inhibition of SR-AI/II which may impair phagocytosis of some pathogens, and the long term 
effects of this treatment on MARCO expression would need to be evaluated. 
COX-2 and PGE2, are elevated following transplantation (58, 68) and inhibition of COX-
2 by indomethacin treatment rescues host defense (58).  PGE2 production is not influenced by SR 
expression as PGE2 levels were similarly elevated in all chimeric BMT mice in this study (not 
shown), however PGE2 can dramatically alter SR profiles and also inhibit bacterial killing.   
Here, we show that in vitro treatment with PGE2 decreases miR-155 and MARCO, while 
increasing SR-AI/II expression.  Although increased SR-AI/II expression enhances S. aureus 
phagocytosis, syn BMT mice remain susceptible to bacteria in vivo.  
Further investigation showed that effective killing of both P. aeruginosa and S. aureus 
was impaired in syn BMT mice compared to their untransplanted controls.  Therefore, a better 
understanding of how killing is impaired remains an area of future investigation. We have 
previously shown that BMT AMs express an immature phenotype (low CD11a and CD11c, high 
CD11b) (55) and that the BAL fluid of BMT mice contains aberrant mediator expression 
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(elevated IL-6, GM-CSF, and PGE2; decreased TNFα, IFN-γ, H2O2 and leukotrienes) (55, 58, 59, 
88).  Overall, BMT AMs appear impaired in their ability to become activated, which is likely 
important for intracellular bacterial killing. Phagocytosis and killing function is rescued upon 
treatment with indomethacin (58) indicating that the impairment is due to overexpression of the 
COX pathway. Microarray analysis also revealed increased expression of miR-27b (15-fold) and 
-29b (20-fold) (Table 3.1). 
Table 3.1 SABiosciences miRNA microarray from syn BMT AMs. 
miRNA Fold Regulation miRNA Fold Regulation 
let-7a 1.4679 miR-295 2.0338 
let-7b 4.8116 miR-297b-3p 3.2249 
let-7c 4.1459 miR-29a 1.0757 
let-7d 1.4218 miR-29b 23.5058 
let-7e 1.2061 miR-29c 1.3683 
let-7f 1.9867 miR-301a 2.4024 
let-7g 1.7013 miR-301b 2.4154 
let-7i 1.8176 miR-302b 2.4645 
miR-106a 2.4503 miR-302d 2.6332 
miR-106b 1.5479 miR-30a 1.5919 
miR-1192 2.4645 miR-30b 1.9533 
miR-126-5p 3.0021 miR-30c 1.9452 
miR-128 1.4976 miR-30d 1.8535 
miR-130a 1.1271 miR-30e 1.196 
miR-130b 1.4905 miR-322 -1.125 
miR-140 1.913 miR-325 1.874 
miR-144 -1.545 miR-338-5p 2.9612 
mir-155 -3.0057 miR-340-5p 2.9737 
miR-15a -1.3451 miR-369-3p 2.0637 
miR-15b 2.1809 miR-374 3.4715 
miR-16 2.1352 miR-384-5p 2.4645 
miR-17 1.8385 miR-410 3.6968 
miR-181a -1.0598 miR-429 -1.1171 
miR-181b 1.7489 miR-466b-3-3p 7.6226 
miR-181c -1.1716 miR-466d-3p 7.0595 
miR-181d 2.5132 miR-466d-5p 2.4645 
miR-182 3.6386 miR-466f-3p 2.7299 
mir-186 1.9054 miR-466k 1.7422 
miR-195 1.8842 miR-495 2.4645 
miR-19a 3.072 miR-497 1.876 
miR-19b 2.0852 miR-590-3p 2.4645 
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miR-200c -1.1613 miR-669f 6.0483 
miR-20a 1.8742 miR-669h-3p 1.1649 
miR-20b 2.321 miR-669k 1.2967 
miR-221 3.5526 miR-692 2.0717 
miR-222 3.9053 miR-694 2.2755 
miR-23a 2.0364 miR-712 1.8727 
miR-23b 4.0324 miR-721 2.4645 
miR-26a 1.7291 miR-743a 1.2518 
miR-26b 1.6209 miR-743b-3p 1.3453 
miR-27a 1.4935 miR-876-3p 2.4645 
miR-27b 15.9657 miR-9 6.1375 
miR-291a-3p -1.2185 miR-93 1.0083 
miR-294 1.173 miR-98 2.2096 
Blue indicates significant upregulation of miRNA expression. Red indicates significant 
downregulation miRNA expression. 
 
NFkB suppresses miR-29b expression (158) and miR-27b was found to inhibit NF-kB 
translocation into the nucleus (186) supporting the idea that these miRNA function in an anti-
inflammatory and perhaps functionally suppressive manner and that their expression pattern is 
influenced by BMT.  Interestingly, miR-29b has been shown to directly regulate DNA 
methyltransferases and affect COX-2 expression in lung epithelial cells(187). Thus, upregulation 
of miR-29b may be promoting COX-2 overexpression in BMT AMs. Here we show that PGE2 
can decrease miR-155 and affect SR-AI/II expression. Furthermore, miR-155 has been shown to 
regulate TNFα by mRNA stabilization.  TNFα is important for macrophage activation and 
immune function, and it is decreased post-BMT (59).  Our results suggest that miR-155 loss 
post-BMT may also play a role in destabilizing TNFα.  These differences related to dysregulated 
miRNA expression, may, in part, be responsible for the defective killing post-BMT.   
Taken together, our results show that AMs undergo significant functional alterations in 
the setting of syn BMT. Our current studies highlight the fact that elevated PGE2 leads to 
alterations in the scavenger receptor profile (decreases MARCO and increases SR-AI/II via 
downregulation of miR-155).  These epigenetic changes differentially affect phagocytosis of P. 
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aeruginosa and S. aureus; however, bacterial killing of both pathogens is impaired post-BMT. It 
is important to note that these changes observed in AMs post-BMT are only seen in the setting of 
myeloablative conditioning.  Tarling et al. suggested that AMs derive from a lung resident stem 
cell that is naturally radio-resistant (98). At lower doses of irradiation, AMs likely repopulate 
from these radio-resistant host stem cells and only upon myeloablative conditioning (8-13 Gy, or 
using high dose chemotherapy combinations) did AM reconstitution derive from the donor bone 
marrow resulting in the PGE2-induced impaired function (54).  Thus, interventions to limit PGE2 
production post-HSCT or reverse these epigenetic alterations may improve outcomes for patients 
developing bacterial infections. Furthermore, as PGE2 is a product of COX-2, future studies will 
explore the etiology of COX-2 overexpression in BMT AMs.
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Chapter 4:  
Cyclooxygenase-2 expression is upregulated by DNA hypomethylation after hematopoietic 
stem cell transplantation 
4.1 Background 
 HSCT is commonly used to treat malignant and nonmalignant hematologic disorders (12, 
25).  Traditionally, a conditioning regimen is implemented prior to intravenous infusion of HSC 
which may consist of chemotherapy with or without TBI (25). TBI is itself myeloablative and 
immunosuppressive and can affect regions within the body that are not easily accessible by 
chemotherapeutic agents delivered via the circulation (12, 25, 188).  Although HSCT has proven 
to be an effective therapeutic option for malignancy, it is also associated with significant 
morbidity and mortality (12, 25, 188-190).  Following either autologous (i.e. recipient HSCs also 
serve as donor cells) or allogeneic (i.e. related or unrelated donor provides HSCs) HSCT, 
transplant recipients are susceptible to developing life-threatening infectious and noninfectious 
complications (25, 28, 53, 176, 188, 191) 
  The lung is a common target organ post-transplant where pulmonary complications account 
for significant mortality and morbidity in HSCT recipients (25, 28, 53, 176, 188, 191).  Such 
complications develop throughout the timeline of pre-engraftment (0-30 days after transplant), 
early post-engraftment (30-100 days after transplant) and late post-engraftment (>100 days) (23).  
Despite full reconstitution or engraftment of donor-derived leukocytes, patients exhibit sustained 
and enhanced susceptibility to infections post-transplant (23, 28, 53, 176, 191).  AMs are the 
resident macrophages in the lung and, together with recruited PMNs, play an important role in 
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regulating an immune response in the lung (58, 96, 97, 168).  Previous studies have reported 
defective phagocytic and bacterial killing function of human alveolar macrophages within 4 
months following HSCT, with some deficiency persisting up to 12 months (34).  Thus, impaired 
innate immune function may explain the prolonged susceptibility to infection observed in post-
transplant individuals.   
 To study the effects of HSCT, our laboratory previously developed a syn BMT murine 
model that simulates autologous HSCT in humans and allows for a direct approach to study 
immune reconstitution and function without the confounding effects of GvHD or 
immunosuppressive drugs. We have shown that even after full immune reconstitution following 
syn BMT, donor-derived AMs from BMT mice are defective in phagocytosis and killing 
compared to mice that did not undergo BMT (54, 58). We discovered this defect is related to 
decreased cysLTs and TNFα production, and increased PGE2 production (24, 58, 68). 
Eicosanoids are lipid mediators derived from arachidonic acid and cells of the myeloid 
lineage are major producers of both cysLTs and PGE2 (24, 192). Synthesis of prostaglandins is 
mediated by the COX enzymes of which there are two isoforms. COX-1 is a constitutive isoform 
of COX responsible for basal COX expression required for homeostasis, whereas COX-2 is 
induced primarily by inflammation (192). PGE2 production post-BMT is attributed to the 
increased activity of COX-2 and PGE2 negatively regulates the innate immune response (58, 76).  
In our model, PGE2 and COX-2 expression were found to be elevated post-BMT within AMs and 
PMNs and this caused functional impairments in the innate immune function of both of these cell 
types (54, 58, 96, 97). However, in our model of P. aeruginosa infection post-BMT, we 
demonstrated that it was the defect in non-opsonized phagocytosis by AMs post-BMT, rather 
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than PMN function which was responsible for the acute clearance of P. aeruginosa (24); thus, 
we have focused our current studies on regulation of COX-2 expression in AMs. 
PGE2 binds to seven transmembrane spanning EP receptors, of which there are 4 discrete EP 
receptors that couple to G proteins involved in mediating the intracellular signaling in response 
to PGE2 (76, 193).  We have shown that binding of the EP2 receptor by PGE2 results in increased 
IRAK-M expression in AMs resulting in the inhibition of non-opsonized phagocytosis (96).  
PGE2 also induces elevation of the enzyme PTEN which results in the inhibition of serum-
opsonized phagocytosis by AMs (97). Thus PGE2 is able to act through distinct signaling 
pathways to compromise host innate immune defense.   
Because COX-2 expression is upregulated in the AMs of mice post-BMT and its 
expression remains elevated in culture (54, 58, 59, 96, 97), we hypothesized that epigenetic 
mechanisms may be responsible for the upregulation of COX-2.  To test this, we sought to 
determine the DNA methylation status of the COX-2 gene promoter.  Using bisulfite conversion 
and pyrosequencing, we discovered that the COX-2 gene was significantly hypomethylated in 
the 5’-UTR and exon 1 of AMs from mice post-BMT. Using in vitro assays, we determined that 
COX-2 mRNA expression is regulated by DNA methylation, as treatment of both a murine 
alveolar macrophage cell line (MHS) and primary AMs with 5-aza-2’-deoxycytidine (a methyl 
transferase inhibitor) increased COX-2 mRNA levels by RT-PCR.  Similarly, transfections in 
MHS cells with methylated COX-2 promoter constructs showed reduced luciferase activity.  
However, COX-2 promoter activity could be enhanced by treatment with TGF-β1, a cytokine 
known to be elevated in BMT lungs (88).  Thus, our data indicate that epigenetic regulation of 
the COX-2 gene is one mechanism driving the observed elevation of both COX-2 and PGE2 in 
BMT mice and this alteration is regulated in part by TGF-β.  
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4.2 Results 
COX-2 mRNA levels are elevated in BMT AMs  
     PGE2 levels were previously reported to be elevated in the plasma of patients undergoing 
autologous  HSCT (83).  The increased PGE2 detected in these individuals post-transplantation 
was independent of conditioning regimen (chemotherapy or radiotherapy).  Similar results were 
previously observed in our established syngeneic BMT mouse model, whereby 13 Gy TBI or a 
dual-chemotherapy regimen induced a defective pulmonary immune response associated with 
elevated levels of PGE2 produced by lung innate immune cells (54, 58).  PGE2 production is 
dependent on the activity of COX enzymes. To determine whether the increase in PGE2 levels 
are a result of increased COX-2 expression, we measured COX-2 mRNA levels in control 
(untransplanted) and BMT mice.  AMs were collected by BAL and COX-2 mRNA expression 
levels were measured by real-time RT-PCR.  These results demonstrate that COX-2 mRNA is 
elevated in BMT AMs when compared to control AMs (Figure 4.1).  
 
Figure 4.1. COX-2 mRNA is increased in BMT mice.  AMs were harvested from control and 
BMT mice at 5 weeks post-BMT. RNA was isolated and COX-2 mRNA was measured by real-
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time RT-PCR. Samples were normalized to β-actin. (n=4, **p<0.01); Representative of two 
experiments. 
BMT AMs are hypomethylated in the 5’-UTR and exon 1 of the COX-2 gene 
     To determine whether epigenetic regulation by DNA methylation was involved in the 
increased expression of COX-2 mRNA levels observed in Figure 4.1, we collected genomic 
DNA from the AMs of control and BMT mice and performed bisulfite sequencing of the COX-2 
promoter.  BMT AMs exhibited significant hypomethylation compared to control AMs at CpG 
loci within the 5’-UTR and exon 1 (Figure 4.2). CpG sites found between -449 and -100 of the 
promoter region located upstream of the transcription start site did not show any differences in 
DNA methylation between the control and BMT AMs (data not shown). 
 
 
Figure 4.2. COX-2 in BMT AMs is hypomethylated around the first exon start site. At week 
5 post-BMT, AMs from control and BMT mice were harvested, DNA was isolated and bisulfite 
converted. Cytosine to thymine conversion was detected by pyrosequencing to determine DNA 
  74 
methylation patterns. Control: n=4, BMT: n=3; *p < 0.05, **p <0.01, ***p < 0.001.  
Representative of 2 experiments showing similar patterns at the same sites. 
5-aza-2'-deoxycytidine increases COX-2 in MHS cells and primary AMs 
     A chemical analog for cytosine, 5-aza-2'-deoxycytidine inhibits DNA methylation by 
blocking DNA methyltransferase activity (194).  The DNA methylation patterns of COX-2 post-
BMT indicate that a decrease in methylation of the COX-2 promoter region may be responsible 
for the elevation of COX-2 and PGE2 observed post-transplant.  To determine whether DNA 
methylation of COX-2 contributes to its diminished expression in control non-BMT cells, we 
treated MHS cells with increasing concentrations of 5-aza-2'-deoxycytidine for 72 h or DMSO as 
a vehicle control.  RNA was extracted from these cells and COX-2 mRNA levels were measured 
by real-time RT-PCR.  COX-2 mRNA expression from MHS cells increased dose-dependently 
in the presence of the methyltransferase inhibitor (Figure 4.3A).  
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Figure 4.3. 5-aza-2'deoxycytidine increases COX-2 mRNA in MHS cells and primary AMs 
and PGE2 in MHS cells. (A) 5x105 MHS cells were cultured with 0.5 or 2.5 μM 5-aza 2’ 
deoxycytidine, or vehicle (DMSO) for 72 h.  RNA was isolated and COX-2 mRNA levels were 
analyzed by real-time RT-PCR. Transcripts were normalized to β actin levels (n=4). (B) Lungs 
from untransplanted mice were lavaged and primary AMs were harvested.  AMs were initially 
stimulated with 1 ng/mL GM-CSF for 2 days and further treated with 2.5μM 5-aza-
2’deoxycytidine in the presence of GM-CSF for an additional 72 h.  RNA was isolated and 
COX-2 mRNA levels calculated by RT-PCR.  (C) MHS cells (5 x 10
5
) were grown in10% 
complete media in the presence or absence of 2.5 μM 5-aza-2’deoxycytidine for 48 h. Media was 
aspirated and fresh serum free media with or without 5-aza-2’deoxycytidine was added for 24 h. 
Supernatants were collected and PGE2 ELISA was performed. (n=3); *p<0.05, **p<0.01, 
***p<0.001. All data are representative of at least 2 experiments.  
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     We next sought to verify these results in primary AMs from control mice. We collected AMs 
by BAL and induced proliferation by initially treating the primary AMs with GM-CSF for 2 
days. AMs were then treated with 5-aza-2'deoxycytidine for 72 additional h in the presence of 
GM-CSF to maintain proliferation (195) and COX-2 mRNA levels were determined by real-time 
RT-PCR (Figure 4.3B).  Expression patterns of COX-2 transcripts from primary AMs shown in 
Figure 4.3B correlate well with the results from DNA demethylation studies in MHS cells. 
Furthermore, treatment of MHS cells with 2.5 μM 5-aza-2'deoxycytidine resulted in increased 
PGE2 levels (Figure 4.3C). Taken together, these data indicate that the regulation of COX-2 is 
heavily influenced at the transcriptional level by DNA methylation.        
 
Cloned COX-2 luciferase vector shows normal transcriptional regulation 
      To further study the regulation of COX-2, the full COX-2 promoter region was cloned into a 
pGL3-basic firefly luciferase expression plasmid. MHS cells were then transfected with the 
cloned COX-2 promoter-driven firefly luciferase vector and control SV-40 promoter-driven 
Renilla luciferase vector via lipofectamine. As COX-2 expression is induced by inflammatory 
stimuli, MHS cells were cultured in the presence or absence of proinflammatory molecules LPS 
or TGF-β1 for 48 h.  Treatment with both LPS and TGF-β1 showed a significant increase in 
firefly luciferase over untreated MHS cells, validating the luciferase assay as an assay of COX-2 
promoter activity (Figure 4.4).  Transfections of the COX-2 promoter-driven expression vector 
and control expression were attempted in primary AMs of wild-type mice but despite using high 
concentrations of plasmid DNA and trying both lipofectamine and electroporation protocols, we 
were unable to achieve significant luciferase expression (even of the control vector) in primary 
AMs. 
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Figure 4.4. Transfected COX-2 promoter-driven luciferase is induced by LPS and TGF-β 
compared to untreated MHS cells.  MHS cells (6.2 x 104) were cultured overnight in the 
presence or absence of either LPS (10 μg/mL), or porcine TGFβ (1 ng/mL).  MHS cells were 
transfected the next day with either luciferase vector alone without COX-2 promoter insert or the 
long COX-2 promoter driven-luciferase vector, and pRL-SV40 (control vector) in a 50:1 ratio 
using lipofectamine LTX and PLUS Reagent.  Firefly and renilla luciferase activities were 
measured and are shown as a ratio. (n=3, representative of 2 experiments); *p<0.05 
 
In vitro DNA methylation suppresses COX-2 promoter activity in MHS cells 
     Both long and short COX-2 promoter constructs were cloned into pGL3-basic firefly 
luciferase expression plasmids. The shorter COX-2 promoter contains only those CpG sites 
analyzed in primary AMs (beginning at -449 to +70) by bisulfite conversion and pyrosequencing 
whereas the long COX-2 construct contains additional upstream CpG sites outside the range of 
our current bisulfite analysis.  To determine whether DNA methylation of the COX-2 promoter-
driven expression vectors decreases COX-2 expression, the long and short COX-2 promoter 
expression plasmids were methylated in vitro with a CpG methyltransferase, M.SssI.  MHS cells 
were then transfected with methylated or unmethylated COX-2 firefly luciferase reporter 
plasmids.  The control vector (pRL-SV40) was not treated with the methyltransferase prior to 
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transfection.  As shown in Figure 4.5A, when unmethylated, the short COX-2 promoter was able 
to stimulate firefly luciferase at levels similar to the long construct.  This suggests that the short 
COX-2 promoter construct contains all relevant sequences for ensuring transcription in MHS 
cells.  Furthermore, when methylated, expression driven by either promoter construct was 
significantly impaired.  Taken together, these results demonstrate that DNA methylation of the 
short promoter region is sufficient to impair transcriptional activity and indicate that the relevant 
CpG sites for analysis lie within the short promoter region which was previously analyzed in 
Figure 4.2. 
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Figure 4.5. COX-2-driven luciferase expression is decreased following treatment with 
methyltransferase, but expression is regulated by TGF-β1.  (A) Transfections of MHS cells 
(6.2 x 104) were performed with a 50:1 ratio of either methylated or unmethylated, full (1179 bp) 
or partially deleted (702bp) COX-2 promoter-driven firefly luciferase plasmid to pRL-SV40 
vector using lipofectamine.   Firefly:Renilla luciferase activities were quantified by a dual 
luciferase assay system.  (n = 6; *p < .05).  (B) MHS were cultured overnight in the presence or 
absence of porcine TGF-β1 (1 ng/mL) and transfected with methylated or umethylated COX-2 
reporter plasmids (702 bp) and pRL-SV40 and assayed as above (n=3, **p<0.001, ***p<0.001). 
 
TGF-β1 can induce expression of COX-2 from methylated constructs 
       We have previously shown that BMT mice exhibit increased levels of TGF-β1 in the lung 
(88).  To determine whether TGF-β1 could stimulate the transcription of COX-2 from a 
methylated promoter, we transfected MHS cells as above with the short COX-2 promoter-driven 
firefly luciferase construct that had either been methylated in vitro by M. Sss1, or left 
unmethylated.  Cells were co-transfected with the SV40-driven renilla luciferase vector as a 
control.  Cells transfected with the methylated construct were also treated with 1 ng/ml TGF-β1 
or vehicle control.  As expected, luciferase expression from the methylated COX-2 construct was 
impaired when compared to the expression from unmethylated constructs (Figure 4.5B).  
However, cells transfected with the methylated constructs exhibited increased luciferase 
expression when treated with TGF-β1. These data suggest that TGF-β1 may be able to promote 
the DNA demethylation of the COX-2 promoter, or may promote the activity of the 
transcriptional machinery on methylated regions of DNA.  Interestingly, LPS was not able to 
increase the transcriptional activity of the methylated COX-2 promoter (Figure 4.6), suggesting 
that this effect may be specific to TGF-β1 signaling. 
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Figure 4.6 LPS does not induce COX-2-mediated luciferase from methylated COX-2 
plasmid. MHS cells were transfected with an umethylated or methylated COX-2 firefly 
luciferase plasmid and a renilla luciferase plasmid (control transfection) in a 50:1 ratio and 
treated with 10 µg/mL LPS for 48h (n=2 combined experiments); **p<0.01, ****p<0.0001.  
 
Improved phagocytosis and partial restoration of COX-2 DNA methylation in AMs from BMT 
mice following reconstitution with donor HSCs from CD11cdnR mice 
      TGF-β1 can play an important role in both the activation and suppression of monocytes and 
macrophages, however, its role in tissue macrophages is primarily immunosuppressive (196). To 
determine how TGF-β1 may contribute to the defect in BMT AMs, we developed bone marrow 
chimeras using HSCs from CD11cdnR donor mice. These mice express a dominant-negative 
TGF-β1 receptor II under the control of the CD11c promoter which results in the generation of 
TGF-β1-resistant myeloid cells including dendritic cells, macrophages and natural killer cells 
(165).  Five weeks post-BMT, AMs were harvested by BAL and phagocytosis was measured and 
compared to WT BMT and control mice. As expected, AMs from WT BMT mice displayed 
defective phagocytosis of P. aeruginosa when compared to cells from control mice.  However, 
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AMs collected from CD11cdnR BMT mice showed enhanced phagocytosis activity compared to 
WT BMTs (Figure 4.7).  
 
Figure 4.7. Improved AM phagocytosis with CD11cdnR bone marrow chimeras.  AMs were 
harvested by BAL 5 weeks post-transplant from BMT mice reconstituted with either WT or 
CD11cdnR donor marrow. Phagocytosis of heat-killed P. aeruginosa was then assessed and 
compared to AMs from control mice (n=5; ***p<0.001). 
 
To determine whether this enhancement in AM function is mediated by a change in 
COX-2 gene methylation, DNA from CD11cdnR BMT AMs was harvested and analyzed for 
extent of DNA methylation. Interestingly, the methylation of the COX-2 promoter from 
CD11cdnR BMT AMs reverted to a pattern more similar to control AMs than WT BMT AMs at 
some, but not all, sites previously found to be demethylated in WT BMT AMs (Figure 4.8).  
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Figure 4.8. CD11cdnR BMT COX-2 promoter methylation is partially rescued. After DNA 
isolation from primary AMs from control, WT BMT, and CD11cdnR BMT mice, DNA was 
subjected to bisulfite conversion and pyrosequencing for DNA methylation analysis. n = 5. WT 
BMT patterns were hypermethylated compared with control AMs at all sites. However, AMs 
from CD11cdnR BMT mice were not significantly different from control AMs except at CpG sites 
32 and 34. **p< 0.01, ***p< 0.001. 
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4.3 Discussion 
     We previously showed that AMs post-BMT are defective in phagocytosis and killing of P. 
aeruginosa, a clinically relevant nosocomial pathogen which can afflict patients following 
hematopoietic stem cell transplantation (54, 58, 59, 96, 97).  Defective AM function post-BMT 
is not exclusive to mice receiving TBI, but is also seen in mice receiving chemotherapy 
conditioning regimens (54), and persists despite immune reconstitution. We have previously 
shown that both PGE2 and TGF-β1 are elevated in lungs of BMT mice following immune 
reconstitution and both can have immunosuppressive effects (58, 88).  We now show that 
irradiated mice receiving CD11c+ donor cells that are unable to respond to TGF-β1 exhibit 
improved AM function (Figure 4.6), indicating that TGF-β1 is contributing to the defect in AMs 
following transplantation.  Overproduction of PGE2 in the lung has been reported following 
hematopoietic reconstitution and is intimately linked with a defective lung innate immune system 
(58).  Here, we show that COX-2 transcription in AMs is elevated in mice post-BMT relative to 
control AMs.  These results correlate with the elevated PGE2 levels reported previously in both 
mice and patients that have undergone HSCT (54, 58, 83, 96, 97), and give insight to a possible 
transcriptional dysregulation of COX-2 expression.   
Upregulation of COX-2 expression and PGE2 production has been associated with a wide 
range of disease processes, of which cancer is most commonly reported (197).  In these 
circumstances, PGE2 may promoter cancer progression and metastasis as well as immune 
suppression.  Furthermore, it was recently reported that chronic influenza infection was 
associated with upregulation of miR-29b (187).  The consequence of miR-29b upregulation was 
the destabilization of DNA methyltransferases and the upregulation of COX-2 gene expression 
secondary to DNA demethylation (187).  It is interesting that we have also observed upregulation 
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of miR-29b in BMT AMs (Table 3.1 and Chapter 5).  Thus, it is possible that the process of 
BMT regulates COX-2 DNA demethylation via miR-29b expression. 
 To further understand the regulation of COX-2 expression in our syngeneic murine model 
for studying innate immune cells post-BMT, we examined DNA methylation patterns of the 
COX-2 promoter of transplanted and untransplanted mice.  Interestingly, we found that the 
COX-2 promoter region analyzed from AMs of transplanted mice was significantly 
hypomethylated, particularly around the transcription start site and into the first exon, compared 
to control untransplanted mice.  The fact that the 702 bp COX-2 promoter drove expression in 
MHS cells and the fact that no CpG sites located upstream of the transcription start site showed 
DNA methylation differences suggests that the region of interest is located near the exon 1 
border.  DNA methylation changes of this magnitude have previously been shown to alter EP2 
expression (154) and methylation around the transcription start site and in gene exons has been 
previously described [e.g. in (187, 198-200)].  It is interesting that in human studies related to 
Helicobacter pylori-induced COX-2 expression and influenza-induced COX-2 expression, DNA 
demethylation occurs at similar sites as those identified in our murine study (187, 200).  
However, there are examples of regulation at different sites as well (e.g. hepatitis B demethylates 
COX-2 in the NFAT sites upstream of the transcription start site (201) and silencing of the COX-
2 gene in human gastric cancers involves DNA hypermethylation of promoter regions upstream 
of exon 1 (202).  When we further explored this epigenetic mechanism of regulation and treated 
a murine AM cell line with a methyltransferase inhibitor, 5-aza-2'-deoxycytidine, an increase in 
COX-2 mRNA levels was detected and this induced expression was dose-dependent with 
increasing concentrations of 5-aza-2'-deoxycytidine.  A similar response was observed in 
primary AMs of untransplanted control mice that were treated with either 5-aza-2'-deoxycytidine 
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or vehicle.  Overall, these results suggest DNA methylation of the promoter and/or beginning of 
exon 1 is an important mechanism for regulating COX-2 mRNA levels. 
 To establish a correlation between elevated levels of mRNA and COX-2 expression in 
response to methylating or demethylating conditions, the COX-2 promoter region was cloned 
into a luciferase vector whereby firefly luciferase activity could be driven by the COX-2 
promoter and serve as a measure of COX-2 expression. MHS cells were successfully transfected, 
measured by pRL-SV40-driven activity, and luciferase activity of the COX-2 plasmid was 
increased in the presence of proinflammatory LPS and TGF-β1.  These data suggest that reporter 
vector is regulated similarly to the native gene in MHS cells.  Despite numerous attempts, 
primary AMs were unable to be transfected by either lipofectamine or electroporation methods.  
We next determined that a shortened COX-2 promoter construct (which contained the CpG sites 
we had analyzed for DNA methylation patterns) was sufficient to induce COX-2 expression in 
MHS cells.  We next studied the effects of DNA methylation on the activity of this construct.  In 
vitro DNA methylation of the COX-2-driven luciferase vector resulted in decreased COX-2 
promoter activity when transfected into the MHS cells.  These results verify that DNA 
methylation inhibits expression of COX-2, and suggest that the methylation of the COX-2 gene 
which is noted in AMs collected from untransplanted mice likely plays a role in the limited 
expression of COX-2 and the limited production of PGE2 in these cells under homeostatic 
conditions. 
 In contrast, treatment of MHS cells transfected with methylated COX-2 reporter plasmids 
with TGF-β1 was able to induce modest expression of COX-2.  These results suggested that the 
increased levels of TGF-β1which have been previously reported in BMT mice (88), may serve to 
induce COX-2 DNA demethylation or increase transcription from the methylated promoter in the 
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AMs in the BMT mice.  Interestingly, this activity was not noted with LPS, a molecule which is 
able to stimulate transcription off of unmethylated COX-2 promoters.  Thus, these results 
suggest that the ability to stimulate transcription off of a methylated COX-2 promoter may be a 
unique action of TGF-β1 signaling.  One caveat to these studies is that we do not know for 
certain whether the level of DNA methylation achieved by in vitro reactions is similar to the 
levels noted in vivo in BMT mice.  However, our finding of improved host defense in the 
CD11cdnR BMT mice, which are unresponsive to TGF-β1 signaling in AMs, is highly supportive. 
 Our results suggest that TGF-β1 may be one mechanism to regulate the increased 
expression of COX-2 and thus, PGE2, which occurs in AMs post-BMT.  However, it is likely 
that other signals occur secondary to conditioning regimen-induced alterations.  The production 
of reactive oxygen species has been observed previously following ionizing radiation and has 
been implicated in compromised lung immunity (203).  Reactive nitrogen species, particularly 
nitric oxide, have been suggested to induce changes in COX within airway epithelium during 
inflammation (204). In these studies, increasing concentrations of nitric oxide was able to induce 
the production of PGE2 in alveolar epithelial cells.  Nitric oxide and PGE2 expression can be 
induced by proinflammatory cytokines (204). Therefore, it is possible that the formation of 
reactive species caused by irradiation or a chemotherapy regimen may also be playing a role in 
the induction of COX-2 transcription and expression.   
 Because irradiation can only directly affect cells that have been irradiated, the fact that 
unirradiated donor AMs are affected suggests that this impaired AM function may be due to an 
alteration in the lung microenvironment. Therefore, it is likely that the changes are induced by 
soluble factors that cause a change in cell behavior or function. Previous data from our lab has 
indicated that alveolar epithelial cells may influence AM function through the secretion of 
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soluble factors like GM-CSF (59). While we have ruled out the contribution of GM-CSF to the 
induction of COX-2 in this model (59), it is possible that other soluble factors, in addition to 
TGF-β1 may trigger the epigenetic changes.  This will be an area for future study. 
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Chapter 5: 
Transforming Growth Factor-β induces microRNA-29b to promote murine alveolar 
macrophage dysfunction post-bone marrow transplantation 
 
5.1 Background 
As an effective therapy for a variety of malignant and inherited disorders, HSCT offers a 
curative option for many patients. Advances in conditioning regimens and stem cell acquisition 
have widened the accessibility and implementation of HSCT.  Traditionally, transplant patients 
receive their own hematopoietic stem cells (autologous HSCT) or receive stem cells from HLA-
matched, related or unrelated donors (allogeneic HSCT) following myeloablative conditioning 
regimens. More recently reduced intensity conditioning regimens have enabled older patients or 
patients unable to undergo conventional conditioning regimens, the opportunity to receive stem 
cell transplantation for their conditions as well (205). However, despite differences in 
conditioning regimens or application of immunosuppressive therapy, HSCT patients exhibit 
increased susceptibility to pulmonary complications both pre- and post-engraftment (23, 28, 206, 
207).  The associated morbidity and mortality associated with microbial infection is further 
confounded by antibiotic-resistant bacteria (52).   
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During the pre-engraftment phase, susceptibility to infection is likely due to the 
neutropenia commonly associated with this stage.  However, less clear is why patients continue 
to exhibit sustained susceptibility to bacterial infections throughout the early post-engraftment 
(30-100 d after transplant) and the late post-engraftment (> 100 d after transplant) phase, where 
the immune compartment has been reconstituted by donor-derived cells (21, 28).  Previous 
studies, including autopsy reports, have revealed that pulmonary complications are a significant 
cause of death for transplant patients and a predictor for poor survival (21). Thus, understanding 
why these pulmonary complications arise is vital to survival and quality of life for HSCT 
patients. 
Existing in the alveolar compartment between air and lung tissue, alveolar macrophages 
(AMs) compose more than 90% of the cells retrieved by bronchoalveolar lavage in a healthy 
individual and represent the first line of defense in the lung (177).  Following HSCT, however, 
phagocytosis and bacterial killing by human AMs is significantly compromised (34), suggesting 
that impaired AM responses support prolonged sensitivity to infection following transplantation. 
To investigate the causes for impaired innate immune responses, our lab utilized a syngeneic 
murine model of BMT as a representation of autologous transplantation. This model sheds light 
on the underlying effects of transplantation on immune cell function independent of 
immunosuppressive therapy or development of GvHD (54).  
Using this model, we previously reported that BMT mice were more susceptible to Gram-
negative (Pseudomonas aeruginosa) and Gram-positive (Staphylococcus aureus) pneumonia (55, 
60). This increased susceptibility was at least partially attributed to functionally defective AMs 
(54, 58-60, 68, 88, 96, 97, 208). As AMs are the sentinel phagocytes in the lung, their ability to 
recognize an invading pathogen, recruit immune cells to the infected lung, and control/clear the 
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invading pathogen is important for preventing widespread infection and alveolar damage. 
However, murine AMs post-BMT exhibit impaired phagocytosis and bacterial killing similarly 
to human HSCT AMs (34, 88, 208). These defects were attributed to overexpression of COX-2 
and subsequent increased production of its downstream effector, PGE2. Previous observations 
also noted elevated PGE2 in the serum of autologous HSCT patients (83).   
Eicosanoids are lipid mediators derived from arachidonic acid metabolism. There are two 
isoforms of the COX enzymes: COX-1 and COX-2 (192). Constitutively expressed, COX-1 is 
important for mediating homeostatic effects while COX-2 is upregulated by inflammatory 
signals. Metabolism of arachidonic acid by COX-1/COX-2 is necessary for the generation of 
PGE2. PGE2 can be recognized by EP receptors (EP1-4) (76, 193, 209). In our BMT model, EP2 
and EP4 are significantly overexpressed and binding of PGE2 via these receptors, particularly 
EP2, results in inhibition of macrophage function (58).  In BMT AMs, basal COX-2 expression 
is significantly higher than in untransplanted control AMs (58, 89) which we previously showed 
was due to hypomethylation of CpG sites within the COX-2 promoter (89).  Hypomethylation 
and increased COX-2 expression has previously also been shown in cancer (201, 210). In our 
model, COX-2 hypomethylation was a result of increased TGF-β signaling (89). Disruption of 
TGF-β signaling resulted in partial restoration of DNA methylation patterns in COX-2 as well as 
AM function, i.e. phagocytosis (89). However, the mechanism by which TGF-β mediated this 
effect was unknown.  
MiRNA are short, noncoding RNA sequences roughly 22 nucleotides in length and have 
been previously dubbed as “fine tuners” of immune responses (211, 212). MiRNA are post-
transcriptional regulators that can inhibit mRNA stability and/or protein translation by binding to 
3’UTRs of their target genes (211, 212). Preliminary studies revealed miR-29b was the most 
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upregulated miRNA in BMT AMs when cellular RNA was analyzed on the mouse inflammation 
miRNA RT2profile miRNA array from SABiosciences (Table 3.1). Interestingly, miR-29b 
contains predicted target sites within the 3’UTR of the de novo DNMTs, DNMT3a and -3b 
(TargetScan) (187, 213-215). DNMTs are responsible for the transfer of methyl groups onto 
CpG residues (216). Here, we determine the role of miR-29b in the ability of TGF-β to induce 
COX-2 promoter hypomethylation in BMT AMs. 
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5.2 Results 
Increased miR-29b and decreased DNMT expression in AMs post-BMT 
We previously showed that increased TGF-β signaling in AMs post-BMT was 
responsible for hypomethylation of COX-2, and that inhibition of TGF-β signaling in AMs post-
BMT resulted in hypermethylation of the COX-2 promoter (89) resulting in decreased expression 
of COX-2, and restored AM function (89). To determine how TGF-β might result in COX-2 
hypomethylation, we investigated the expression of various DNMT isoforms in AMs from 
control (untransplanted) and syngeneic BMT mice. As DNMTs are responsible for the transfer of 
methyl groups onto CpG sites, we measured the expression of maintenance (DNMT1) and de 
novo (DNMT3a and -3b) DNA methylation enzymes following BMT. The expression of all three 
DNMTs was decreased two-fold compared to untransplanted controls (Figure 5.1A). We 
originally ran a microarray analysis to look for alterations in miRNA that may regulate DNMTs 
and found miR29b to be elevated (Table 3.1).  Thus, we verified using real-time RT-PCR that 
AMs from BMT mice express higher levels of miR29b than do AMs from control mice (Figure 
5.1B).   
Figure 5.1. MiR-29b and DNA methyltransferase (DNMT) expressions are altered post-
BMT. Untransplanted control and BMT AMs were measured for (A) DNMT 1, 3a, and 3b (n=3-
4) or (B) miR-29b (n=2-3) by real-time RT-PCR; *p<0.05. 
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Similarly, AMs from both autologous and allogeneic HSCT patients exhibited high 
expression of miR-29b relative to the U6 control when compared to AMs collected from normal 
healthy volunteers (Figure 5.2).  Interestingly, high expression levels of miR-29b were noted 
even in patients more than two years post-HSCT when compared to healthy controls. HSCT 
patient characteristics are outlined in Table 5.1. Thus, these data support our murine model as an 
appropriate representation of the alterations observed in HSCT patients and suggest sustained 
elevation of miR-29b.  
 
Figure 5.2. MiR-29b is overexpressed in HSCT patients. Expression by human AMs of miR-
29b relative to U6 was determined in autologous (n=3 auto) and allogeneic HSCT patients (n=11 
allo) and compared to healthy individuals (n=6). 
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Table 5.1. Healthy and HSCT patient characteristics for miR-29b studies. 
Patient Age Gender Days post-
transplant 
Conditioning Underlying 
disease 
Control 1 58 Female N/A N/A No disease, 
never smoker 
Control 2 20 Male N/A N/A No disease, 
never smoker 
Control 3 30 Female N/A N/A No disease, 
never smoker 
Control 4 39 Female N/A N/A No disease, 
never smoker 
Control 5 54 Female N/A N/A No disease, 
never smoker 
Control 6 20 Female N/A N/A No disease, 
never smoker 
Allo 1 
 
65 Male 357 FluBu 
Acute 
myelomonocytic 
leukemia (AML) 
Allo 2 
 
60 Male 768 Flu/Bu/TLI 
Chronic 
lymphocytic 
leukemia, b-
cell/Small 
lymphocytic 
lymphoma 
Allo 3 
 60 Male 10 FluBu 
Multiple 
Myeloma 
Allo 4 
 
57 Female 341 FluBu/TBI 
Acute 
undifferentiated 
leukemia 
Allo 5 
 
63 Female 10 FluBu 
Acute 
lymphoblastic 
leukemia 
Allo 6 34 Female 617 FluBu AML 
Allo 7 52 Female 552 CloBu AML 
Allo 8 
21 Male 2179 FluCy/TBI 
Precursor B-cell 
ALL 
Allo 9 
25 Female 176 
FluBu, 
ATG/thymoglobulin 
Myelodysplastic 
Syndrome 
(MDS) 
Allo 10 
60 Female 758 FluBu 
AML/mixed 
lineage leukemia 
Allo 11 42 Female 4137 BAC MDS  
Auto 1 59 Male 19 MEL Multiple 
Myeloma –IgG 
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Auto 2 57 Female 174 BEAM Anaplastic large-
cell lymphoma, 
T/null cell, 
primary systemic 
type 
Auto 3 35 Male 12 Cy, 
ATG/thymoglobulin 
Systemic 
sclerosis 
MEL, melphalan; BEAM, BCNU-Etoposide-AraC-Melphalan; Flu, fludarabine; Bu, busulfan; 
TLI, total lymphocyte infusion ; TBI, total body irradiation; Clo, clofarabine; Cy, cytoxan; ATG, 
anti-thymocyte globulin; BAC bendamustine and cytarabine. 
 
TGF-β upregulates miR-29b and downregulates DNMT expression 
Previous data showed elevated levels of TGF-β in BMT lungs compared to 
untransplanted controls (88). Furthermore, TGF-β promotes upregulation of COX-2 (204, 217).  
To determine whether TGF-β-induced COX-2 promoter hypomethylation was due to increased 
miR-29b and decreased DNMT, primary AMs from wild-type untransplanted mice were treated 
with TGF-β for 24 h prior to RNA isolation. Real-time RT-PCR analysis revealed that TGF-β-
treated AMs exhibited decreased DNMT3a and -3b expression (Figure 5.3A) and increased 
expression of miR-29b (Figure 5.3B; white bars).  To further verify the effects of TGF-β on 
DNMT expression, CD11cdnR mice expressing a dominant-negative TGF-βRII regulated by 
CD11c promoter activity were used. Under these conditions, cells expressing CD11c (i.e. 
dendritic cells, macrophages, natural killer cells) would be unresponsive to TGF-β signaling. 
AMs from CD11cdnR mice did not show significant changes in miR-29b (Figure 5.3B; black 
bars) or DNMT (Figure 5.3C) expression in response to TGF-β stimulation. Loss of altered 
DNMT and miR-29b expression in AMs insensitive to TGF-β supports TGF-β as the mediator of 
these transcriptional changes. 
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Figure 5.3. TGF-β promotes altered miR-29b and DNMT expression. (A) Primary 
untransplanted control AMs (WT AMs) (n=4-8) and (B) WT or CD11cdnR AMs (n=2-3) or (C) 
CD11cdnR AMs (n=3-5) were treated with 2 ng/mL TGF-β for 24 h and DNMT 1, 3a, 3b or miR-
29b expression was measured by real-time RT-PCR; *p<0.05, **p<0.01, ***p<0.001. 
 
MiR-29b downregulates DNMT expression and upregulates the COX-2 pathway 
DNMT 3a and 3b contain a miR-29b target sequence in their 3’untranslated region 
(TargetScan) (187).  To determine whether the altered expression of DNMTs were a result of 
direct regulation by miR-29b, primary AMs from WT mice were transiently transfected with 
miR-29b for 24 h. Following overexpression of miR-29b, DNMT 3a and 3b as well as DNMT1 
expression decreased significantly (Figure 5.4A). These data indicate that miR-29b negatively 
regulates DNMTs in AMs. 
    
 
97 
 
Figure 5.4. MiR-29b overexpression in primary AMs inhibits DNMT expression and 
upregulates COX-2/PGE2. (A) Primary AMs were transfected with 30 nM miR-29b or a control 
scrambled miRNA at the same concentration for 24 h prior to measuring DNMT expression by 
real-time RT-PCR (n=2-4). MiR-29b or a control scrambled miR (30 nM) were transfected into 
primary wild-type AMs for 48 h prior to measuring COX-2 expression by (B) real-time RT-PCR 
(n=2-4) or (C) Western blot (pooled from n=3-4), and (D) PGE2 was measured following 
miR29b transfection by ELISA (n=3); *p<0.05, **p<0.01; ***p<0.001. 
 
Increased activity of COX-2 and its downstream effector, PGE2, were previously shown 
to promote the defective functional phenotype in BMT AMs (54, 58-60, 68, 88, 89, 97, 208). 
Furthermore, TGF-β promotes COX-2/PGE2 (217) (Figure 5.5) and miR-29b (Figure 5.4B) while 
decreasing DNMT expression (Figure 5.4A). To determine if miR-29b could affect the COX 
pathway, primary AMs from WT mice were transfected with miR-29b. In response to transient 
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miR-29b overexpression, COX-2 mRNA (Figure 5.4B) and protein (Figure 5.4C) were 
upregulated.  Increased PGE2 production in miR-29-transfected AMs following 24 and 48 h 
transfections indicate that the upregulation of COX-2 resulted in increased COX-2 activity 
(Figure 5.4D).  
 
 
Figure 5.5. TGF-β upregulates COX-2 in primary AMs. Primary AMs were treated with 5 
ng/mL TGF-β for 24 h. (A) COX-2 mRNA was measured by real-time RT-PCR following RNA 
extraction by TRIzol (n=4) and (B) PGE2 released in the supernatant was measured by ELISA 
(n=4); *p<0.05, **p<0.01. 
 
Since TGF-β increased expression of miR-29b and decreased expression of DNMT3a and 
-3b, we sought to determine whether miR-29b is responsible for the hypomethylation of COX-2 
in BMT AMs (89). Primary AMs were transfected with miR-29b and COX-2 promoter 
methylation was determined by bisulfite conversion and pyrosequencing. The location of CpG 
sites 1-6 is outlined in Figure 5.6A. COX-2 was hypomethylated in CpG sites 1-6 following 
miR-29b-transfection compared to AMs transfected with a control miR (Figure 5.6B).  
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Figure 5.6. MiR-29b overexpression promotes hypomethylation of COX-2. Primary AMs 
were transfected with miR-29b or control scrambled miR (30 nM) for 48 h prior to bisulfite 
conversion and pyrosequencing analysis of CpG sites 1-6 (n=4 separate experiments). The 
locations of the depicted CpG sites in the COX-2 promoter are depicted above the graph. The 
transcription start site is denoted by the “+1”; *p<0.05. **p<0.01, ****p<0.0001. 
 
This decreased DNA methylation pattern at CpG sites 1-6 was similarly observed in BMT AMs 
(Figure 5.7A) and primary AMs treated with a methyltransferase inhibitor, 5-aza-2’-
deoxycytidine (Figure 5.7B). While our previous results suggested that CpG sites near exon 1 
were hypomethylated in BMT AMs (89), we did not see these sites regulated by miR29b 
transfection (data not shown). 
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Figure 5.7. BMT AMs exhibit decreased COX-2 methylation at CpG sites 1-6. (A) DNA 
methylation of upstream CpG sites 1-6 were measured in untransplanted control and BMT AMs 
(n= 2 separate experiments). (B) Primary wild-type AMs harvested by BAL were initially 
supplemented with GM-CSF (1ng/mL) for 24 h prior to the addition of 2.5 µM 5-aza-
2’deoxycytidine (5-aza) for 72 h.  DNA methylation of CpG sites 1-6 were determined by 
bisulfite conversion and pyrosequencing (n=3-4); *p<0.05, **p<0.01, ****p<0.0001. 
 
Inhibition of TGF-β rescues bacterial killing defect in BMT AMs 
As the data thus far points to a TGF-β-induced dysregulation of miR-29b and DNMTs in 
BMT AMs, the effects of TGF-β on AM function post-BMT were determined. Killing of 
phagocytized S. aureus was measured in BMT and untransplanted control AMs. BMT AMs 
exhibited impaired bacterial killing compared to control AMs, supporting previous publications 
(58, 96, 208).  However, reconstituting the alveolar compartment with donor AMs insensitive to 
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TGF-β (CD11cdnR BMT) rescued this killing defect (Figure 5.8). These data suggest that TGF-β 
signaling mediates the functional defect seen in AMs post-BMT. 
 
Figure 5.8. CD11cdnR BMT AMs exhibit intact bacterial killing of S. aureus.  AMs from 
untransplanted control, B6 BMT (Syn BMT), and CD11cdnR BMT mice were measured for their 
ability to kill S. aureus intracellularly (n=5-8); *p<0.05, ****p<0.0001. 
 
MiR-29b compromises effective bacterial killing in BMT AMs 
To determine the functional effects of miR-29b post-BMT, primary BMT AMs were 
transfected with an antagomir of miR-29b (antimiR-29b) or a control miR, and measured for 
their ability to clear S. aureus intracellularly. Compared to untransplanted control AMs, BMT 
AMs allowed increased intracellular bacterial survival (Figure 5.9A). However, upon inhibition 
of miR-29b (antimiR-29b), bacterial killing was restored in BMT AMs to levels similar to 
control AMs transfected with a control miRNA (Figure 5.9A). Interestingly, transient 
transfection of miR-29b in control AMs was sufficient to drive a defective functional response 
comparable to control transfected BMT AMs (Figure 5.9B). Previous data support an integral 
role for COX-2 in mediating the bacterial killing defect in BMT AMs by upregulating the 
production of PGE2. Thus, we investigated whether inhibition of bacterial clearance caused by 
overexpression of miR-29b was due to miR-29b-dependent upregulation of the COX-2 pathway. 
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Treatment of miR-29b-transfected AMs with indomethacin, a COX inhibitor, rescued the 
defective phenotype. Interestingly, blocking PGE2 signaling with a novel EP2 antagonist (EP2a; 
PF-04418948) (170, 171) similarly restored miR-29b-transfected AM function (Figure 5.9B). 
Figure 5.9. MiR-29b compromises bacterial killing in AMs through PGE2 signaling. (A) 
AMs from untransplanted control mice were transfected with a control miR (30 nM) or miR-29b 
(30 nM), and BMT mice were transfected with a control antimiR (10 nM) or the antagomiR (10 
nM) for 48 h prior to measuring bacterial killing of S. aureus (n=5-8). (B) S. aureus killing by 
miR-29b-transfected wild-type AMs was determined in the presence or absence of EP2 
antagonist (PF-04418948; 10nM) or indomethacin (5µM) and compared to AMs transfected with 
a control miR (n=4-5); *p<0.05, **p<0.01, ***p<0.0001.
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5.3 Discussion 
The results presented here show that DNMT1, DNMT3a and DNMT3b expression are 
diminished in AMs post-BMT, and that TGF-β downregulates DNMT expression in control 
AMs.  CD11cdnr AMs are insensitive to TGF-β and thus expression of DNMT isoforms are 
unaffected by TGF-β.  MiR-29b on the other hand was increased in AMs post-BMT, and in 
control AMs treated with TGF-β. The effects on DNMT expression are miR-29b-dependent as 
wild-type AMs transfected with miR-29b, but not control miRNA revealed decreased DNMT 
expression. As mentioned earlier, miR-29b contains putative binding sites in the 3’UTR of 
DNMT 3a and 3b. A previous study confirmed these binding sites and showed direct binding of 
miR-29b on the 3’UTR (187). A previous study also showed that miR-29b can indirectly down-
regulate DNMT1 by targeting Sp1 (153). Thus, our results showing that miR29b transfection can 
also inhibit DNMT1 correlate with this earlier observation. However, the effects of TGF-β on 
miR-29b in our system are different than previous studies in other cell types where TGF-β 
negatively regulates miR-29b (218-220).  These conflicting reports highlight the tissue-specific 
nature of TGFβ regulation of miR-29b.  
HSCT patients suffer from pulmonary complications that commonly manifest as 
infectious pneumonias (12, 23, 28). Interestingly, observations made in HSCT patients note 
impaired function in the innate immune compartment (i.e. AMs and PMNs) (26, 34, 83).  Using 
a murine model of BMT to understand the correlation between these defective innate immune 
cells and the increased susceptibility of these patients, we previously published that BMT AMs 
are unable to phagocytize and kill engulfed bacteria (55, 58, 88, 208). These defects were 
primarily mediated by the overproduction of PGE2 as inhibition of PGE2 or the COX-2 pathway 
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rescued bacterial phagocytosis and killing by BMT AMs in vitro (58). These data highlight the 
importance of the COX-2 pathway and its effector, PGE2 in mediating the defects observed in 
our BMT model. However, the mechanism for enhanced basal expression of COX-2 remained 
elusive. Recently, we published that the COX-2 promoter was significantly hypomethylated in 
BMT AMs, allowing for enhanced COX-2 expression (89).  Interestingly, BMT AMs insensitive 
to TGF-β exhibited partially restored DNA methylation and phagocytic function (89).  This 
study sought to shed light on a possible mechanism by which TGF-β could affect immune 
responses in BMT mice through regulating DNA methylation of COX-2.   
The data presented show that overexpression of miR-29b in primary AMs induces COX-
2 and PGE2 by inhibition of DNMTs, resulting in the hypomethylation of COX-2.  Previous 
studies have implicated COX-2 and subsequently, PGE2, in mediating immunosuppressive 
effects on macrophages (221-224). We have shown that the inability of BMT AMs to function 
effectively in response to bacteria is due to the elevated basal PGE2 levels (58, 60). 
Consequently, understanding the source for upregulation of PGE2 would identify pathways that 
could potentially be targeted for therapy.  
Here we propose that elevated TGF-β in the alveolar space of BMT mice 1) signals the 
upregulation of miR-29b which then 2) targets DNMTs resulting in the 3) hypomethylation of 
COX-2, and the subsequent 4) COX-2-dependent synthesis of PGE2.   In turn, PGE2 binding to 
elevated EP2 receptors on AMs post-BMT impairs phagocytosis and bacterial killing.  TGF-β 
has previously been characterized to have dual effects on COX-2 (217, 225-228). A study in 
human non-small cell lung cancer A549 cells showed that TGF-β was able to downregulate 
COX-2 (227). However, the bulk of the literature has shown induction of COX-2 in response to 
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TGF-β in models using mammary epithelial cells (229), human mesangial cells (217), and 
macrophages in muscle tissue (228). Activation of ERK1/2, p38 MAPK, and PI3K signaling 
pathways are suggested to mediate the TGF-β-dependent activation of COX-2 (217). Here we 
show that overexpression of miR-29b in primary AMs induces COX-2 and PGE2 by indirectly 
promoting the hypomethylation of COX-2 through its regulatory effects on DNMTs. At least one 
source of elevated TGFβ in the lungs post-BMT is from alveolar epithelial cells (88).  BMT AMs 
show hypomethylation on CpG sites 1-4 and near exon 1 of COX-2 (89), however, miR-29b 
induces hypomethylation on the former CpG sites and not the latter. Previous studies showed 
that the COX-2 gene contained an NF-kB, a C/EBP, and a cAMP response element-1 (CRE-1) 
site in the promoter, however, Kang and colleagues identified three additional functional 
elements (CRE-2, an AP-1 site, and an E-box overlapping CRE-1) (230, 231).  Interestingly, our 
DNA methylation data following miR-29b transfection show significant hypomethylation in 
CpG sites that overlap with CRE-2 but not the other sites.  Moreover, deletion of the CRE-2 site 
resulted in 50% reduction of LPS-induced COX-2, highlighting the importance of this regulatory 
site in COX-2 expression (231).  Thus, it is possible that despite changes in DNA methylation at 
CpG sites near exon 1 of COX-2 (89) following transplantation, hypomethylation of the more 
upstream CpG sites observed both post-BMT and in response to miR-29b are the critical CpG 
sites that result in enhanced COX-2.   
We also show that blocking miR-29b in BMT AMs is sufficient to rescue the bacterial 
killing defect in vitro and overexpression of miR-29b in primary AMs alone inhibits proper 
bacterial clearance in vitro. These effects are due to the miR-29b-induced PGE2 as blocking 
PGE2 signaling (using an EP2 receptor antagonist) and the COX pathway (using indomethacin) 
are able to rescue the killing defect despite overexpression of miR-29b. These data highlight an 
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immunoregulatory role for miR-29b on AM function. More importantly, they can be translated to 
HSCT patients as both autologous and allogeneic HSCT patients exhibit increased miR-29b 
expression. 
Taken together, these data reveal a novel pathway that regulates the immunosuppressive 
effects of COX-2 and highlights miR-29b as a potential therapeutic target for improving 
pulmonary immune responses in HSCT patients. Although miRNA biology is not fully 
understood, the knowledge gathered thus far and the progress made in the development of 
strategies to block or enhance miRNA activity have propelled the therapeutic promise of these 
small RNAs (232). Currently there are no FDA-approved miRNA therapies available, however, 
commercial development of miRNA therapies are underway and are in pre-clinical stages for the 
treatment of non-small cell lung cancer, prostate cancer, muscle and cardiovascular disease, and 
fibrosis (232, 233). Thus, the possibility of delivering miR-29b antagomirs to AMs is a 
promising strategy for targeted immunoregulatory therapy for HSCT patients who are likely to 
suffer from infectious pulmonary complications. 
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Chapter 6: 
Prostaglandin E2 signaling through Epac-1 inhibits PMN extracellular trap formation  
 
6.1 Background 
PMNs are derived from myeloid precursors (234, 235). Along with macrophages, they are 
innate immune cells and are important mediators in acute immune responses. Aside from their 
segmented nucleus, PMNs contain cytoplasmic granules formed during maturation from the 
promyelocyte stage and primarily remain in circulation, awaiting activating signals (234, 235). 
There are three types of granules, each carrying proinflammatory proteins. The “primary” or 
azurophilic granules are peroxidase-positive and contain myeloperoxidase; the “secondary” or 
specific granules are peroxidase-negative, and carry proteins like lactoferrin; finally, the 
“tertiary” or gelatinase granules contain enzymes like matrix metalloproteinase-9 (234-237). The 
latter, unlike the former two, contain relatively few antimicrobials and instead, seem to function 
as storage for enzymes like gelatinase.  These granules are important for mediating PMN 
immune responses against pathogens, both intracellular and extracellular. 
In response to inflammation, the circulating PMN migrates to the site of infection through 
adherence to the activated endothelium, supporting extravasation. At the site of infection PMNs 
can phagocytize the invading pathogen, and granule fusion with the phagosome exposes the 
phagosomal cargo to azurophilic and specific granule antimicrobial enzymes. Importantly, fusion 
of specific granules and the phagosome is particularly important for formation of reactive 
oxygen species as flavocytochrome b558, a component of the NADPH oxidase machinery, is 
present on specific granular membranes (235, 238). Thus, production of the reactive oxygen 
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species together with primary and secondary granular proteins is important for creating the 
antimicrobial milieu for efficient intracellular killing.  Similarly, these granules can also bind to 
the plasma membrane, activate NADPH oxidase machinery, and release their bactericidal 
components to the extracellular space (234).  
More recently, the production of extracellular traps has provided another mechanism by 
which PMNs can capture and kill pathogens extracellularly. Considered to be an active form of 
cell death, PMN extracellular traps or NETs are web-like structures composed of decondensed 
chromatin, histones, and granular proteins (160, 235, 239).  It is thought that NETs function to 
trap pathogens and kill via the localized concentration of antimicrobials that decorate these 
structures. Although the mechanisms regulating NET formation or NETosis are not entirely 
clear, NADPH oxidase, myeloperoxidase (MPO) and PMN elastase (NE) activity are required 
(240-242).  Moreover, patients with chronic granulomatous disease (CGD), a congenital disorder 
affecting the NADPH oxidase system, exhibit impaired NET formation (243). Phorbol myristate 
acetate (PMA)-induced NETosis studies similarly show that upon inhibition of NADPH oxidase 
activity with diphenylene iodonium (DPI), NETs production significantly decreases compared to 
DPI-untreated PMNs, highlighting the importance of respiratory burst in the regulation of NETs 
(161).  
Hematopoietic stem cell transplantation (HSCT) is an effective therapy for the treatment of 
malignant and congenital disorders. However both autologous (self donor stem cells) and 
allogeneic (HLA-matched donor stem cells) transplant patients exhibit higher susceptibility to 
infectious pulmonary complications long after transplant (23, 28, 173). Despite immune 
reconstitution, persistent susceptibility to infection suggests functional immune defects.  
Alveolar macrophages constitute more than 90% of the immune cells in the alveoli and are 
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important for the initiation of host responses against invading pathogens (244-246). One way that 
AMs are able to clear infection is through the recruitment and activation of circulating PMNs, 
key innate cells important for combating fungal and bacterial pathogens.  HSCT patients are 
more susceptible to P. aeruginosa and S. aureus, pathogens also afflicting CGD patients (108). 
Interestingly, PMNs from bone marrow transplant (BMT) patients exhibit impaired superoxide 
production, bactericidal function and chemotaxis (26).     
Using a murine BMT model, we have previously published that bactericidal function 
against both P. aeruginosa and S. aureus is impaired (55, 58, 60). As NETs have been previously 
shown to effectively kill both S. aureus and P. aeruginosa (160, 161, 247), it is unclear whether 
this observed bactericidal defect could be attributed to impaired NETosis following 
transplantation. We previously published that the defect in PMN function was partly due to 
overproduction of PGE2 (58). PGE2 is an effector of the cyclooxygenase enzyme, of which there 
are two isoforms (basal COX-1 and inducible COX-2) (197). The rate-limiting enzyme of PGE2 
synthesis, COX-2, is upregulated in murine BMT PMNs (58).  Interestingly, inhibition of COX 
with indomethacin rescued the functional defect and intracellular bacterial killing improved (58). 
As intracellular bacterial killing relies on pathways shared with NETosis (e.g. NADPH oxidase 
for superoxide production), it is possible that NET formation is also impaired post-BMT. Aside 
from the requirement of NADPH oxidase activity and autophagy (248) to promote NETosis, 
regulation of this process is not fully understood. Additionally, no previous studies have 
documented any factors that may serve to limit this process physiologically.  Here, we propose a 
novel role for PGE2 as an inhibitor of effective NET production.  
  
110 
 
6.2 Results 
NETs are impaired post-syn/allo BMT 
Previously, our lab published that syn BMT PMNs phagocytized P. aeruginosa, similarly 
to untransplanted control PMNs. However, intracellular bacterial killing was impaired.  As NETs 
are web-like structures made of chromatin, nuclear proteins and cytoplasmic granule proteins 
that contain antimicrobial functions, it is also possible that NETs are impaired.  To determine 
whether the capacity to NET was deficient or intact, NETosis was measured via sytox green 
fluorescence detection, as sytox binds to extracellular DNA. Following recruitment into the lung 
by intratracheal LPS injections, PMNs were treated with PMA and NETosis was compared to 
untreated PMNs.   PMA, a known inducer of NETosis, was able to stimulate NETs in 
untransplanted control PMNs; however, PMA-treated syn and allo BMT PMNs were unable to 
NET as effectively as untransplanted controls (Figure 6.1A and 6.1B).  These observations were 
supported by immunofluorescence studies that showed little NETosis across mouse groups when 
untreated (Figure 6.1C, first row), but upon PMA-induction, extensive and intact NETs were 
seen in untransplanted controls while in both syn and allo BMTs, NETs were significantly 
decreased and appeared structurally less intact (Figure 6.1C, second row). BMT PMNs were able 
to form NETs or NET-like structures that appeared shorter and more fragile than untransplanted 
controls (Figure 6.1C).  Interestingly, the impaired NETosis following syn BMT extended to 
NETosis in response to physiologically relevant stimuli like Streptococcus pneumonia (Figure 
6.1A) 
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Figure 6.1. NETosis is impaired post-syn and allo BMT.  LPS-recruited PMNs from the lung 
of (A) syn BMT (n=4-6) or (B) allo BMT (n=3) and untransplanted control mice were stimulated 
for 5 h with PMA (100 nM), Streptococcus pneumoniae (S. pneumo), or left untreated and 
NETosis was measured by sytox green fluorescence.  (C) NETosis following 7 h PMA treatment 
in LPS-recruited PMNs from untransplanted control, syn BMT, and allo BMT mice was 
visualized by immunofluorescence via staining of DNA (Hoechst) and PMN elastase (control 
and syn BMT 20x; allo BMT 40x magnification); arrowheads show colocalization of neutrophil 
elastase and DNA in NET structures, **p<0.01, ***p<0.001.   
 
Indomethacin restores NET formation 
Impaired AM and PMN function post-BMT were previously shown to be primarily 
mediated by the overexpression of the COX pathway. Thus, to determine whether NETosis was 
negatively regulated by increased COX activity, syn BMT mice were intraperitoneally injected 
with indomethacin, a COX inhibitor. Interestingly, in vivo inhibition of COX rescued impaired 
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NETosis post-syn BMT (Figure 6.2A). Immunofluorescence studies again confirmed the effects 
of indomethacin on NETosis, as in vivo inhibition of COX was able to visibly enhance NET 
production in syn BMT PMNs compared to untransplanted PMNs (Figure 6.2B). Similarly, 
NETosis was also increased in allo BMT mice upon COX inhibition with indomethacin (Figure 
6.2C).  
 
Figure 6.2. Indomethacin rescues impaired NETosis. LPS-recruited pulmonary PMNs from 
untransplanted control, syn BMT, or syn BMT mice following i.p. injection with indomethacin 
(1.2 mg/kg) were treated with PMA (100 nM) or left untreated for 5 h and NETosis was 
measured via (A) sytox fluorescence (n=4-5) or (B) immunofluorescence studies (gray scale of 
Hoechst DNA staining at 20x magnification).  (C) Sytox fluorescence were performed in LPS-
recruited allo BMT PMNs to measure NETosis following 5 h in vitro treatment with 
indomethacin (10 µM), PMA (100 nM), PMA and indomethacin, or left untreated (n=4-6); 
arrowheads denote NET structures, *p<0.05, **p<0.01, ***p<0.001. 
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PGE2 inhibits PMA-induced NETs 
Activation of the COX pathway results in increased synthesis of PGE2.  Our lab has 
shown that PGE2 promotes functional defects in AMs and PMNs. Thus, to further understand the 
role of the COX pathway in the regulation of NETosis, we focused our studies to effects of 
PGE2. Interestingly, in vitro treatment with PGE2 was able to decrease NET release in response 
to a known inducer of NETs, PMA (Figure 6.3A), suggesting an immunosuppressive role for 
PGE2 in the context of NETosis. This was confirmed with immunofluorescence studies that 
showed a significant absence of clear and intact NET formation upon the simultaneous treatment 
of PMA with PGE2 (Figure 6.3B, right). PMA-treated untransplanted control PMNs recruited 
into the lung displayed extensive NET release (Figure 6.3B, middle).   
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Figure 6.3. PGE2 inhibits PMA-induced NETs. LPS-recruited PMNs from untransplanted 
control mice were stimulated with (A) PGE2 (10 µM), PMA (100 nM), PMA + PGE2 or left 
untreated for 5 h and measured for NETosis via sytox fluorescence (n=4-6) or (B) PMA, PMA + 
PGE2, or untreated for 7 h and NETs were visualized by immunofluorescence (Hoechst, DNA; 
FITC, PMN elastase; 60x magnification); arrowheads show colocalization of neutrophil elastase 
and DNA in NET structures, *p<0.05, **p<0.01, ***p<0.001. 
 
Inhibition of PGE2 signaling restores NET production 
 Although Figure 6.7 supports an inhibitory effect for PGE2 on NET release, the role of 
PGE2 on NETs in the context of transplantation remained unclear.  PGE2 signals through EP 
receptors 1-4 and our lab previously showed that EP2 was enhanced on BMT AMs. Furthermore, 
inhibition of EP2 rescued multiple defects observed in BMT AMs.  Thus, to determine whether 
the impaired NETs observed in BMT PMNs was primarily due to PGE2, BMT PMNs were 
treated with a novel EP2 receptor antagonist (provided by Pfizer).  Interestingly, treatment with 
the EP2 antagonist was able enhance NETosis in both Syn and Allo BMT PMNs (Figure 6.4A 
and 6.4B). PGE2 signaling is mediated through PKA or Epac-dependent pathways. Thus, to shed 
light on the PGE2 signaling important for mediating the inhibitory effects on NETs, PKA and 
Epac agonists were used.  Activation of the PKA pathway did not inhibit PMA-induced NETs, 
however, the Epac agonist was able to effectively block NET production. Furthermore, PKA and 
Epac agonists together, similarly inhibited PMA-induced NETosis similarly as the Epac agonist 
with PMA alone (Figure 6.4C).  These results suggest that in murine PMNs, EP2 activation of 
Epac is responsible for the inhibition of NETosis. 
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Figure 6.4. Inhibition of PGE2 signaling rescues NET production and inhibition is mediated 
by Epac, but not PKA activation in mice. LPS-recruited PMNs from (A) syn (n=5-6) and (B) 
allo (n=4-5) BMT mice were treated with PMA (100 nM), an EP2 antagonist (EP2a, 1 nM), or 
PMA and EP2a for 5 h and NETs were measured by sytox fluorescence. (C) Effects of 
downstream PGE2 signaling on NETosis were determined with 5 h PKA (500 µM) and Epac 
(500 µM) agonist treatments on untransplanted control PMNs. NET production was determine 
by sytox fluorescence (n=4-6); *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.   
 
Blocking PGE2 signaling rescues NETs in both autologous and allogeneic HSCT patients 
Our murine BMT model suggests an impairment of NETosis in BMT PMNs mediated by 
PGE2 signaling primarily via Epac. To understand its relevance in HSCT patients, the effect of 
PGE2 on NETosis was measured in PMNs harvested from a bronchoalveolar lavage sample of an 
autologous HSCT patient (Figure 6.5A) and from peripheral blood from an allogeneic HSCT 
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patient (Figure 6.5B). Blocking PGE2 signaling via the EP2 receptor was able to enhance NET 
production, measured by increased sytox fluorescence. These data were compatible with the data 
collected from our murine BMT model.  
 
NETosis in human PMN is inhibited by both PKA and Epac activation by EP2 signaling 
To further validate our murine findings, human untransplanted healthy PMNs were 
collected from peripheral blood. Following purification, they were treated with PMA, PGE2, 
and/or Epac or PKA agonists.  Similar to our murine data, PMA was able to induce NETs.  This 
induction was decreased both by concurrent treatment with PGE2 an Epac agonist or a PKA 
agonist (Figure 6.5C).  These sytox findings correlated with immunofluorescence studies. NETs 
were undetected in PGE2-treated and untreated human PMNs (Figure 6.6; Rows 1 and 2). Upon 
treatment with PMA, release of web-like DNA structures colocalizing with PMN elastase 
indicated formation of NETs (Figure 6.6; Row 3). However, NETs were visually absent in 
response to PGE2 treatment, despite addition of PMA (Figure 6.6; Row 4). These results 
highlight that PGE2 signaling via Epac can limit NETosis in murine PMNs; however, both Epac 
and PKA signaling may be involved in inhibition of human PMN NETosis. 
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Figure 6.5. Blocking PGE2 signaling rescues NETs in both autologous and allogeneic HSCT 
patients. NETosis was measured by sytox fluorescence using PMNs from (A) a bronchoalveolar 
lavage of an autologous transplant patient (n=5) and (B) peripheral blood from an allogeneic 
patient (n=10-12) following 2.5-3 h in vitro treatment with PMA (100 nM), EP2a (1 nM), or 
PMA + EP2a. (C) PMNs from n=2 healthy human volunteers were harvested from peripheral 
blood and treated with PGE2, Epac agonist (Epac ag., 500 µM), PKA agonist (PKA ag., 500 
µM), PMA, PMA + PGE2, PMA + Epac ag., PMA + PKA ag., or left unstimulated for 3 h and 
NETosis was measured by sytox fluorescence (n=4 experimental replicates); *p<0.05, **p<0.01, 
***p<0.001, ****p<0.0001. 
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Figure 6.6. PGE2 inhibits PMA-induced NETosis in human PMNs. Human PMNs were 
harvested from n=4 healthy volunteers and stimulated with PGE2 (10 µM), PMA (100 nM), 
PMA + PGE2, or left untreated for 3 h. NETosis was measured by staining for DNA (Hoescht) 
and PMN elastase (N. elastase; FITC) and visualized via immunofluorescence (40x 
magnification). 
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6.3 Discussion 
 HSCT patients suffer from a myriad of infectious pulmonary complications, likely due to 
impaired alveolar macrophage and PMN function. PMN function has been shown to be 
particularly important for host response to pulmonary infection. We have previously shown that 
PMNs are unable to clear engulfed pathogens. Here we show that PMNs recruited to the lung 
exhibit impaired NETosis in response to PMA following either syngeneic or allogeneic BMT. 
Consistent with previous findings suggesting defective PMN function post-BMT is dependent on 
overexpression of COX-2 and PGE2 signaling.  Here we show that NETosis is similarly inhibited 
post-BMT, as inhibition of the COX pathway alone both in vivo and in vitro rescued impaired 
NETosis.  
Multiple changes in the lung have been reported (e.g. elevated IL-6, GM-CSF; decreased 
TNFα, IFNγ, leukotrienes) (55, 59, 88, 208) which may contribute to immunosuppressive effects 
on PMN function and NETosis. Furthermore, induction of COX-2 may result in the 
overproduction of multiple downstream effectors (e.g. thromboxane). However, PGE2 treatment 
decreased NETosis in control PMNs despite the presence of a known NET inducer, PMA, 
indicating that negative NETosis regulation via upregulation of COX-2 was mediated by PGE2 
signaling. This was further supported by the specific inhibition of the EP2 receptor using an EP2 
antagonist. Both syngeneic and allogeneic PMNs exhibited rescued NETosis following a block 
in PGE2-EP2 signaling. This was partly surprising as we previously measured EP4 receptor 
expression to be 4.7-fold higher in BMT PMNs while EP2 was 2.2-fold higher compared to 
untransplanted controls (58). However, we see that an EP2-specific antagonist was able to 
mediate a protective effect. Thus it is possible that inhibition by PGE2 is mediated mostly 
through EP2, EP2 and EP4 are performing redundant inhibitory functions, or that blocking 
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signaling through EP4 along with EP2 may illustrate an additive effect. Still these data reveal 
PGE2 as an important negative regulator of NETosis.  
As PGE2 intracellular signaling relies on PKA and Epac-dependent pathways (79), here 
we show that PGE2 negatively regulates NETosis in mice through induction of the Epac pathway 
as an Epac agonist, but not a PKA agonist, inhibited NETosis similarly to PGE2 treatment. Thus, 
these data illustrate a novel pathway by which NETs can be negatively regulated.  Similarly, 
PMNs collected from the bronchoalveolar lavage of an autologous HSCT patient exhibit 
enhanced NETosis upon inhibition of PGE2-EP2 signaling. Interestingly, PMNs collected from 
the peripheral blood of an allogeneic HSCT patient exhibited similar results. These data indicate 
that the negative effects of PGE2 signaling are independent of the location of the PMN and the 
type of transplant.  What was different between the murine and human studies however was that 
the inhibitory effects of PGE2 are both Epac- and PKA-dependent in human PMNs.  The reasons 
for this species divergence is currently unclear.  We previously showed that hydrogen peroxide, a 
product of reactive oxygen species synthesis, was decreased in the murine lung post-BMT. As 
ROS production is required for NETosis, it is possible that Epac-dependent inhibition of 
NETosis is mediated through the inhibition of ROS. Recently, a renal ischemia-reperfusion study 
found that activation of Epac reduced mitochondrial ROS production via interaction with Rap1 
in tubular epithelial cells (249). Thus it is possible that Epac signaling upstream of NAPDPH 
oxidase or mitochondrial ROS production mediates inhibition of NETs. Furthermore, the effect 
of PGE2 and Epac on autophagy is unknown. Remijsen et al. 2011 reported the requirement for 
both ROS and autophagy in promoting induction of NETs. Thus, whether autophagy is defective 
in BMT PMNs remains to be determined. Additionally, whether there is differential regulation of 
these downstream pathways by Epac and PKA in humans remains to be determined. 
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Still, these observations implicate an important regulatory role for PGE2 in NETosis. 
Additionally, they offer a potential therapeutic avenue by which NETosis can be inhibited, 
particularly in diseases whereby uncontrolled induction of NETs promote disease exacerbation, 
as in the case of systemic lupus erythematous (SLE) (250-252).  
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Chapter 7:  
Conclusion 
 
7.1 Summary of results  
7.1.1 Scavenger Receptor Studies 
 
 The observations that human HSCT patients harbored defective AM function and that 
PGE2 was elevated in circulation of HSCT patients, propelled our studies to characterize and 
investigate the link between these two observations (34, 83). Using a murine model, our lab 
previously showed that AM phagocytosis was impaired and that this was mediated by elevated 
PGE2 in the lungs (58). These experiments were performed using P. aeruginosa, a Gram-
negative bacterium. However, HSCT patients are also susceptible to Gram-positive bacteria like 
S. pneumoniae and S. aureus (208). Here we show differential phagocytosis of pathogens post-
BMT is dependent on the pathogen. AM phagocytosis of P. aeruginosa was indeed decreased, as 
was previously published; however, S. aureus phagocytosis by BMT AMs was enhanced (60). 
These differences were attributed to dysregulation of scavenger receptors, particularly MARCO 
was reduced and SR-A was upregulated.  These studies highlight the importance of MARCO for 
P. aeruginosa recognition and SR-A for S. aureus recognition. Importantly, we show that 
changes in scavenger receptor expression were due to the effects of PGE2. PGE2 was shown to 
decrease MARCO and increase SR-A, correlating with the profile obtained post-BMT (60).  
In addition, we show that PGE2 is able to mediate these effects by inhibiting miR-155, a 
negative regulator of SR-A (60). Blocking miR-155 through transfection of the antagomiR of 
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155 in primary AMs, increased SR-A mRNA levels, supporting a role for miR-155 in 
destabilizing SR-A mRNA. Interestingly, inhibition of miR-155 in primary AMs resulted in 
increased phagocytosis of S. aureus. Thus, PGE2 signaling inhibits miR-155 and supports 
overexpression of SR-A.  However, the mechanism for how PGE2 mediates downregulation of 
MARCO remains unclear. Despite reduced phagocytosis, BMT mice remain more susceptible to 
S. aureus, a result that we found correlated with defective bacterial intracellular killing (60).  
 
7.1.2 COX-2 hypomethylation studies 
We have shown that AM and PMN dysfunction is mediated by overproduction of PGE2 
in the BMT lung (58). As PGE2 overproduction is a result of increased COX-2, our studies 
focused on understanding the etiology for its upregulation. Using bisulfite conversion and 
pyrosequencing analysis, we show that COX-2 was significantly hypomethylated in its promoter 
and into the first exon (89). The effects of COX-2 DNA methylation were further explored by 
using a COX-2 promoter-driven luciferase plasmid. In vitro DNA methylation of the COX-2 
promoter-driven luciferase plasmid silenced luciferase activity following transfection in MHS 
cells. Interestingly, DNA methylation-induced inhibition of luciferase expression was overcome 
by TGF-β, suggesting that TGF-β was able to demethylate the luciferase plasmid. That TGF-β 
was able to demethylate COX-2 was supported by bisulfite conversion and pyrosequencing 
studies using CD11cdnR BMT mice. CD11cdnR BMT AMs exhibited partially rescued DNA 
methylation of CpG sites that were significantly hypomethylated in WT BMT mice. Interestingly 
these same CD11cdnR BMT AMs exhibited rescued phagocytosis function, compared to 
untransplanted control and WT BMT AMs. Thus these studies showed that the overexpression of 
COX-2 post-BMT was mediated by dysregulation of the DNA methylation of CpG sites in COX-
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2. Furthermore, changes in DNA methylation were due to TGF-β, previously shown in our lab to 
be overexpressed in BMT lungs (88, 253). 
7.1.3 TGF-β and miR-29b studies 
Our lab has shown that increased COX-2 and PGE2 promote impaired AM responses 
(58). We now know TGF-β signaling post-BMT can promote hypomethylation of the COX-2 
gene. Here, we provide mechanistic insight into how this occurs and show that TGF-β induces 
miR-29b while decreasing DNMT 1, DNMT 3a and DNMT 3b in AMs post-BMT. De novo 
DNMT 3a and 3b were decreased upon transient transfection of miR-29b, resulting in decreased 
DNA methylation of the COX-2 promoter, and induction of COX-2.  As a consequence, miR-
29b-driven upregulation of COX-2 promoted AM dysfunction, and transfection of BMT AMs 
with a miR-29b inhibitor rescued the bacterial killing defect. MiR-29b-mediated defects in BMT 
AMs were dependent on increased levels of PGE2 as miR-29b-transfected AMs treated with an 
EP2 antagonist abrogated the impaired bacterial killing. We also demonstrate that HSCT patients 
exhibit increased miR-29b expression and also increased PGE2 expression; thus, these studies 
highlight miR-29b in driving defective AM responses and identify this miRNA as a potential 
therapeutic target. Our AM findings, tying the projects together, are shown below, in a working 
model.  
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Figure 7.1. Effects of TGF-β-induced expression of COX-2 on BMT AMs: A model. 
Elevated TGF-β in the lung, likely produced by type II alveolar epithelial cells, signal to BMT 
AMs resulting in the upregulation of miR-29b. Elevated miR-29b targets DNMTs to allow for 
hypomethylation of COX-2. Decreased DNA methylation of COX-2 enhances COX-2 
expression and induces PGE2 synthesis. Increased PGE2 by BMT AMs can signal in an autocrine 
and paracrine fashion via EP2 receptors to mediate its inhibitory effect on AM function (altered 
scavenger receptor (SR) profiles, decreased miR-155, impaired phagocytosis, and defective 
bacterial killing). 
 
7.1.4 PGE2 and NETosis studies 
NETs have emerged as important DNA structures, decorated with granular proteins like 
myeloperoxidase and PMN elastase, with a role in trapping and killing invading pathogens (160).  
Defects in their production have been implicated to contribute to an impaired innate immune 
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response against bacterial infections (243). Furthermore, using our BMT model, we previously 
reported that PMNs over express COX-2 and PGE2 and exhibit defective bacterial killing 
following BMT (58). To further characterize the defects in BMT PMNs, we measured their 
capacity to NET. Here we show that PMNs recruited into the lung following either syn or allo 
BMT exhibit a reduced ability to produce NETs upon treatment with PMA. This impaired NET 
formation was rescued following treatment with indomethacin, a pharmacological inhibitor of 
the COX pathway, both in vitro and in vivo. The defect is likely secondary to PGE2 elevations 
post-BMT and signaling via the EP2 receptor.   
Treatment of BMT PMNs with an EP2 receptor antagonist (PF-04418948) restored NET 
formation whereas exogenous PGE2 treatment could limit NET formation in control PMNs. 
PGE2 signaling involves PKA and Epac-dependent pathways. Interestingly, treatment with an 
Epac agonist, but not a PKA agonist, mimicked the inhibition on NETosis post-PMA in the same 
way as exogenous PGE2 treatment in mice.  Human PMNs also showed the ability of PGE2 to 
limit NETosis, but in this case, inhibition could be mediated by both Epac and PKA. The reasons 
for this species-specific dichotomy are currently unclear.  These findings suggest that enhanced 
activity of the COX pathway leading to PGE2 elevations suppresses NET formation post-HSCT, 
thus providing significant insight into why HSCT recipients exhibit impaired innate immunity to 
bacterial pathogens.       
7.2 Critical Review and Future directions 
7.2.1 Scavenger receptor studies  
Scavenger receptor studies demonstrate that MARCO is important for P. aeruginosa 
while SR-A is utilized for S. aureus recognition. Our studies have primarily focused on the 
measurement of MARCO levels at baseline, both mRNA and cell-surface expression, at which 
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time point expression of both is decreased. However, MARCO expression has previously been 
characterized as inducible (102, 181). Thus it is possible that upon infection, MARCO 
expression may increase and we may have missed this observation by only looking at baseline 
analyses. Thus, future experiments could include the careful analysis of MARCO expression 
(mRNA and protein) upon stimulation with bacteria or LPS post-BMT.  
 SR-A expression has been linked to promoting polarization of macrophages to an 
alternatively activated (M2) phenotype (254, 255).   Prototypical M2 macrophages harbor an 
overall anti-inflammatory phenotype and are important for wound healing (5).  Upregulation of 
SR-A in M2 macrophages is thought to facilitate apoptotic cell clearance (5), however how it 
might negatively regulate macrophage clearance of intracellular bacteria remains unclear. 
Furthermore, whether AMs post-BMT harbor a phenotype aligned with classical or alternatively 
activated macrophages has remained unexplored and may provide interesting insight into the 
mechanisms driving decreased immune responses in the lung. Finally, SR-A expression was 
upregulated upon transfection of antimiR-155. Our data suggested that PGE2-mediated decrease 
in miR-155 resulted in the overexpression of SR-A. However, further experiments could have 
fortified this argument by investigating whether overexpression of miR-155 in BMT AMs 
decreased SR-A expression and S. aureus phagocytosis compared to control miR-transfected 
BMT AMs.    
The work presented here highlights the importance of miRNA in macrophage function. 
We showed that miR-155 expression is decreased while miR-29b is increased. We reported that 
decreased miR-155 resulted in increased SR-A and increased S. aureus phagocytosis by BMT 
AMs. Recently, it has been shown that miR-155 can induce autophagy by targeting Rheb, a 
negative regulator of autophagy (256). Autophagy is a tightly controlled self-degradative process 
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utilized by host cells to maintain cellular homeostasis (257). It has also been shown to play a role 
in host responses, promoting engulfment and degradation of intracellular bacteria that may 
otherwise escape detection (i.e. Mycobacterium tuberculosis) (256, 258).  Furthermore, miR-155 
was also shown to promote phagosome maturation (256). Thus, future studies could explore 
whether autophagy defects that are secondary to miR-155 loss may also help to explain the 
inhibition of bacterial killing that occurs post-BMT.  In fact, there is recent evidence that 
autophagy is critical for killing of P. aeruginosa (259) and thus, how PGE2 regulates autophagy 
could be an important area for future study. 
Type II alveolar epithelial cells produce and secrete pulmonary surfactant, a mixture of 
phospholipids, cholesterol, and proteins (260). The proteins associated with pulmonary 
surfactant are surfactant proteins (SP) A, B, C, and D, which can be subdivided into hydrophilic 
and hydrophobic classes (260). However, the most abundant surfactant protein is SP-A. SP-B 
and SP-C have been more closely associated with promoting adsorption of surfactant lipids onto 
the lung surface (260, 261). Aside from their role in lowering surface tension in the alveolus, SP-
A, as well as SP-D, have more recently been shown to play important roles in modulating 
immune responses (262) via recognition of inhaled pathogens. Interestingly, SP-A knockout 
mice exhibit increased susceptibility to various bacterial (e.g. P. aeruginosa) and viral (e.g. 
respiratory syncytial virus) pathogens (263-266). It has been shown that SP-A can function in an 
opsonin-like fashion through the recognition of carbohydrates present on pathogens and 
interaction with macrophages to promote immune responses (267).  In addition, Kuronuma and 
colleagues showed SP-A but not SP-D enhanced uptake of S. pneumoniae in AMs via interaction 
with SR-A (92).  As SR-A is enhanced on BMT AMs, it is possible that opsonizing bacteria that 
are not normally dependent on SR-A for phagocytosis with SP-A may prove beneficial. Thus, 
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future studies may explore the possibility of utilizing SP-A as a method for enhancing uptake of 
P. aeruginosa by BMT AMs through SP-A and SR-A interaction.  
Previous studies have shown that SP-A binds P. aeruginosa flagellin and enhances 
uptake of the bacteria (268-270).  Furthermore, it is well-known that SP-A can induce respiratory 
burst in rat and human macrophages (91, 271, 272). It is possible that addition of surfactant may 
not only promote effective phagocytosis of P. aeruginosa, but also activation of macrophages, as 
previous data in our lab showed that BMT AMs have impaired respiratory burst.  Currently 
surfactant preparations are given to pre-term infants to improve lung ventilation, but at this time 
the preparation that is approved for human use contains only the lipid components and not the 
protein components.  Our work suggests that a surfactant therapy that was composed of both 
lipid and SPA could improve host defense in these infants.  Potentially, HSCT patients might 
only need treatment with the nebulized SPA as no current evidence suggests that the lipid 
fraction of surfactant is dysregulated in this more mature population. 
7.2.2 Hypomethylation studies 
 These data explore the importance of DNA methylation as a regulator of COX-2 
expression.  TGF-β is also identified as a cytokine driving the demethylation of COX-2 as DNA 
methylation of COX-2 is maintained in CD11cdnR BMT mice. However, BMT mice have 
multiple dysregulated pathways. Therefore, to clarify the role of TGF-β, studies measuring 
COX-2 DNA methylation using untransplanted CD11cdnR mice and control mice treated with or 
without TGF-β would fortify the BMT findings. Furthermore, we had previously described that 
BMT mice exhibit higher susceptibility to both P. aeruginosa and S. aureus. If TGF-β does in 
fact mediate COX-2 expression, then CD11cdnR BMT mice should be protected and exhibit intact 
immune responses against both pathogens. While we studied TGF-β as a regulator of miR29 
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expression, we did not determine whether TGF-β also contributed to the downregulation of miR-
155.  Perhaps the biggest weakness with the hypomethylation data is that the changes noted in 
percent DNA methylation of each CpG residue were relatively small.  It is hard to know what 
percent of DNA methylation is functionally important.  It is also hard to know, from our work, 
whether all BMT AMs showed a similar degree of DNA methylation or whether we were 
studying a population with heterogenous DNA methylation patterns (some cells showing 
hypomethylation, but others not).  Future studies exploring the effects of individual or 
combinatorial mutation of these CpG sites in the context of BMT, TGF-β, and miR-29b 
transfection would provide insight into which CpG sites are critical sites affected by changes in 
DNA methylation that regulate COX-2 expression. This could be done by creating site directed 
mutations in particular CpG sites and then testing expression plasmids carrying mutated 
promoters for activity following transfection of AMs or MHS cells. 
Kang et al. showed that the CRE-2 site within the COX-2 promoter was an important 
regulatory site for COX-2 expression (231). Interestingly, the CRE-2 site and not the other sites 
(e.g. AP-1, CRE-1, NF-kB) that have been previously characterized coincided with the CpG sites 
that were significantly hypomethylated post-BMT and in response to miR-29b transfection and 
5-aza-2’deoxycytidine treatment. Future studies could explore whether the hypomethylation of 
these CpG sites supports COX-2 transcription from this CRE-2 site. This could be achieved by 
mutating the sequence of the CRE-2 site without disturbing the CpG sites, and measuring COX-2 
expression. 
7.2.3 MiR-29b studies 
The human cohort used in these studies measures miR-29b expression in HSCT patients  
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relative to non-smoker healthy human controls. However, the smoking status in the HSCT 
population is not known. A precedent study suggests miR-29b can be altered in response to 
smoking (273), however this study focused on the effects of smoking on plasma microvesicles 
and miRNA (including miR-29b), and did not extend their studies to cells within the lung. Thus, 
future studies could carefully select control samples and HSCT patient samples to exclude any 
factors that may confound the results while at the same time providing beneficial information on 
miR-29b post-HSCT.  
The murine BMT studies identify a miR-29b-dependent pathway in mediating TGF-β 
effects on COX-2 DNA methylation.  Most of the literature reveals an inhibitory effect of TGF-β 
on miR-29b; however, these studies were not performed using AMs (218-220). Thus, 
experiments exploring TGF-β induction of miR-29b could have been characterized in multiple 
macrophage populations (e.g. bone marrow-derived, peritoneal, etc.) to see if this phenomenon is 
cell-type or tissue specific or both.  TGF-β intracellular signaling via SMADs and their effects on 
miR-29b may elucidate a more specific pathway by which TGF-β can upregulate miR-29b in 
some cell types but not others.  Perhaps in other cell types inhibitory SMAD7 is induced, 
whereas this does not occur in AMs.  Furthermore, as miR-29b is elevated post-BMT, studies 
utilizing loss-of-function models of miR-29b may provide further proof that miR-29b is critical 
for TGF-β-mediated induction of COX-2.  
Classical knockout mice of miR-29b (274) could have been utilized as donor HSCs and 
TGF-β induction of COX-2 could have been further analyzed. If TGF-β were still able to induce 
COX-2 expression even in a miR-29b-/- mouse, this would suggest that there are other pathways 
by which TGF-β exerts its effects.  Most likely this would be at the level of increasing gene 
transcription, but potentially TGFβ could also regulate mRNA stability to increase COX-2 levels. 
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Alternatively, use of GS29 mice (transgenic mouse expressing a ‘sponge’ target to compete with 
endogenous miR-29b targets), first described in 2011 by Feng and colleagues (158), could be 
used as donors for stem cell transplantation and COX-2 expression and promoter methylation 
could be analyzed.   
 We also explored the effects of miR-29b on COX-2 DNA methylation. We reported that 
miR-29b induces small but significant hypomethylation of CpG sites 1-6 but not 28-34. 
Interestingly, CD11cdnR BMT AMs exhibited hypomethylation of CpG sites 28-34, however, 
sites 1-6 were not examined, as primers measuring sites 1-6 had not yet been designed. Thus, 
studies measuring DNA methylation of CpG sites 1-6 in CD11cdnR BMT AMs are warranted to 
confirm how TGF-β-induced miR-29b ultimately affects COX-2 expression. Furthermore, miR-
29b-specific changes in COX-2 post-BMT may be supported by DNA methylation studies 
following transfection of BMT AMs with antimiR-29b.  Still, taken together, the data we have 
generated do suggest that perhaps CpG sites 1-6 are the more important sites mediating COX-2 
induction.  It is also curious that our DNA methylation studies identified two independent 
regions for regulation by TGF-β, one in the upstream promoter and one near exon 1.  One site is 
regulated by miR-29b, but the other is not.  Given that miR-29b inhibits DNMTs, it is hard to 
know why there would be sequence specificity.  One possibility is that TGF-β is a much stronger 
stimulus to inhibit DNMTs than is miR-29b, thus the magnitude of DNMT suppression may be 
greater in response to the cytokine, thus leading to both sites being targeted.  Alternatively, 
perhaps the induction of gene transcription or translation near the first exon that is triggered by 
TGF-β stimulation creates a more accessible site for DNMT action near the first exon.  
Transfection of miR-29b would not necessarily be expected to upregulate the same 
transcriptional and translational machinery that TGF-β does. It is also possible that the 
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downstream CpG sites are not as important in mediating COX-2 expression as the upstream CpG 
sites within the COX-2 promoter. This would be supported by the fact that miR-29b transfection 
was able to induce COX-2 mRNA and protein by hypomethylating CpG sites 1-6 and not CpG 
sites 28-34. Future experiments could potentially investigate the importance of these different 
CpG sites as described in the future directions section for the hypomethylation studies. 
Overexpression of miR-29b post-BMT indirectly supports increased COX-2, and 
ultimately promotes PGE2 expression and the downstream effects of PGE2 (e.g. impaired 
bacterial killing) on BMT AMs. However, miR-29b can have other downstream targets that may 
also be important for propagating AM function in response to infection. Recently, a study 
investigating mechanisms driving chemoresistance and relapse of ovarian cancer identified a 
correlation between miR-29b and autophagy-related protein 9A (ATG9A) (275). Furthermore, a 
bioinformatic analysis predicting possible targets for miR-29b identified ATG9A (276). 
However, neither study confirmed ATG9A was in fact a target for miR-29b or studied miR-29b 
effects on autophagy. ATG9A was recently shown to be required for the formation of the 
isolation membrane, later developing into the autophagosome (277). Thus, it is possible that 
overexpression of miR-29b in AMs post-BMT may inhibit ATG9A. In a cell with the inability to 
initiate the production of an isolation membrane, autophagy is inhibited, and this may be a 
mechanism that also impairs bacterial killing.  
Alternatively, miR-29b can be inhibiting autophagy through a separate pathway. In 2012, 
Tumaneng et al. described their novel findings on the molecular mechanism associated with Yes-
associated protein (YAP) 1, a transcriptional co-activator in the Hippo pathway, and its 
regulation on organ size (278).  They suggested that miR-29b induces mammalian target of 
rapamycin, or mTOR, activity. mTOR is a known inhibitor of autophagy (279, 280), thus miR-
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29b upregulation of mTOR may be another mechanism causing defective autophagy in BMT 
AMs, and as we speculated above, autophagy may be critical to bacterial killing. Future studies 
could focus on delineating the mechanism(s) driving PGE2-mediated inhibition of autophagy. 
Overcoming this negative regulation may rescue impaired bacterial killing of bacteria like S. 
aureus.   
 
7.2.4 NETosis studies 
 NETosis studies described here utilize PMNs recruited to the lung following intratracheal 
injection of LPS. It has been previously shown that LPS can induce NETosis, thus our method of 
recruiting PMNs to the lung may induce NETosis on its own. This highlights a limitation to this 
study, as PMNs do not commonly exist in the lung without recruitment. To get around this, one 
possibility would be to measure NETosis in vivo in response to NET-inducing stimulation, i.e. 
using killed or live bacteria, and exogenous PGE2, to measure PGE2 inhibitory effects on 
NETosis.  NETs could then be determined via immunohistochemistry on formalin-fixed lung 
sections and stained for NET-associated proteins like myeloperoxidase and neutrophil elastase, 
as well as histones (281).  These in vivo studies would also provide insight into the importance of 
NETosis in BMT and untransplanted control mice in providing protection against invading 
pathogens.  Another possibility would be to harvest PMNs from the bone marrow. Although 
these cells would not be exposed to the lung-specific environment, this would allow for the study 
of PGE2 effects on NETosis in the absence of a stimulatory agent, like LPS.  
 Quantification of NETs in this study has been particularly difficult to assess, as most of 
the existing methods for measuring NETosis are indirect. Furthermore, distinguishing cell death 
versus NETosis can be particularly challenging and requires immunofluorescence imaging for 
the identification of NET formation. One way to differentiate between NETosis and other modes 
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of cell death could be through the measurement of MPO, NE, or histones (NETosis), and caspase 
activation, Bid cleavage, cytochrome c release, or and HMGB1 (apoptosis and necrosis) (282). 
Recently, Brinkmann and colleagues described a semi-automatic protocol for NET quantification 
(239). This method involves the use of anti-chromatin antibodies and relies on the observations 
that these antibodies bind decondensed chromatin more efficiently than condensed chromatin. 
Relating detection of this subnucleosomal complex with the anti-chromatin antibodies to total 
cell number through Hoescht 33342 staining allowed the quantification of the percentage of 
netting PMNs. Thus, this may be another way in which NETs can be directly quantified through 
immunofluorescence studies. 
Here we show how PGE2 negatively regulates NETosis in BMT PMNs and 
untransplanted control PMNs. Our studies also reveal that this inhibition is Epac-dependent in 
mice. However, how PGE2 is able to promote NETosis through Epac is not entirely clear. As 
ROS synthesis is decreased in BMT PMNs, it is possible that PGE2   is able to inhibit ROS. ROS 
is required for proper NETosis, thus this may be a mechanism by which PGE2 inhibits NETs. We 
would also need to determine whether regulation of ROS is differentially affected by Epac and 
PKA in humans, as both of these mediators inhibited NETosis in human PMNs.  Alternatively, a 
role for autophagy in mediating NET production has recently been proposed. Inhibition of 
autophagy, despite intact NADPH oxidase activity, impaired NET induction (248). Thus, it is 
possible PGE2 may be downregulating autophagy in PMNs post-BMT. Preliminary studies 
investigating autophagy-induced NETosis in our BMT model revealed that syn BMT PMNs 
were unable to NET as efficiently as untransplanted control cells upon rapamycin treatment. 
Rapamycin targets mTOR and relieves inhibition of autophagy promoted by mTOR (Figure 7.2). 
Thus, these preliminary data support a possible role for PGE2 in blocking autophagy. 
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Furthermore, studies exploring Epac-dependent effects on ROS and autophagy would be 
beneficial in understanding the defect in BMT PMNs. Focus in this area may identify possible 
pathways that can be targeted in the future. It should be noted however that PMNs present a 
particularly tough cell type for studies of autophagy as the inducer of NETosis due to their short 
half-life in culture. 
 
 
 
Figure 7.2.  PGE2 inhibits autophagy-induced NETosis. (A) LPS-recruited PMNs from the 
lungs of Syn BMT and untransplanted control mice were treated with rapamycin (200 nM) or 
untreated (media) for 5 h and NETosis was measured via Sytox fluorescence (n=6-12 wells). (B) 
Untransplanted control PMNs were collected from BAL of LPS-challenged mice and treated 
with PGE2 (10 µM), rapamycin (200 nM), or both. NETosis was measured via Sytox 
fluorescence (n=4-6 wells). (C) LPS-recruited PMNs from untransplanted control mice were 
treated with rapamycin (200 nM) or rapamycin and PGE2 (10 µM) for 5 h prior to treatment of 
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the supernatants with DNase I, acetone precipitation, and western blot analysis; *p<0.05, 
****p<0.0001.  
 
7.3 Contributions to the field/Final remarks 
 Taken together, our studies use a murine BMT model to explore mechanisms in BMT 
AMs and PMNs that contribute to host susceptibility to infections. We show the importance of 
SRs in mediating phagocytosis of P. aeruginosa and S. aureus, pathogens that afflict HSCT 
patients. Furthermore, we show that miR-155 is a negative regulator of SR-A and that in the 
context of transplantation, overexpression of PGE2 inhibits miR-155, allowing elevated SR-A. 
This novel finding has implications in other disease models as miR-155 is a multifunctional 
miRNA and has been shown to be important for development of immune cells, initiation of 
immune responses, as well as macrophage polarization (125, 147). We also explore BMT PMN 
NETosis and identify a novel role for PGE2 in negatively regulating NET induction. As the 
defects observed in BMT AMs and PMNs are mediated through the upregulation of COX-2 and 
PGE2, the etiology of COX-2 overexpression was also investigated. Our findings highlight the 
importance of TGF-β and miRNA in epigenetic regulation of gene expression and promoting 
dysfunction of BMT AMs.  
TGF-β is a pleiotropic cytokine and targeting TGF-β may have adverse effects on 
patients as TGF-β action is context-specific and cell-specific (283). Reductions in TGF-β may 
induce autoimmunity.  Here we show the importance of TGF-β1 in modulating BMT AM 
immune responses. Thus, while our results suggest that anti-TGF-β therapies may be beneficial, 
they must be entered into with caution.  Therapies targeting different components of the TGF-β 
signaling pathway as well as TGF-β isoforms are under development or in clinical trials (283). 
Along with infectious complications, pulmonary pneumonitis and fibrosis also occurs in HSCT 
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patients (41). Aberrant TGF-β1 production by alveolar epithelial cells promotes fibrotic 
responses and severely compromises lung function (88, 284). Thus, potential targeting of TGF-β 
in HSCT patients could have two-fold benefit (improved immunity and reduced fibrosis) but as 
mentioned before, would require careful targeting.   Differential targeting of TGF-β isoforms 
would likely decrease the magnitude of adverse effects and inhibition of TGF-β1 expression or 
utilization of drugs like LY2383770 which is a TGF-β1 ligand-selective blocking antibody from 
Ely Lilly rather than blocking TGF-β signaling as a whole may provide more specific protection.  
As TGF-β targeting strategies remain to be optimized, here we identify multiple other 
potential targets for therapeutic development for the enhancement of immune responses that may 
prove beneficial to HSCT patients. Use of indomethacin or COX-2 inhibitors may reverse the 
immunosuppressed state of AMs in HSCT patients and provide protection against the 
development of bacterial pneumonias. Alternatively, use of the EP2 antagonist examined in these 
studies would similarly augment HSCT AM immune responses. Furthermore, we previously 
discussed the importance of SP-A in opsonizing bacteria and enhancing bacterial uptake by 
macrophages. Thus, utilizing SP-A to promote phagocytosis of P. aeruginosa by BMT AMs 
through SP-A and SR-A interaction may be a useful method to overcome decreased uptake of 
pathogens that do not depend on SR-A for engulfment. MiRNAs comprise a new class of RNAi 
that contain attractive properties as targets for therapeutic development. Although therapies 
targeting miR-29b specifically remain in their infancy, there is promise in this area highlighted 
by the development of Miravirsen (SPC3649), an antimiR drug candidate that inhibits miR-122. 
Miravirsen is currently in clinical trials for the treatment of hepatitis C virus (285).  Thus, the 
work highlighted here provides multiple avenues by which HSCT AM immune defects may be 
overcome and productive immune responses promoted.      
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 Finally, perhaps the most important thing that can be done next is to advance all of our 
murine studies into AMs and PMNs isolated from HSCT patients.  While we provide data that 
miR29 is regulated in HSCT patients, we have not yet verified that other changes, e.g. MARCO 
expression are as expected in human HSCT patients.  If we determine that human AMs and 
PMNs mirror the defects noted in our BMT studies (as we anticipate they will) we will be well 
poised to move forward with experiments to determine drug efficacy. 
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